WO2008064345A2 - Microorganism killing compounds - Google Patents
Microorganism killing compounds Download PDFInfo
- Publication number
- WO2008064345A2 WO2008064345A2 PCT/US2007/085448 US2007085448W WO2008064345A2 WO 2008064345 A2 WO2008064345 A2 WO 2008064345A2 US 2007085448 W US2007085448 W US 2007085448W WO 2008064345 A2 WO2008064345 A2 WO 2008064345A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- exemplary embodiment
- substituted
- unsubstituted
- member selected
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 693
- 244000005700 microbiome Species 0.000 title claims abstract description 40
- 230000002147 killing effect Effects 0.000 title claims description 17
- 238000000034 method Methods 0.000 claims abstract description 106
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 45
- 210000000282 nail Anatomy 0.000 claims description 145
- 239000000203 mixture Substances 0.000 claims description 89
- -1 2-pyridinyl Chemical group 0.000 claims description 84
- 150000003839 salts Chemical class 0.000 claims description 61
- 241000282414 Homo sapiens Species 0.000 claims description 50
- 125000000217 alkyl group Chemical group 0.000 claims description 44
- 238000009472 formulation Methods 0.000 claims description 44
- 241000233866 Fungi Species 0.000 claims description 43
- 125000003118 aryl group Chemical group 0.000 claims description 43
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 40
- 210000004209 hair Anatomy 0.000 claims description 38
- 201000010099 disease Diseases 0.000 claims description 37
- 125000001072 heteroaryl group Chemical group 0.000 claims description 34
- 208000015181 infectious disease Diseases 0.000 claims description 32
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 28
- 229910052736 halogen Inorganic materials 0.000 claims description 27
- 150000002367 halogens Chemical class 0.000 claims description 25
- 108010076876 Keratins Proteins 0.000 claims description 24
- 102000011782 Keratins Human genes 0.000 claims description 24
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 24
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 23
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 23
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 21
- 241000894007 species Species 0.000 claims description 21
- 230000002401 inhibitory effect Effects 0.000 claims description 19
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 18
- 230000012010 growth Effects 0.000 claims description 17
- 210000004904 fingernail bed Anatomy 0.000 claims description 14
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 13
- 241001480043 Arthrodermataceae Species 0.000 claims description 12
- 241000223238 Trichophyton Species 0.000 claims description 12
- 125000002619 bicyclic group Chemical group 0.000 claims description 12
- 230000037304 dermatophytes Effects 0.000 claims description 12
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 10
- 229920002554 vinyl polymer Polymers 0.000 claims description 10
- 241000228212 Aspergillus Species 0.000 claims description 7
- 239000000460 chlorine Substances 0.000 claims description 7
- 230000000149 penetrating effect Effects 0.000 claims description 7
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 6
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 claims description 5
- 229910052794 bromium Inorganic materials 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 5
- 229910052731 fluorine Inorganic materials 0.000 claims description 5
- 239000011737 fluorine Substances 0.000 claims description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000003107 substituted aryl group Chemical group 0.000 claims description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 56
- 239000000417 fungicide Substances 0.000 description 54
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 48
- 230000000855 fungicidal effect Effects 0.000 description 38
- 210000003491 skin Anatomy 0.000 description 36
- 239000003795 chemical substances by application Substances 0.000 description 35
- 239000002904 solvent Substances 0.000 description 33
- 239000003814 drug Substances 0.000 description 32
- 210000000003 hoof Anatomy 0.000 description 32
- 210000000078 claw Anatomy 0.000 description 29
- 229940079593 drug Drugs 0.000 description 29
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 27
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 26
- 239000000243 solution Substances 0.000 description 25
- 125000001424 substituent group Chemical group 0.000 description 25
- 241001465754 Metazoa Species 0.000 description 24
- 239000013543 active substance Substances 0.000 description 24
- 235000019441 ethanol Nutrition 0.000 description 24
- 239000012049 topical pharmaceutical composition Substances 0.000 description 24
- 238000003786 synthesis reaction Methods 0.000 description 23
- 208000010195 Onychomycosis Diseases 0.000 description 21
- 230000015572 biosynthetic process Effects 0.000 description 21
- 239000000463 material Substances 0.000 description 21
- 201000005882 tinea unguium Diseases 0.000 description 21
- 125000004429 atom Chemical group 0.000 description 19
- 230000035515 penetration Effects 0.000 description 18
- 239000000126 substance Substances 0.000 description 18
- 238000011282 treatment Methods 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 17
- 241000700605 Viruses Species 0.000 description 16
- 239000003921 oil Substances 0.000 description 16
- 239000003755 preservative agent Substances 0.000 description 16
- 239000007787 solid Substances 0.000 description 16
- 239000004480 active ingredient Substances 0.000 description 15
- 239000003995 emulsifying agent Substances 0.000 description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 15
- 230000000699 topical effect Effects 0.000 description 15
- 241000894006 Bacteria Species 0.000 description 14
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 14
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 239000003974 emollient agent Substances 0.000 description 12
- 235000019198 oils Nutrition 0.000 description 12
- FGVVTMRZYROCTH-UHFFFAOYSA-N pyridine-2-thiol N-oxide Chemical class [O-][N+]1=CC=CC=C1S FGVVTMRZYROCTH-UHFFFAOYSA-N 0.000 description 12
- 229960002026 pyrithione Drugs 0.000 description 12
- 239000003981 vehicle Substances 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 11
- 239000000839 emulsion Substances 0.000 description 11
- 125000005842 heteroatom Chemical group 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 11
- 229910052757 nitrogen Inorganic materials 0.000 description 11
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 11
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 10
- 241000223229 Trichophyton rubrum Species 0.000 description 10
- 239000003963 antioxidant agent Substances 0.000 description 10
- 235000006708 antioxidants Nutrition 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 231100000252 nontoxic Toxicity 0.000 description 10
- 230000003000 nontoxic effect Effects 0.000 description 10
- 229920001451 polypropylene glycol Polymers 0.000 description 10
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 9
- 241001045770 Trichophyton mentagrophytes Species 0.000 description 9
- 239000006071 cream Substances 0.000 description 9
- 239000003883 ointment base Substances 0.000 description 9
- 150000003254 radicals Chemical class 0.000 description 9
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 0 CC(C)**(N)OC(C)(*(C)C)C(C)(C)C(*)(*)I(C)* Chemical compound CC(C)**(N)OC(C)(*(C)C)C(C)(C)C(*)(*)I(C)* 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- 239000000969 carrier Substances 0.000 description 8
- 239000003623 enhancer Substances 0.000 description 8
- 239000000543 intermediate Substances 0.000 description 8
- 244000045947 parasite Species 0.000 description 8
- 230000009885 systemic effect Effects 0.000 description 8
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 7
- 241000222122 Candida albicans Species 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 229910052796 boron Inorganic materials 0.000 description 7
- 229960000541 cetyl alcohol Drugs 0.000 description 7
- 239000002537 cosmetic Substances 0.000 description 7
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 7
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 229910052717 sulfur Inorganic materials 0.000 description 7
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- 241001225321 Aspergillus fumigatus Species 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- 206010017533 Fungal infection Diseases 0.000 description 6
- 208000031888 Mycoses Diseases 0.000 description 6
- 244000309464 bull Species 0.000 description 6
- 239000002738 chelating agent Substances 0.000 description 6
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 230000002335 preservative effect Effects 0.000 description 6
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 6
- 239000007921 spray Substances 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 239000000375 suspending agent Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 239000003765 sweetening agent Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000011200 topical administration Methods 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 230000000843 anti-fungal effect Effects 0.000 description 5
- 229940121375 antifungal agent Drugs 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 229940091771 aspergillus fumigatus Drugs 0.000 description 5
- 229940095731 candida albicans Drugs 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000003086 colorant Substances 0.000 description 5
- 239000007859 condensation product Substances 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 235000003599 food sweetener Nutrition 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 125000004474 heteroalkylene group Chemical group 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 5
- 230000003472 neutralizing effect Effects 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 229910052703 rhodium Inorganic materials 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 239000002562 thickening agent Substances 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- 102000004506 Blood Proteins Human genes 0.000 description 4
- 108010017384 Blood Proteins Proteins 0.000 description 4
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 4
- 241000711573 Coronaviridae Species 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 4
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 4
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 4
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 4
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000003429 antifungal agent Substances 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000013553 cell monolayer Substances 0.000 description 4
- SCKYRAXSEDYPSA-UHFFFAOYSA-N ciclopirox Chemical compound ON1C(=O)C=C(C)C=C1C1CCCCC1 SCKYRAXSEDYPSA-UHFFFAOYSA-N 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 235000019439 ethyl acetate Nutrition 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 244000053095 fungal pathogen Species 0.000 description 4
- 239000004922 lacquer Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 239000003961 penetration enhancing agent Substances 0.000 description 4
- 239000008177 pharmaceutical agent Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000037317 transdermal delivery Effects 0.000 description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 description 4
- 239000008158 vegetable oil Substances 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 3
- ILCOCZBHMDEIAI-UHFFFAOYSA-N 2-(2-octadecoxyethoxy)ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCO ILCOCZBHMDEIAI-UHFFFAOYSA-N 0.000 description 3
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- 102000052866 Amino Acyl-tRNA Synthetases Human genes 0.000 description 3
- 108700028939 Amino Acyl-tRNA Synthetases Proteins 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 3
- 241000221204 Cryptococcus neoformans Species 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 241000283073 Equus caballus Species 0.000 description 3
- 241000588722 Escherichia Species 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- 241000699694 Gerbillinae Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 3
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 3
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 3
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 241000555688 Malassezia furfur Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000186359 Mycobacterium Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 241000009328 Perro Species 0.000 description 3
- 239000004264 Petrolatum Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000282898 Sus scrofa Species 0.000 description 3
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 229960002916 adapalene Drugs 0.000 description 3
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 125000000129 anionic group Chemical group 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 229960003749 ciclopirox Drugs 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 229960001484 edetic acid Drugs 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 229940075507 glyceryl monostearate Drugs 0.000 description 3
- 208000005252 hepatitis A Diseases 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 3
- 229910052738 indium Inorganic materials 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 125000005647 linker group Chemical group 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 3
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 3
- 229960002216 methylparaben Drugs 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 3
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 229940066842 petrolatum Drugs 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- 230000000704 physical effect Effects 0.000 description 3
- 239000002798 polar solvent Substances 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 235000011069 sorbitan monooleate Nutrition 0.000 description 3
- 239000001593 sorbitan monooleate Substances 0.000 description 3
- 229940035049 sorbitan monooleate Drugs 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- 230000000475 sunscreen effect Effects 0.000 description 3
- 239000000516 sunscreening agent Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 229960000565 tazarotene Drugs 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 229960001727 tretinoin Drugs 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- KPRZOPQOBJRYSW-UHFFFAOYSA-N 2-(aminomethyl)phenol Chemical compound NCC1=CC=CC=C1O KPRZOPQOBJRYSW-UHFFFAOYSA-N 0.000 description 2
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 235000006491 Acacia senegal Nutrition 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- 241000186046 Actinomyces Species 0.000 description 2
- 241000589158 Agrobacterium Species 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 241001116389 Aloe Species 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- 206010001935 American trypanosomiasis Diseases 0.000 description 2
- 241000272525 Anas platyrhynchos Species 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 241000272814 Anser sp. Species 0.000 description 2
- 241000256844 Apis mellifera Species 0.000 description 2
- 235000003911 Arachis Nutrition 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 241000304886 Bacilli Species 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 206010005098 Blastomycosis Diseases 0.000 description 2
- 241000588807 Bordetella Species 0.000 description 2
- 241001416153 Bos grunniens Species 0.000 description 2
- 241000589562 Brucella Species 0.000 description 2
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- ONAIRGOTKJCYEY-XXDXYRHBSA-N CCCCCCCCCCCCCCCCCC(O)=O.O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 Chemical compound CCCCCCCCCCCCCCCCCC(O)=O.O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 ONAIRGOTKJCYEY-XXDXYRHBSA-N 0.000 description 2
- 241000282836 Camelus dromedarius Species 0.000 description 2
- 241000589876 Campylobacter Species 0.000 description 2
- 241000222173 Candida parapsilosis Species 0.000 description 2
- 241000282994 Cervidae Species 0.000 description 2
- 241001432959 Chernes Species 0.000 description 2
- 241000606161 Chlamydia Species 0.000 description 2
- 241000193403 Clostridium Species 0.000 description 2
- 241000272201 Columbiformes Species 0.000 description 2
- 241000186216 Corynebacterium Species 0.000 description 2
- 201000003075 Crimean-Congo hemorrhagic fever Diseases 0.000 description 2
- 201000007336 Cryptococcosis Diseases 0.000 description 2
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 241001480035 Epidermophyton Species 0.000 description 2
- 241001480036 Epidermophyton floccosum Species 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 208000002584 Fungal Eye Infections Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 241000606790 Haemophilus Species 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- 241000228402 Histoplasma Species 0.000 description 2
- 241000430519 Human rhinovirus sp. Species 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000588748 Klebsiella Species 0.000 description 2
- 241001233242 Lontra Species 0.000 description 2
- 241000406668 Loxodonta cyclotis Species 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241001299738 Malassezia pachydermatis Species 0.000 description 2
- 241001480037 Microsporum Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 241000893976 Nannizzia gypsea Species 0.000 description 2
- 241000272458 Numididae Species 0.000 description 2
- 241000712464 Orthomyxoviridae Species 0.000 description 2
- 241000606860 Pasteurella Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 241000186429 Propionibacterium Species 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 241000283011 Rangifer Species 0.000 description 2
- 241000725643 Respiratory syncytial virus Species 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 208000009163 Sebaceous of Jadassohn Nevus Diseases 0.000 description 2
- 241000607768 Shigella Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
- 206010041736 Sporotrichosis Diseases 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 229930182558 Sterol Natural products 0.000 description 2
- 241001478878 Streptobacillus Species 0.000 description 2
- 241000187747 Streptomyces Species 0.000 description 2
- 241000272534 Struthio camelus Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 241001480048 Trichophyton tonsurans Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 241000700647 Variola virus Species 0.000 description 2
- 241000607598 Vibrio Species 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 208000003152 Yellow Fever Diseases 0.000 description 2
- 241000607734 Yersinia <bacteria> Species 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 235000011399 aloe vera Nutrition 0.000 description 2
- 231100000360 alopecia Toxicity 0.000 description 2
- 239000002280 amphoteric surfactant Substances 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 2
- 229960002882 calcipotriol Drugs 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 239000003093 cationic surfactant Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 229940120503 dihydroxyacetone Drugs 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 239000013583 drug formulation Substances 0.000 description 2
- 230000036267 drug metabolism Effects 0.000 description 2
- 229950007919 egtazic acid Drugs 0.000 description 2
- 239000008387 emulsifying waxe Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- RWMJRMPOKXSHHI-UHFFFAOYSA-N ethenylboron Chemical compound [B]C=C RWMJRMPOKXSHHI-UHFFFAOYSA-N 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 229960004884 fluconazole Drugs 0.000 description 2
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 150000002540 isothiocyanates Chemical class 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- RMGJCSHZTFKPNO-UHFFFAOYSA-M magnesium;ethene;bromide Chemical compound [Mg+2].[Br-].[CH-]=C RMGJCSHZTFKPNO-UHFFFAOYSA-M 0.000 description 2
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000003228 microsomal effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 231100000344 non-irritating Toxicity 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- QWVGKYWNOKOFNN-UHFFFAOYSA-N o-cresol Chemical compound CC1=CC=CC=C1O QWVGKYWNOKOFNN-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 150000004986 phenylenediamines Chemical class 0.000 description 2
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000000473 propyl gallate Substances 0.000 description 2
- 235000010388 propyl gallate Nutrition 0.000 description 2
- 229940075579 propyl gallate Drugs 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical class OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229910052702 rhenium Inorganic materials 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 201000005404 rubella Diseases 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 229960004274 stearic acid Drugs 0.000 description 2
- 235000003702 sterols Nutrition 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000005309 thioalkoxy group Chemical group 0.000 description 2
- 210000004906 toe nail Anatomy 0.000 description 2
- WRECIMRULFAWHA-UHFFFAOYSA-N trimethyl borate Chemical compound COB(OC)OC WRECIMRULFAWHA-UHFFFAOYSA-N 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 1
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 description 1
- RGEMJCLUPGZKTQ-WAUHAFJUSA-N (3s,8r,9s,10r,13s,14s)-3-[2-(dimethylamino)ethoxy]-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one Chemical compound C([C@@H]12)C[C@]3(C)C(=O)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OCCN(C)C)C1 RGEMJCLUPGZKTQ-WAUHAFJUSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- SRUQARLMFOLRDN-UHFFFAOYSA-N 1-(2,4,5-Trihydroxyphenyl)-1-butanone Chemical compound CCCC(=O)C1=CC(O)=C(O)C=C1O SRUQARLMFOLRDN-UHFFFAOYSA-N 0.000 description 1
- AFNXATANNDIXLG-SFHVURJKSA-N 1-[(2r)-2-[(4-chlorophenyl)methylsulfanyl]-2-(2,4-dichlorophenyl)ethyl]imidazole Chemical compound C1=CC(Cl)=CC=C1CS[C@H](C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 AFNXATANNDIXLG-SFHVURJKSA-N 0.000 description 1
- SNUSZUYTMHKCPM-UHFFFAOYSA-N 1-hydroxypyridin-2-one Chemical class ON1C=CC=CC1=O SNUSZUYTMHKCPM-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- UGDAWAQEKLURQI-UHFFFAOYSA-N 2-(2-hydroxyethoxy)ethanol;hydrate Chemical compound O.OCCOCCO UGDAWAQEKLURQI-UHFFFAOYSA-N 0.000 description 1
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- YZBOVSFWWNVKRJ-UHFFFAOYSA-M 2-butoxycarbonylbenzoate Chemical compound CCCCOC(=O)C1=CC=CC=C1C([O-])=O YZBOVSFWWNVKRJ-UHFFFAOYSA-M 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- CNXZMGRWEYQCOQ-UHFFFAOYSA-N 2-methoxy-3-phenylprop-2-enoic acid Chemical class COC(C(O)=O)=CC1=CC=CC=C1 CNXZMGRWEYQCOQ-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- ICIDSZQHPUZUHC-UHFFFAOYSA-N 2-octadecoxyethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCO ICIDSZQHPUZUHC-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- ODJQKYXPKWQWNK-UHFFFAOYSA-N 3,3'-Thiobispropanoic acid Chemical compound OC(=O)CCSCCC(O)=O ODJQKYXPKWQWNK-UHFFFAOYSA-N 0.000 description 1
- NYPYPOZNGOXYSU-UHFFFAOYSA-N 3-bromopyridine Chemical compound BrC1=CC=CN=C1 NYPYPOZNGOXYSU-UHFFFAOYSA-N 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 239000005725 8-Hydroxyquinoline Substances 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 241000589291 Acinetobacter Species 0.000 description 1
- 241000588626 Acinetobacter baumannii Species 0.000 description 1
- 206010056508 Acquired epidermolysis bullosa Diseases 0.000 description 1
- 241000186041 Actinomyces israelii Species 0.000 description 1
- 241000701242 Adenoviridae Species 0.000 description 1
- 208000000230 African Trypanosomiasis Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 1
- 241001545522 Aguacate virus Species 0.000 description 1
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical class NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000191412 Alternaria infectoria Species 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000004881 Amebiasis Diseases 0.000 description 1
- 208000003829 American Hemorrhagic Fever Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010001980 Amoebiasis Diseases 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 241000712892 Arenaviridae Species 0.000 description 1
- 201000009695 Argentine hemorrhagic fever Diseases 0.000 description 1
- 201000002909 Aspergillosis Diseases 0.000 description 1
- 241000228197 Aspergillus flavus Species 0.000 description 1
- 208000036641 Aspergillus infections Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 208000011068 Bazex syndrome Diseases 0.000 description 1
- 208000034068 Bazex-Dupré-Christol syndrome Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- 241000335423 Blastomyces Species 0.000 description 1
- 241000228405 Blastomyces dermatitidis Species 0.000 description 1
- 206010005913 Body tinea Diseases 0.000 description 1
- 208000034200 Bolivian hemorrhagic fever Diseases 0.000 description 1
- 241000589567 Brucella abortus Species 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 244000197813 Camelina sativa Species 0.000 description 1
- 241000589874 Campylobacter fetus Species 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 241000222178 Candida tropicalis Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 208000024699 Chagas disease Diseases 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- BHYOQNUELFTYRT-UHFFFAOYSA-N Cholesterol sulfate Natural products C1C=C2CC(OS(O)(=O)=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 BHYOQNUELFTYRT-UHFFFAOYSA-N 0.000 description 1
- 206010008761 Choriomeningitis lymphocytic Diseases 0.000 description 1
- 206010008803 Chromoblastomycosis Diseases 0.000 description 1
- 208000015116 Chromomycosis Diseases 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 241000223205 Coccidioides immitis Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 208000000307 Crimean Hemorrhagic Fever Diseases 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- 208000008953 Cryptosporidiosis Diseases 0.000 description 1
- 206010011502 Cryptosporidiosis infection Diseases 0.000 description 1
- 241000223936 Cryptosporidium parvum Species 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-araboascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 1
- 208000002506 Darier Disease Diseases 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- GHKOFFNLGXMVNJ-UHFFFAOYSA-N Didodecyl thiobispropanoate Chemical compound CCCCCCCCCCCCOC(=O)CCSCCC(=O)OCCCCCCCCCCCC GHKOFFNLGXMVNJ-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 239000003508 Dilauryl thiodipropionate Substances 0.000 description 1
- 241001466953 Echovirus Species 0.000 description 1
- 241000224432 Entamoeba histolytica Species 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 206010015146 Erysipeloid Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- FPVVYTCTZKCSOJ-UHFFFAOYSA-N Ethylene glycol distearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCCCCCCCC FPVVYTCTZKCSOJ-UHFFFAOYSA-N 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- OLLIUVRBWLLOJZ-UHFFFAOYSA-N FC1=CC=C(C=C1)BC=COC=1C=CC=C2C=CC=NC12 Chemical compound FC1=CC=C(C=C1)BC=COC=1C=CC=C2C=CC=NC12 OLLIUVRBWLLOJZ-UHFFFAOYSA-N 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 241000589602 Francisella tularensis Species 0.000 description 1
- 208000014260 Fungal keratitis Diseases 0.000 description 1
- 241000223218 Fusarium Species 0.000 description 1
- 241000427940 Fusarium solani Species 0.000 description 1
- 241001427367 Gardena Species 0.000 description 1
- 241000224467 Giardia intestinalis Species 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 241000147041 Guaiacum officinale Species 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000700739 Hepadnaviridae Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 241000700586 Herpesviridae Species 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- 241000701027 Human herpesvirus 6 Species 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 240000007597 Hymenaea verrucosa Species 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000002078 Ingrown Nails Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 206010023369 Keratosis follicular Diseases 0.000 description 1
- 206010054999 Koilonychia Diseases 0.000 description 1
- 235000000072 L-ascorbyl-6-palmitate Nutrition 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 208000004204 Larva Migrans Diseases 0.000 description 1
- 206010023927 Lassa fever Diseases 0.000 description 1
- 241000589242 Legionella pneumophila Species 0.000 description 1
- 241000222738 Leishmania aethiopica Species 0.000 description 1
- 241000222724 Leishmania amazonensis Species 0.000 description 1
- 241000222727 Leishmania donovani Species 0.000 description 1
- 241000222697 Leishmania infantum Species 0.000 description 1
- 241000012072 Leishmania mexicana venezuelensis Species 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010066945 Lichen striatus Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 241000711828 Lyssavirus Species 0.000 description 1
- 241000555676 Malassezia Species 0.000 description 1
- 241001291474 Malassezia globosa Species 0.000 description 1
- 241001291477 Malassezia restricta Species 0.000 description 1
- 241001291475 Malassezia slooffiae Species 0.000 description 1
- 241001291478 Malassezia sympodialis Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical class SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 241001480000 Microsporum audouinii Species 0.000 description 1
- 241000893980 Microsporum canis Species 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000041810 Mycetoma Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 206010028698 Nail dystrophy Diseases 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 239000006057 Non-nutritive feed additive Substances 0.000 description 1
- 241000714209 Norwalk virus Species 0.000 description 1
- 244000020186 Nymphaea lutea Species 0.000 description 1
- FSZKLYCUEQGCKW-UHFFFAOYSA-N O=C(N=C=O)Oc1ccccc1 Chemical compound O=C(N=C=O)Oc1ccccc1 FSZKLYCUEQGCKW-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010048886 Onychoclasis Diseases 0.000 description 1
- 208000006187 Onycholysis Diseases 0.000 description 1
- 241000702259 Orbivirus Species 0.000 description 1
- 241000150452 Orthohantavirus Species 0.000 description 1
- 241000700629 Orthopoxvirus Species 0.000 description 1
- 206010033767 Paracoccidioides infections Diseases 0.000 description 1
- 201000000301 Paracoccidioidomycosis Diseases 0.000 description 1
- 208000005775 Parakeratosis Diseases 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 206010034016 Paronychia Diseases 0.000 description 1
- 241000029132 Paronychia Species 0.000 description 1
- 241000701945 Parvoviridae Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 208000031956 Phaehyphomycosis Diseases 0.000 description 1
- 201000011404 Phaeohyphomycosis Diseases 0.000 description 1
- 241000222831 Phialophora <Chaetothyriales> Species 0.000 description 1
- 201000000239 Phlebotomus fever Diseases 0.000 description 1
- 241000713137 Phlebovirus Species 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 240000009188 Phyllostachys vivax Species 0.000 description 1
- 241000235645 Pichia kudriavzevii Species 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 241000224017 Plasmodium berghei Species 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 241000223821 Plasmodium malariae Species 0.000 description 1
- 206010035501 Plasmodium malariae infection Diseases 0.000 description 1
- 206010035502 Plasmodium ovale infection Diseases 0.000 description 1
- 241000233872 Pneumocystis carinii Species 0.000 description 1
- 241000711902 Pneumovirus Species 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010037575 Pustular psoriasis Diseases 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 241000702263 Reovirus sp. Species 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 208000004364 Rhinosporidiosis Diseases 0.000 description 1
- 241000235527 Rhizopus Species 0.000 description 1
- 241000606697 Rickettsia prowazekii Species 0.000 description 1
- 241000606695 Rickettsia rickettsii Species 0.000 description 1
- 208000000705 Rift Valley Fever Diseases 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 241000315672 SARS coronavirus Species 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 241000132889 Scedosporium Species 0.000 description 1
- 241000223255 Scytalidium Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 241000713311 Simian immunodeficiency virus Species 0.000 description 1
- 244000044822 Simmondsia californica Species 0.000 description 1
- 235000004433 Simmondsia californica Nutrition 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193985 Streptococcus agalactiae Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 description 1
- WPMWEFXCIYCJSA-UHFFFAOYSA-N Tetraethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCO WPMWEFXCIYCJSA-UHFFFAOYSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 239000003490 Thiodipropionic acid Substances 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 208000007712 Tinea Versicolor Diseases 0.000 description 1
- 206010043866 Tinea capitis Diseases 0.000 description 1
- 201000010618 Tinea cruris Diseases 0.000 description 1
- 206010049591 Tinea imbricata Diseases 0.000 description 1
- 206010043871 Tinea nigra Diseases 0.000 description 1
- 206010056131 Tinea versicolour Diseases 0.000 description 1
- 241000710924 Togaviridae Species 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- 241000224527 Trichomonas vaginalis Species 0.000 description 1
- 241000893963 Trichophyton concentricum Species 0.000 description 1
- 241001480046 Trichophyton schoenleinii Species 0.000 description 1
- 241000985906 Trichophyton soudanense Species 0.000 description 1
- 241001480050 Trichophyton violaceum Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 241001442399 Trypanosoma brucei gambiense Species 0.000 description 1
- 241001442397 Trypanosoma brucei rhodesiense Species 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 208000034784 Tularaemia Diseases 0.000 description 1
- 208000001924 Tungiasis Diseases 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 241001661641 Verrucosa Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 241000607272 Vibrio parahaemolyticus Species 0.000 description 1
- 206010047505 Visceral leishmaniasis Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 239000004164 Wax ester Substances 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 206010061418 Zygomycosis Diseases 0.000 description 1
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 1
- WYWZRNAHINYAEF-AWEZNQCLSA-N [(2s)-2-ethylhexyl] 4-(dimethylamino)benzoate Chemical compound CCCC[C@H](CC)COC(=O)C1=CC=C(N(C)C)C=C1 WYWZRNAHINYAEF-AWEZNQCLSA-N 0.000 description 1
- WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
- OCRUMFQGIMSFJR-FSAWCSQFSA-N [(2s,3s,4r,5r)-4-hydroxy-5-(hydroxymethyl)-3-[(z)-octadec-9-enoyl]oxy-2-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl (z)-octadec-9-enoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCC\C=C/CCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC OCRUMFQGIMSFJR-FSAWCSQFSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XGKPLOKHSA-N [2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XGKPLOKHSA-N 0.000 description 1
- 241000222126 [Candida] glabrata Species 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- RRUDCFGSUDOHDG-UHFFFAOYSA-N acetohydroxamic acid Chemical compound CC(O)=NO RRUDCFGSUDOHDG-UHFFFAOYSA-N 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 108700010877 adenoviridae proteins Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000005237 alkyleneamino group Chemical group 0.000 description 1
- 125000005530 alkylenedioxy group Chemical group 0.000 description 1
- 125000005529 alkyleneoxy group Chemical group 0.000 description 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 229940031955 anhydrous lanolin Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000002827 antifungal susceptibility testing Methods 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960003872 benzethonium Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 150000001277 beta hydroxy acids Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 229940036350 bisabolol Drugs 0.000 description 1
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 125000005620 boronic acid group Chemical group 0.000 description 1
- 238000002815 broth microdilution Methods 0.000 description 1
- 229940056450 brucella abortus Drugs 0.000 description 1
- 208000000594 bullous pemphigoid Diseases 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 229960002962 butenafine Drugs 0.000 description 1
- ABJKWBDEJIDSJZ-UHFFFAOYSA-N butenafine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)CC1=CC=C(C(C)(C)C)C=C1 ABJKWBDEJIDSJZ-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000010376 calcium ascorbate Nutrition 0.000 description 1
- 239000011692 calcium ascorbate Substances 0.000 description 1
- 229940047036 calcium ascorbate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 description 1
- 208000032343 candida glabrata infection Diseases 0.000 description 1
- 229940055022 candida parapsilosis Drugs 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000001913 cellulose Chemical class 0.000 description 1
- 229920002678 cellulose Chemical class 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 229930183167 cerebroside Natural products 0.000 description 1
- RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- BHYOQNUELFTYRT-DPAQBDIFSA-N cholesterol sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 BHYOQNUELFTYRT-DPAQBDIFSA-N 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 239000011280 coal tar Substances 0.000 description 1
- 201000003486 coccidioidomycosis Diseases 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229960000860 dapsone Drugs 0.000 description 1
- DIOQZVSQGTUSAI-NJFSPNSNSA-N decane Chemical compound CCCCCCCCC[14CH3] DIOQZVSQGTUSAI-NJFSPNSNSA-N 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- JQKJEPJLCSCBGW-UHFFFAOYSA-N dibutoxy(ethenyl)borane Chemical compound CCCCOB(C=C)OCCCC JQKJEPJLCSCBGW-UHFFFAOYSA-N 0.000 description 1
- 235000019304 dilauryl thiodipropionate Nutrition 0.000 description 1
- SIYLLGKDQZGJHK-UHFFFAOYSA-N dimethyl-(phenylmethyl)-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethyl]ammonium Chemical compound C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 SIYLLGKDQZGJHK-UHFFFAOYSA-N 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229960003913 econazole Drugs 0.000 description 1
- 229940007078 entamoeba histolytica Drugs 0.000 description 1
- 229940032049 enterococcus faecalis Drugs 0.000 description 1
- 201000011114 epidermolysis bullosa acquisita Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 235000010350 erythorbic acid Nutrition 0.000 description 1
- 239000004318 erythorbic acid Substances 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 208000011323 eye infectious disease Diseases 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000004905 finger nail Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- PTCGDEVVHUXTMP-UHFFFAOYSA-N flutolanil Chemical compound CC(C)OC1=CC=CC(NC(=O)C=2C(=CC=CC=2)C(F)(F)F)=C1 PTCGDEVVHUXTMP-UHFFFAOYSA-N 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229940118764 francisella tularensis Drugs 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 201000006592 giardiasis Diseases 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 229940091561 guaiac Drugs 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 201000005473 herpetic whitlow Diseases 0.000 description 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 1
- 208000029080 human African trypanosomiasis Diseases 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- ZCYVEMRRCGMTRW-YPZZEJLDSA-N iodine-125 Chemical compound [125I] ZCYVEMRRCGMTRW-YPZZEJLDSA-N 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 229940026239 isoascorbic acid Drugs 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 201000004607 keratosis follicularis Diseases 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940115932 legionella pneumophila Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 201000006506 lobomycosis Diseases 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 208000001419 lymphocytic choriomeningitis Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940067190 mentholatum Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000006682 monohaloalkyl group Chemical group 0.000 description 1
- 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 201000000626 mucocutaneous leishmaniasis Diseases 0.000 description 1
- 201000007524 mucormycosis Diseases 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- DIOQZVSQGTUSAI-UHFFFAOYSA-N n-butylhexane Natural products CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- RIWRFSMVIUAEBX-UHFFFAOYSA-N n-methyl-1-phenylmethanamine Chemical compound CNCC1=CC=CC=C1 RIWRFSMVIUAEBX-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960004313 naftifine Drugs 0.000 description 1
- OZGNYLLQHRPOBR-DHZHZOJOSA-N naftifine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)C\C=C\C1=CC=CC=C1 OZGNYLLQHRPOBR-DHZHZOJOSA-N 0.000 description 1
- 208000026721 nail disease Diseases 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 201000009838 otomycosis Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229960003540 oxyquinoline Drugs 0.000 description 1
- 229960002638 padimate o Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000003209 petroleum derivative Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical class OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 208000005814 piedra Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 206010035116 pityriasis rubra pilaris Diseases 0.000 description 1
- 201000000508 pityriasis versicolor Diseases 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 125000006684 polyhaloalkyl group Polymers 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229940093625 propylene glycol monostearate Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000007430 reference method Methods 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 229940046939 rickettsia prowazekii Drugs 0.000 description 1
- 229940075118 rickettsia rickettsii Drugs 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- VIDTVPHHDGRGAF-UHFFFAOYSA-N selenium sulfide Chemical compound [Se]=S VIDTVPHHDGRGAF-UHFFFAOYSA-N 0.000 description 1
- 229960005265 selenium sulfide Drugs 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 201000002612 sleeping sickness Diseases 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 1
- 239000001570 sorbitan monopalmitate Substances 0.000 description 1
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 235000011078 sorbitan tristearate Nutrition 0.000 description 1
- 239000001589 sorbitan tristearate Substances 0.000 description 1
- 229960004129 sorbitan tristearate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- OGGVRVMISBQNMQ-MDGIRFSOSA-N sordarin Chemical compound O[C@H]1[C@H](O)[C@H](OC)[C@@H](C)O[C@H]1OC[C@]1([C@@]2(C(C(C)C)=C3)C(O)=O)[C@H]3C[C@]2(C=O)[C@@H]2CC[C@@H](C)[C@H]2C1 OGGVRVMISBQNMQ-MDGIRFSOSA-N 0.000 description 1
- OGGVRVMISBQNMQ-UHFFFAOYSA-N sordarin Natural products OC1C(O)C(OC)C(C)OC1OCC1(C2(C(C(C)C)=C3)C(O)=O)C3CC2(C=O)C2CCC(C)C2C1 OGGVRVMISBQNMQ-UHFFFAOYSA-N 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940098760 steareth-2 Drugs 0.000 description 1
- 229940100458 steareth-21 Drugs 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229960002607 sulconazole Drugs 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 201000009862 superficial mycosis Diseases 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000037946 swimming pool granuloma Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000004250 tert-Butylhydroquinone Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 235000019281 tert-butylhydroquinone Nutrition 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- XAGUNWDMROKIFJ-UHFFFAOYSA-J tetrapotassium;2-[2-[[8-[bis(carboxylatomethyl)amino]-6-methoxyquinolin-2-yl]methoxy]-n-(carboxylatomethyl)-4-methylanilino]acetate Chemical compound [K+].[K+].[K+].[K+].C1=CC2=CC(OC)=CC(N(CC([O-])=O)CC([O-])=O)=C2N=C1COC1=CC(C)=CC=C1N(CC([O-])=O)CC([O-])=O XAGUNWDMROKIFJ-UHFFFAOYSA-J 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 235000019303 thiodipropionic acid Nutrition 0.000 description 1
- 201000009642 tinea barbae Diseases 0.000 description 1
- 201000003875 tinea corporis Diseases 0.000 description 1
- 208000009189 tinea favosa Diseases 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 201000002311 trypanosomiasis Diseases 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 125000004417 unsaturated alkyl group Chemical group 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 235000019386 wax ester Nutrition 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229960001296 zinc oxide Drugs 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
Definitions
- the invention provides a compound described herein.
- the compound is a salt of a compound of the invention.
- the compound is a pharmaceutically acceptable salt of a compound of the invention.
- the compound has a structure according to the following formula:
- Y is a member selected from substituted or unsubstituted vinyl and substituted or unsubstituted aryl.
- Z, R ⁇ R , R c and R are members independently selected from members independently selected from H, OR*, NR*R**, SR*, -S(O)R*.
- R b and R c together with the atoms to which they are attached, are optionally joined to form a 4- to 8-membered ring.
- R d and R e together with the atoms to which they are attached, are optionally joined to form a 4- to 8-membered ring.
- Y and Z together with the atoms to which they are attached, are optionally joined to form a member selected from a 4- to 8- membered ring and a 6- to 12-membered bicyclic ring.
- Each R* and R** are members independently selected from H, nitro, halogen, cyano, substituted or unsubstituted aikyi, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyi, substituted or unsubstituted heterocycloaikyi, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
- said compound has a structure which is a member selected from:
- said compound has a structure according to the following formula:
- said Z is substituted or unsubstituted vinyl.
- said compound is a member selected from
- said compound is a member selected from
- said compound is a member selected from
- said compound is a member selected from
- said Z is substituted or unsubstituted alkyl, and wherein said substituted or unsubstituted alkyl is substituted or unsubstituted alkenyl.
- said Z is substituted or unsubstituted vinyl.
- said Z is substituted or unsubstituted aryl.
- said Z is substituted aryl, and has a structure according to the following formula:
- R is a member selected from H, nitro, halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl. substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
- said R 1 is a member selected from nitro, halogen, cyano and substituted or unsubstituted alkyl.
- said R 1 is a member selected from fluorine, chlorine and bromine.
- said Z is F . In an exemplary embodiment, said
- said compound is F XJT H 2 N- .
- said Z is substituted or unsubstituted heteroaryl, In an exemplary embodiment, said Z is a member selected from substituted or unsubstituted 2-pyridinyl, substituted or unsubstituted 3-pyridinyl and substituted or unsubstituted 4-pyridinyI. In an exemplary embodiment, said Z is substituted or unsubstituted 3-pyridinyl. In an exemplary embodiment, said compound is
- R b and R c together with the atoms to which they are attached, are joined to form a substituted or unsubstituted 4- to 6-membered
- said compound i tsc In an exemplary embodiment, said compound is a member selected from
- said compound is a member selected from
- said compound is a member selected from
- said compound is a member selected from exemplary embodiment, Y and Z, together with the atoms to which they are attached, are joined to form a member selected from a 4- to 8- membered ring and a 6- to 12-membered bicyclic ring.
- Y and Z, together with the atoms to which they are attached, are joined to form an 8-membered bicyclic ring.
- wherein said 8-membered bicyclic ring is unsubstituted.
- the compound has a structure which is a
- the compound has a structure which is a member selected from an j.
- the compound has a structure which is a member selected from and In an exemplary embodiment, the compound has a structure which is a member selected from
- the invention provides a method of inhibiting the growth of, or killing, a fungus, said method comprising: contacting said fungus with a compound of the invention, in an amount sufficient to inhibit or kill said fungus.
- the compound is a salt of a compound of the invention.
- the compound is a pharmaceutically acceptable salt of a compound of the invention.
- said fungus is a member selected from a dermatophyte, Trichophyton species, Microsporium species, Candida species, Aspergillus species and yeast-like fungus.
- the compound is described above.
- said fungus is a member selected from Candida albicans, Candida neoformans, Aspergillus fumigatus, Trichophyton mentagrophytes (T. mentagrophytes) and Trichophyton rubrum (T. rubrum).
- there is a proviso that the molecular weight of said compound is not greater than about 200.
- there is a proviso that the c log P of said compound is between about -2 and about 2.
- there is a proviso that the efficacy coefficient of said compound is greater than about 10.
- the compound has a structure described in section HA '"Boron- Containing Compounds * '.
- the compound has a structure described from paragraph 58 to paragraph 79. In an exemplary embodiment, the compound has a structure described from paragraph 58 to paragraph 72. In an exemplary embodiment, the compound has a structure described in section HB ''Acyclic Boronic Acids". In an exemplary embodiment, the compound has a structure described from paragraph 80 to paragraph 83, In an exemplary embodiment, the compound has a structure described in paragraph 80. In an exemplary embodiment, the compound has a structure described in section OC ''Low MW Pyridone/Pyrithione derivatives". In an exemplary embodiment, the compound has a structure described from paragraph 84 to paragraph 87. In an exemplary embodiment, the compound has a structure described in paragraph 84.
- the compound has a structure described in section HD "Low MW fungicide moiety F. In an exemplary embodiment, the compound has a structure described from paragraph 88 to paragraph 91. In an exemplary embodiment, the compound has a structure described in paragraph 88. In an exemplary embodiment, the compound has a structure described in section HE "Low MW fungicide moiety II". In an exemplary embodiment, the compound has a structure described from paragraph 92 to paragraph 95. In an exemplary embodiment, the compound has a structure described in paragraph 92. In an exemplary embodiment, the compound has a structure described in section HF "Low MW fungicide moiety III”. In an exemplary embodiment, the compound has a structure described from paragraph 96 to paragraph 115.
- the compound has a structure described in paragraph 96. In an exemplary embodiment, the compound has a structure described in section HG "Commercial Fungicides * '. In an exemplary embodiment, the compound has a structure described from paragraph 116 to paragraph 1 17. In an exemplary embodiment, the compound has a structure described in paragraph 1 16.
- the invention provides a method of treating a disease in a subject, said method comprising administering to said subject a therapeutically effective amount of a compound, thereby treating said disease.
- the disease is an ungual, periungual or subungual infection
- the compound is described herein.
- the compound is a salt of a compound of the invention.
- the compound is a pharmaceutically acceptable salt of a compound of the invention.
- the compound is described above.
- the disease is caused by, or involves a fungus is a member selected from Candida albicans, Candida neoformans, Aspergillus fumigatus, Trichophyton mentagrophytes ⁇ T. mentagrophytes) and Trichophyton rubrum (T. rubrum).
- said disease is onychomycosis.
- there is a proviso that the molecular weight of said compound is not greater than about 200.
- there is a proviso that the c log P of said compound is between about -2 and about 2.
- there is a proviso that the efficacy coefficient of said compound is greater than about 10.
- the compound has a structure described in section HA '"Boron-Containing Compounds".
- the compound has a structure described from paragraph 58 to paragraph 79.
- the compound has a structure described from paragraph 58 to paragraph 72.
- the compound has a structure described in section OB "Acyclic Boronic Acids”.
- the compound has a structure described from paragraph 80 to paragraph 83.
- the compound has a structure described in paragraph 80.
- the compound has a structure described in section HC "Low MW Pyridone/Pyrithione derivatives".
- the compound has a structure described from paragraph 84 to paragraph 87. In an exemplary embodiment, the compound has a structure described in paragraph 84. In an exemplary embodiment, the compound has a structure described in section HD "Low MW fungicide moiety F'. In an exemplary embodiment, the compound has a structure described from paragraph 88 to paragraph 91. In an exemplary embodiment, the compound has a structure described in paragraph 88. In an exemplary embodiment, the compound has a structure described in section HE "Low MW fungicide moiety II". In an exemplary embodiment, the compound has a structure described from paragraph 92 to paragraph 95. In an exemplary embodiment, the compound has a structure described in paragraph 92.
- the compound has a structure described in section HF "Low MW fungicide moiety III". In an exemplary embodiment, the compound has a structure described from paragraph 96 to paragraph 1 15. In an exemplary embodiment, the compound has a structure described in paragraph 96. In an exemplary embodiment, the compound has a structure described in section HG "Commercial Fungicides”. In an exemplary embodiment, the compound has a structure described from paragraph 116 to paragraph 117. In an exemplary embodiment, the compound has a structure described in paragraph 1 16.
- the invention provides a pharmaceutical formulation comprising: a) a pharmaceutically acceptable excipient; and b) a compound of the invention.
- the compound is described above.
- the compound is a salt of a compound of the invention.
- the compound is a pharmaceutically acceptable salt of a compound of the invention,
- there is the proviso that the molecular weight of said compound is not greater than about 200.
- there is the proviso that the c log P of said compound is between about -2 and about 2.
- there is the proviso that the efficacy coefficient of said compound is greater than about 10.
- the compound has a structure described in section HA '"Boron-Containing Compounds " '.
- the compound has a structure described from paragraph 58 to paragraph 79.
- the compound has a structure described from paragraph 58 to paragraph 72.
- the compound has a structure described in section HB "Acyclic Boronic Acids' * .
- the compound has a structure described from paragraph 80 to paragraph 83.
- the compound has a structure described in paragraph 80.
- the compound has a structure described in section HC "Low MW Pyridone/Pyrithione derivatives".
- the compound has a structure described from paragraph 84 to paragraph 87. In an exemplary embodiment, the compound has a structure described in paragraph 84. In an exemplary embodiment, the compound has a structure described in section HD "Low MW fungicide moiety I". In an exemplary embodiment, the compound has a structure described from paragraph 88 Io paragraph 91. In an exemplary embodiment, the compound has a structure described in paragraph 88. In an exemplary embodiment, the compound has a structure described in section HE "Low MW fungicide moiety II”. In an exemplary embodiment, the compound has a structure described from paragraph 92 to paragraph 95. In an exemplary embodiment, the compound has a structure described in paragraph 92.
- the compound has a structure described in section HF '"Low MW fungicide moiety III". In an exemplary embodiment, the compound has a structure described from paragraph 96 to paragraph 115. In an exemplary embodiment, the compound has a structure described in paragraph 96. In an exemplary embodiment, the compound has a structure described in section HG "Commercial Fungicides”. In an exemplary embodiment, the compound has a structure described from paragraph 116 to paragraph 117, In an exemplary embodiment, the compound has a structure described in paragraph 1 16.
- the invention provides a formulation comprising: (a) a keratin containing component which is a member selected from a human nail unit, skin and hair; (b) a compound having a structure described herein.
- the compound has a structure described above.
- the compound is a salt of a compound of the invention.
- the compound is a pharmaceutically acceptable salt of a compound of the invention.
- the compound has a structure described in section HA "Boron-Containing Compounds".
- the compound has a structure described from paragraph 58 to paragraph 79.
- the compound has a structure described from paragraph 58 to paragraph 72, In an exemplary embodiment, the compound has a structure described in section IIB "Acyclic Boronic Acids". In an exemplary embodiment, the compound has a structure described from paragraph 80 to paragraph 83, In an exemplary embodiment, the compound has a structure described in paragraph 80. In an exemplary embodiment, the compound has a structure described in section HC "Low MW Pyridone/Pyrithione derivatives". In an exemplary embodiment, the compound has a structure described from paragraph 84 to paragraph 87. In an exemplary embodiment, the compound has a structure described in paragraph 84. In an exemplary embodiment, the compound has a structure described in section IID "Low MW fungicide moiety I".
- the compound has a structure described from paragraph 88 to paragraph 91. In an exemplary embodiment, the compound has a structure described in paragraph 88. In an exemplary embodiment, the compound has a structure described in section HE "Low MW fungicide moiety II " '. In an exemplary embodiment, the compound has a structure described from paragraph 92 to paragraph 95, In an exemplary embodiment, the compound has a structure described in paragraph 92. In an exemplary embodiment. the compound has a structure described in section HF "'Low MW fungicide moiety III”. In an exemplary embodiment, the compound has a structure described from paragraph 96 to paragraph 1 15. In an exemplary embodiment, the compound has a structure described in paragraph 96.
- the compound has a structure described in section HG "'Commercial Fungicides''. In an exemplary embodiment, the compound has a structure described from paragraph 1 16 to paragraph 117. In an exemplary embodiment, the compound has a structure described in paragraph 116.
- the invention provides a method of inhibiting the growth of, or killing, a microorganism present in a human nail unit, wherein said human nail unit comprises a nail plate, comprising: contacting a dorsal layer of the nail plate with a compound capable of penetrating the nail plate, traveling through the nail plate to a nail bed underlying said nail plate, and contacting said microorganism, under conditions sufficient for said compound to penetrate said nail plate, wherein said compound has a structure described herein.
- the compound has a structure described above.
- the compound is a salt of a compound of the invention.
- the compound is a pharmaceutically acceptable salt of a compound of the invention.
- said microorganism is a member selected from a bacteria, a fungus, a virus, a parasite, and a yeast.
- said microorganism is a fungus, and said fungus is a member selected from a dermatophyte, Trichophyton species.
- said fungus is a member selected from Candida albicans, Candida neoformans, Aspergillus fumigatus. Trichophyton mentagrophytes (T. mentagrophyles) and Trichophyton rubrwn (T rubruni).
- the compound has a structure described in section HA "Boron-Containing Compounds", In an exemplary embodiment, the compound has a structure described from paragraph 58 to paragraph 79. In an exemplary embodiment, the compound has a structure described from paragraph 58 to paragraph 72. In an exemplary embodiment, the compound has a structure described in section HB "Acyclic Boronic Acids".
- the compound has a structure described from paragraph 80 to paragraph 83. In an exemplary embodiment, the compound has a structure described in paragraph 80. In an exemplary embodiment, the compound has a structure described in section OC "Low MW Pyridone/Pyrithione derivatives". In an exemplary embodiment, the compound has a structure described from paragraph 84 to paragraph 87. In an exemplary embodiment, the compound has a structure described in paragraph 84. In an exemplary embodiment, the compound has a structure described in section IID "Low MW fungicide moiety I”. In an exemplary embodiment, the compound has a structure described from paragraph 88 to paragraph 91. In an exemplary embodiment, the compound has a structure described in paragraph 88.
- the compound has a structure described in section OE "Low MW fungicide moiety II " '. In an exemplary embodiment, the compound has a structure described from paragraph 92 to paragraph 95. In an exemplary embodiment, the compound has a structure described in paragraph 92. In an exemplary embodiment, the compound has a structure described in section IfF "Low MW fungicide moiety IH' ' . In an exemplary embodiment, the compound has a structure described from paragraph 96 to paragraph 1 15. In an exemplary embodiment, the compound has a structure described in paragraph 96. In an exemplary embodiment, the compound has a structure described in section HG "Commercial Fungicides". In an exemplary embodiment, the compound has a structure described from paragraph 116 to paragraph 1 17. In an exemplary embodiment, the compound has a structure described in paragraph 1 16.
- the invention provides a method of inhibiting the growth of, or killing, a fungus, said method comprising: contacting said fungus with a compound in an amount sufficient to inhibit or kill said fungus, wherein said fungus is a member selected from a dermatophyte, Trichophyton species, Microsporhtm species, Candida species, Aspergillus species and yeast-like fungus.
- the compound is described herein.
- the compound is a salt of a compound of the invention.
- the compound is a pharmaceutically acceptable salt of a compound of the invention.
- the compound is provided above.
- the compound has a structure described in section ⁇ IA "Boron-Containing Compounds". In an exemplary embodiment, the compound has a structure described from paragraph 58 to paragraph 79. In an exemplary embodiment, the compound has a structure described from paragraph 58 to paragraph 72. In an exemplary embodiment, the compound has a structure described in section HB "Acyclic Boronic Acids". In an exemplary embodiment, the compound has a structure described from paragraph 80 to paragraph 83. In an exemplary embodiment, the compound has a structure described in paragraph 80. In an exemplary embodiment, the compound has a structure described in section HC "Low MW Pyridone/Pyrithione derivatives".
- the compound has a structure described from paragraph 84 to paragraph 87. In an exemplary embodiment, the compound has a structure described in paragraph 84. In an exemplary embodiment, the compound has a structure described in section HD "Low MW fungicide moiety I' ⁇ In an exemplary embodiment, the compound has a structure described from paragraph 88 to paragraph 91. In an exemplary embodiment, the compound has a structure described in paragraph 88. In an exemplary embodiment, the compound has a structure described in section HE ''Low MW fungicide moiety II". In an exemplary embodiment, the compound has a structure described from paragraph 92 to paragraph 95.
- the compound has a structure described in paragraph 92, In an exemplary embodiment, the compound has a structure described in section IIP ''Low MW fungicide moiety HI", In an exemplary embodiment, the compound has a structure described from paragraph 96 to paragraph 1 15. In an exemplary embodiment, the compound has a structure described in paragraph 96. In an exemplary embodiment, the compound has a structure described in section HG "Commercial Fungicides”. In an exemplary embodiment, the compound has a structure described from paragraph 1 16 to paragraph 1 17. In an exemplary embodiment, the compound has a structure described in paragraph 1 16.
- the invention provides a method of treating a disease in a subject, said method comprising administering to said subject a therapeutically effective amount of a compound, thereby treating said disease; wherein said disease is an ungual. periungual or subungual infection.
- the compound is described herein.
- the compound is a salt of a compound of the invention.
- the compound is a pharmaceutically acceptable salt of a compound of the invention.
- the compound is provided above.
- the compound has a structure described in section HA "Boron- Containing Compounds".
- the compound has a structure described from paragraph 58 to paragraph 79.
- the compound has a structure described from paragraph 58 to paragraph 72. In an exemplary embodiment, the compound has a structure described in section HB "Acyclic Boronic Acids". In an exemplary embodiment, the compound has a structure described from paragraph 80 to paragraph 83. 3n an exemplary embodiment, the compound has a structure described in paragraph 80. In an exemplary embodiment, the compound has a structure described in section HC "Low MW Pyridone/Pyrithione derivatives". In an exemplary embodiment, the compound has a structure described from paragraph 84 to paragraph 87. In an exemplary embodiment, the compound has a structure described in paragraph 84. In an exemplary embodiment, the compound has a structure described in section HD '"Low MW fungicide moiety I".
- the compound has a structure described from paragraph 88 to paragraph 91. In an exemplary embodiment, the compound has a structure described in paragraph 88. In an exemplary embodiment, the compound has a structure described in section HE "Low MW fungicide moiety II". In an exemplary embodiment, the compound has a structure described from paragraph 92 to paragraph 95. In an exemplary embodiment, the compound has a structure described in paragraph 92. In an exemplary embodiment, the compound has a structure described in section HF "Low MW fungicide moiety III " . In an exemplary embodiment, the compound has a structure described from paragraph 96 to paragraph 1 15. In an exemplary embodiment, the compound has a structure described in paragraph 96.
- the compound has a structure described in section HG '"Commercial Fungicides". In an exemplary embodiment, the compound has a structure described from paragraph 116 to paragraph 1 17. In an exemplary embodiment, the compound has a structure described in paragraph 1 16.
- the invention provides a pharmaceutical formulation comprising: a) a pharmaceutically acceptable excipient; and b) a compound of the invention.
- the compound is a salt of a compound of the invention.
- the compound is a pharmaceutically acceptable salt of a compound of the invention.
- the compound has a structure described in section HA "Boron- Containing Compounds", In an exemplary embodiment, the compound has a structure described in section HA "Boron-Containing Compounds".
- the compound has a structure described from paragraph 58 to paragraph 79. In an exemplary embodiment, the compound has a structure described from paragraph 58 to paragraph 72.
- the compound has a structure described in section HB "Acyclic Boronic Acids". In an exemplary embodiment, the compound has a structure described from paragraph 80 to paragraph 83. In an exemplary embodiment, the compound has a structure described in paragraph 80. In an exemplary embodiment, the compound has a structure described in section HC "Low MW Pyridone/Pyrithione derivatives". In an exemplary embodiment, the compound has a structure described from paragraph 84 to paragraph 87. In an exemplary embodiment, the compound has a structure described in paragraph 84. In an exemplary embodiment, the compound has a structure described in section UD “Low MW fungicide moiety I”. In an exemplary embodiment, the compound has a structure described from paragraph 88 to paragraph 91.
- the compound has a structure described in paragraph 88. In an exemplary embodiment, the compound has a structure described in section HE "Low MW fungicide moiety II". In an exemplary embodiment, the compound has a structure described from paragraph 92 to paragraph 95, In an exemplary embodiment, the compound has a structure described in paragraph 92. In an exemplary embodiment, the compound has a structure described in section OF '"Low MW fungicide moiety III". In an exemplary embodiment, the compound has a structure described from paragraph 96 to paragraph 1 15. In an exemplary embodiment, the compound has a structure described in paragraph 96. In an exemplary embodiment, the compound has a structure described in section HG "Commercial Fungicides". In an exemplary embodiment, the compound has a structure described from paragraph 116 to paragraph 1 17. In an exemplary embodiment, the compound has a structure described in paragraph 1 16.
- the invention provides a formulation comprising: (a) a keratin containing component which is a member selected from a human nail unit, skin and hair; (b) a compound of the invention.
- the compound is a salt of a compound of the invention.
- the compound is a pharmaceutically acceptable salt of a compound of the invention.
- the compound has a structure described in section HA "Boron-Containing Compounds".
- the compound has a structure described from paragraph 58 to paragraph 79.
- the compound has a structure described from paragraph 58 to paragraph 72.
- the compound has a structure described in section HB "Acyclic Boronic Acids * '. In an exemplary embodiment, the compound has a structure described from paragraph 80 to paragraph 83. In an exemplary embodiment, the compound has a structure described in paragraph 80. In an exemplary embodiment, the compound has a structure described in section HC "Low MW Pyridone/Pyrithione derivatives". In an exemplary embodiment, the compound has a structure described from paragraph 84 to paragraph 87. In an exemplary embodiment, the compound has a structure described in paragraph 84. In an exemplary embodiment, the compound has a structure described in section HD "Low MW fungicide moiety I". In an exemplary embodiment, the compound has a structure described from paragraph 88 to paragraph 91.
- the compound has a structure described in paragraph 88. In an exemplary embodiment, the compound has a structure described in section HE "Low MW fungicide moiety II". In an exemplary embodiment, the compound has a structure described from paragraph 92 to paragraph 95. In an exemplar ⁇ ' embodiment, the compound has a structure described in paragraph 92. In an exemplary embodiment, the compound has a structure described in section HF '"Low MW fungicide moiety IH''. In an exemplary embodiment, the compound has a structure described from paragraph 96 to paragraph 1 15. In an exemplary embodiment, the compound has a structure described in paragraph 96. In an exemplary embodiment, the compound has a structure described in section HG "Commercial Fungicides". In an exemplary embodiment, the compound has a structure described from paragraph 1 16 to paragraph 117. In an exemplary embodiment, the compound has a structure described in paragraph 1 16.
- the invention provides a method of inhibiting the growth of, or killing, a microorganism present in a human nail unit, wherein said human nail unit comprises a nail plate, comprising: contacting a dorsal layer of the nail plate with a compound capable of penetrating the nail plate, traveling through the nail plate to a nail bed underlying said nail plate, and contacting said microorganism, under conditions sufficient for said compound to penetrate said nail plate.
- the compound is described herein.
- the compound is a salt of a compound of the invention.
- the compound is a pharmaceutical] y acceptable salt of a compound of the invention.
- the compound has a structure described in section HA "Boron-Containing Compounds". In an exemplary embodiment, the compound has a structure described from paragraph 58 to paragraph 79. In an exemplary embodiment, the compound has a structure described from paragraph 58 to paragraph 72. In an exemplary embodiment, the compound has a structure described in section HB "Acyclic Boronic Acids". In an exemplary embodiment, the compound has a structure described from paragraph 80 to paragraph 83. In an exemplary embodiment, the compound has a structure described in paragraph 80. In an exemplary embodiment, the compound has a structure described in section HC "Low MW Pyridone/Pyrithione derivatives".
- the compound has a structure described from paragraph 84 to paragraph 87. In an exemplary embodiment, the compound has a structure described in paragraph 84. In an exemplary embodiment, the compound has a structure described in section HD "Low MW fungicide moiety I". In an exemplary embodiment, the compound has a structure described from paragraph 88 to paragraph 91. In an exemplary embodiment, the compound has a structure described in paragraph 88, In an exemplary embodiment, the compound has a structure described in section HE "Low MW fungicide moiety II'". In an exemplary embodiment, the compound has a structure described from paragraph 92 to paragraph 95. In an exemplary embodiment, the compound has a structure described in paragraph 92.
- the compound has a structure described in section HF "Low MW fungicide moiety III". In an exemplary embodiment, the compound has a structure described from paragraph 96 to paragraph 115. In an exemplary embodiment, the compound has a structure described in paragraph 96. In an exemplary embodiment, the compound has a structure described in section HG "Commercial Fungicides”. In an exemplary embodiment, the compound has a structure described from paragraph 116 to paragraph 1 17. In an exemplary embodiment, the compound has a structure described in paragraph 116,
- FIG. 1 shows selected compounds of the invention and MlC data against various microorganisms.
- substituent groups are specified by their conventional chemical formulae, written from left to right, they equally encompass the chemically identical substituents, which would result from writing the structure from right to left, e.g., -CH 2 O- is intended to also recite -OCH 2 -.
- poly as used herein means at least 2.
- a polyvalent metal ion is a metal ion having a valency of at least 2,
- Moiety refers to the radical of a molecule that is attached to another moiety.
- alkyl by itself or as part of another substituent, means, unless otherwise stated, a straight or branched chain, or cyclic hydrocarbon radical, or combination thereof, which may be fully saturated, mono- or polyunsaturated and can include di- and multivalent radicals, having the number of carbon atoms designated (Le. C
- saturated hydrocarbon radicals include, but are not limited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl. sec-butyl, cyclohexyl, (cyclohexyl)methyl.
- An unsaturated aikyl group is one having one or more double bonds or triple bonds. Examples of unsaturated alkyl groups include, but are not limited to, vinyl, 2-propenyl, crotyl. 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3 -(1.4- pentadienyl), ethynyl, 1- and 3-propynyl, 3-butynyl, and the higher homoiogs and isomers.
- alkyl unless otherwise noted, is also meant to include those derivatives of alkyl defined in more detail below, such as "heteroaikyl.” Alkyi groups that are limited to hydrocarbon groups are termed "homoalkyl".
- alkyiene by itself or as part of another substituent means a divalent radical derived from an alkane, as exemplified, but not limited, by -CH 2 CH 2 CH 2 CH 2 -, and further includes those groups described below as “heteroalkylene.”
- an alkyi (or alkyiene) group will have from 1 to 24 carbon atoms, with those groups having 10 or fewer carbon atoms being preferred in the present invention.
- a “lower alkyl” or “lower alkyiene” is a shorter chain alkyi or alkyiene group, generally having eight or fewer carbon atoms.
- alkoxy alkylamino and “alkylthio” (or thioalkoxy) are used in their conventional sense, and refer to those alkyl groups attached to the remainder of the molecule via an oxygen atom, an amino group, or a sulfur atom, respectively.
- heteroalkyl by itself or in combination with another term, means, unless otherwise stated, a stable straight or branched chain, or cyclic hydrocarbon radical, or combinations thereof, consisting of the stated number of carbon atoms and at least one heteroatom.
- the heteroatoms can be selected from the group consisting of B, O, N and S. and wherein the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized.
- the heteroatom(s) B, O. N and S may be placed at any interior position of the heteroalkyl group or at the position at which the alkyl group is attached to the remainder of the molecule.
- Examples include, but are not limited to, -CH 2 -CH 2 -O-CH 3 , -CH 2 -CH 2 -NH-CH 3 , -CH 2 -CH 2 -N (CH 3 J-CH 3 , -CH 2 -S- CII 2 -CH 3 , -CH 2 -CH ⁇ -S(O)-CII 3 .
- -CH 2 -CH 2 -S(O) 2 -CH 3 -CH-CH-O-CH 3
- -CH 2 -CH N- OCH 3
- -CH CH-N(CH 3 )-CH 3 .
- heteroalkylene by itself or as part of another substituent means a divalent radical derived from heteroalkyl, as exemplified, but not limited by, -CH 2 -CH 2 -S-CH 2 -CH 2 - and -CH 2 -S-CH 2 -CH 2 -NH-CH 2 -.
- heteroatoms can also occupy either or both of the chain termini (e g , alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediarnino. and the like).
- cycloalkyl and ''heterocycloalkyl. by themselves or in combination with other terms, represent, unless otherwise stated, cyclic versions of “alkyl” and “heteroalkyl”, respectively. Additionally, for heterocycloalkyl, a heteroatom can occupy the position at which the heterocycle is attached to the remainder of the molecule. Examples of cycloalkyl include, but are not limited to, cyclopentyl, cyclohexyl, 1 -cyclohexenyl. 3- cyclohexeny], cycloheptyl, and the like.
- heterocycloalkyl examples include, but are not limited to, 1 ⁇ (l,2.5,6-tetrahydropyridyl), 1 -piperidinyl, 2-piperidinyl, 3-piperidinyl, 4- morpholinyl, 3-morpholinyl. tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, 1 -piperazinyl, 2-piperazinyl, and the like.
- * 'halo(Ci-C 4 )alkyr is mean to include, but not be limited to, trifluoromethyl, 2,2,2-trifluoroethyI, 4-chlorobutyl, 3-bromopropyl, and the like.
- aryl means, unless otherwise stated, a polyunsaturated, aromatic, substituent that can be a single ring or multiple rings (preferably from 1 to 3 rings), which are fused together or linked covalently.
- heteroaryl refers to aryl groups (or rings)
- heteroatom is selected from B, N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized.
- a heteroaryl group can be attached to the remainder of the molecule through a heteroatom.
- aryl and heteroaryl groups include phenyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl.
- the term "'aryl” when used in combination with other terms includes both aryl and heteroaryl rings as defined above.
- the term ''arylalkyl'' is meant to include those radicals in which an aryl group is attached to an alkyl group (e.g., benzyl, phenethyl, pyridylmethyl and the like) including those alky! groups in which a carbon atom (e.g., a methylene group) has been replaced by, for example, an oxygen atom (e.g., phenoxymethyl, 2-pyridyloxymethyl. 3-(l- naphthyloxy)propyl, and the like).
- alkyl and heteroalkyl radicals including those groups often referred to as alkylene, alkenyl, heteroalkylene, heteroalkenyl, alkynyi, cycloalkyl, heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl
- R " , R", R'" and R" each preferably independently refer to hydrogen, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, e.g. , aryl substituted with 1-3 halogens, substituted or unsubstituted alkyl, alkoxy or thioalkoxy groups, or arylalky] groups.
- each of the R groups is independently selected as are each R', R", R" * and R'" " groups when more than one of these groups is present.
- R' and R" are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring.
- -NR ' R" is meant to include, but not be limited to. 1 -pyrrolidinyl and 4-morpholinyl.
- alkyl is meant to include groups including carbon atoms bound to groups other than hydrogen groups, such as haloalkyl ⁇ e.g., -CF 3 and ⁇ CH 2 CF 3 ) and acyl (e g , -C(O)CH 3 , -C(O)CF 3 , -C(O)CH 2 OCH 3 , and the like).
- substituents for the aryl and heteroaryl groups are generkally referred to as "aryl group substituents.”
- R', R", R'" and R'" are preferably independently selected from hydrogen, substituted or unsubslituted alkyl, substituted or unsubstituted heteroalkyi, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.
- R groups are independently selected as are each R', R", R'" and R'"" groups when more than one of these groups is present.
- Two of the substituenls on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -T-C(O)-(CRR ⁇ q -U-, wherein T and U are independently -NR-, -0-, -CRR'- or a single bond, and q is an integer of from O to 3.
- two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -A-(CH 2 VB-, wherein A and B are independently -CRR'-, -O-, -NR-. -S-, -S(O)-.
- r is an integer of from 1 to 4.
- One of the single bonds of the new ring so formed may optionally be replaced with a double bond.
- two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula - (CRR') s -X-(CR"R"')d-, where s and d are independently integers of from O to 3, and X is -O- , -NR'-. -S-, -S(O)-, -S(O) 2 -. or -S(O) 2 NR ' -.
- the substituents R, R% R" and R'"' are preferably independently selected from hydrogen or substituted or unsubstituted (Q- C 6 )alkyl.
- Ring means a substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl,
- a ring optionally includes fused ring moieties. Substituents on the ring may be optionally joined to form additional ring systems (bicyclic or tricyclic ring systems, for example).
- the number of atoms in a ring is typically defined by the number of members in the ring. For example, a "5- to 7-membered ring" means there are 5 to 7 atoms in the encircling arrangement.
- the ring optionally included a heteroatom.
- the term “5- to 7-membered ring " ' includes, for example pyridinyl and pipcridinyl.
- the term “'ring'' further includes a ring system comprising more than one "'ring", wherein each "ring"' is independently defined as above.
- heteroatom includes atoms other than carbon (C) and hydrogen (H). Examples include oxygen (O). nitrogen (N) sulfur (S), silicon (Si), germanium (Ge), aluminum (Al) and boron (B).
- R is a general abbreviation that represents a substituent group that is selected from substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl. substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl and substituted or unsubstituted heterocycloalkyl groups.
- 'effective amount of a drug, formulation, or permeant is meant a sufficient amount of a active agent to provide the desired local or systemic effect.
- a “Topically effective,” “'Cosmetically effective,” “pharmaceutically effective,” or “therapeutically effective” amount refers to the amount of drug needed to effect the desired therapeutic result.
- Topicically effective refers to a material that, when applied to the skin, nail, hair, claw or hoof produces a desired pharmacological result cither locally at the place of application or systemically as a result of transdermal passage of an active ingredient in the material
- Cosmetically effective refers to a material that, when applied to the skin, nail, hair, claw or hoof, produces a desired cosmetic result locally at the place of application of an active ingredient in the material.
- pharmaceutically acceptable salts is meant to include salts of the compounds of the invention which are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein. When compounds of the present invention contain relatively acidic functionalities, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt.
- acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent.
- pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic.
- phthalic, benzene sulfonic, p-tolylsulfonic, citric, tartaric, methanesulfonic, and the like are also included.
- salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, for example, Berge el al.. Journal of Pharmaceutical Science 66: 1-19 (1977)).
- Certain specific compounds of the present invention contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.
- the neutral forms of the compounds are preferably regenerated by contacting the salt with a base or acid and isolating the parent compounds in the conventional manner.
- the parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents.
- the present invention provides compounds which are in a prodrug form.
- Prodrugs of the compounds or complexes described herein readily undergo chemical changes under physiological conditions to provide the compounds of the present invention. Additionally, prodrugs can be converted to the compounds of the present invention by chemical or biochemical methods in an ex vivo environment.
- Certain compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are encompassed within the scope of the present invention. Certain compounds of the present invention may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present invention and are intended to be within the scope of the present invention.
- Certain compounds of the present invention possess asymmetric carbon atoms (optical centers) or double bonds; the racemates, diastereomers, geometric isomers and individual isomers are encompassed within the scope of the present invention.
- the compounds of the present invention may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds.
- the compounds may be radiolabeled with radioactive isotopes, such as for example tritium ( 1 H), iodine- 125 ( 123 I) or carbon- 14 ( 14 C). All isotopic variations of the compounds of the present invention, whether radioactive or not, are intended to be encompassed within the scope of the present invention.
- the term ''pharmaceutically acceptable carrier refers to any formulation or carrier medium that provides the appropriate delivery of an effective amount of a active agent as defined herein, does not interfere with the effectiveness of the biological activity of the active agent, and that is sufficiently non-toxic to the host or patient.
- Representative carriers include water, oils, both vegetable and mineral, cream bases, lotion bases, ointment bases and the like. These bases include suspending agents, thickeners, penetration enhancers, and the like. Their formulation is well known to those in the art of cosmetics and topical pharmaceuticals. Additional information concerning carriers can be found in Remington: The Science and Practice of Pharmacy, 21st Ed., Lippincott, Williams & Wilkins (2005) which is incorporated herein by reference.
- “Pharmaceutically acceptable topical carrier” refers to pharmaceutically acceptable carriers, as described herein above, suitable for topical application.
- An inactive liquid or cream vehicle capable of suspending or dissolving the active agent(s), and having the properties of being nontoxic and non-inflammatory when applied to the skin, nail, hair, claw or hoof is an example of a pharmaceutically-acceptable topical carrier. This term is specifically intended to encompass carrier materials approved for use in topical cosmetics as well.
- the term ''pharmaceutically acceptable additive refers to preservatives, antioxidants, fragrances, emulsifiers, dyes and excipients known or used in the field of drug formulation and that do not unduly interfere with the effectiveness of the biological activity of the active agent, and that is sufficiently non-toxic to the host or patient.
- Additives for topical formulations are well-known in the art, and may be added to the topical composition. as long as they are pharmaceutically acceptable and not deleterious to the epithelial cells or their function. Further, they should not cause deterioration in the stability of the composition.
- inert fillers for example, inert fillers, anti- irritants, tackifiers, excipients, fragrances, opacifiers, antioxidants, gelling agents, stabilizers, surfactant, emollients, coloring agents, preservatives, buffering agents, other permeation enhancers, and other conventional components of topical or transdermal delivery formulations as are known in the art.
- penetration enhancement or “permeation enhancement” relate to an increase in the permeability of the skin, nail, hair, claw or hoof to a drug, so as to increase the rate at which the drug permeates through the skin, nail, hair, claw or hoof.
- the enhanced permeation effected through the use of such enhancers can be observed, for example, by measuring the rate of diffusion of the drug through animal or human skin, nail, hair, claw or hoof using a diffusion cell apparatus.
- a diffusion cell is described by Merritt et al, J of Controlled Release, 1 : 161 - 162 ( 1984).
- permeation enhancer or “penetration enhancer” intends an agent or a mixture of agents, which, alone or in combination, act to increase the permeability of the skin, nail, hair or hoof to a drug.
- excipients is conventionally known to mean carriers, diluents and/or vehicles used in formulating drug compositions effective for the desired use.
- Topical administration refers to the application of a pharmaceutical agent to the external surface of the skin, nail, hair, claw or hoof, such that the agent crosses the external surface of the skin, nail, hair, claw or hoof and enters the underlying tissues.
- Topical administration includes application of the composition to intact skin, nail, hair, claw or hoof, or to a broken, raw or open wound of skin, nail, hair, claw or hoof.
- Topical administration of a pharmaceutical agent can result in a limited distribution of the agent to the skin and surrounding tissues or, when the agent is removed from the treatment area by the bloodstream, can result in systemic distribution of the agent.
- Transdermal delivery refers to the diffusion of an agent across the barrier of the skin, nail, hair, claw or hoof resulting from topical administration or other application of a composition.
- stratum corneum acts as a barrier and few pharmaceutical agents are able to penetrate intact skin.
- the epidermis and dermis are permeable to many solutes and absorption of drugs therefore occurs more readily through skin, nail, hair, claw or hoof that is abraded or otherwise stripped of the stratum corneum to expose the epidermis.
- Transdermal delivery includes injection or other delivery through any portion of the skin, nail, hair, claw or hoof or mucous membrane and absorption or permeation through the remaining portion.
- Absorption through intact skin, nail, hair, claw or hoof can be enhanced by placing the active agent in an appropriate pharmaceutically acceptable vehicle before application to the skin, nail, hair, claw or hoof.
- Passive topical administration may consist of applying the active agent directly to the treatment site in combination with emollients or penetration enhancers.
- transdermal delivery is intended to include delivery by permeation through or past the integument, i.e. skin, nail, hair, claw or hoof.
- microbial infection refers to any infection of a host tissue by an infectious agent including, but not limited to, viruses, bacteria, mycobacteria, fungus and parasites (see, e.g., Harrison's Principles of Internal Medicine, pp. 93-98 (Wilson et ah, eds.. 12th ed. 1991 ); Williams et al., J. of Medicinal Chern. 42: 1481 -1485 (1999), herein each incorporated by reference in their entirety).
- Bio medium refers to both in vitro and in vivo biological milieus.
- exemplary in vitro “biological media” include, but are not limited to, cell culture, tissue culture, homogenates, plasma and blood. In vivo applications are generally performed in mammals, preferably humans.
- MIC or minimum inhibitory concentration
- Inhibiting' 1 and “blocking,” are used interchangeably herein to refer to the partial or full blockade of an editing domain of a tRNA synthetase.
- the present invention provides compounds which are capable of inhibiting the growth of, or killing, microorganisms and/or treating diseases in an animal (such as a human) or a plant. These compounds may be included within a pharmaceutical formulation,
- the invention provides a compound which has a structure which is a member selected from the following formulae: wherein Y is a member selected from substituted or unsubstituted vinyl and substituted or unsubstituted aryi, Z, R a , R b , R ⁇ and R d are members independently selected from members independently selected from H, OR*, NR*R**. SR*, -S(O)R*, -S(O) 2 R*, -S(O) 2 NR*R**, nitro, halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl.
- R b and R c together with the atoms to which they are attached, are optionally joined to form a 4- to 8-membered ring.
- R ⁇ and R e together with the atoms to which they are attached, are optionally joined to form a 4- to 8-membered ring.
- Y and Z together with the atoms to which they are attached, are optionally joined to form a member selected from a 4- to 8- membered ring and a 6- to 12-membered bicyclic ring. Substituents on the ring may be optionally joined to form additional ring systems, for example
- Each R* and R** are members independently selected from H, nitro, halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl. substituted or unsubstituted heterocycloalkyl. substituted or unsubslituted aryl, and substituted or unsubstituted heteroaryl, and pharmaceutically acceptable salts thereof.
- said compound has a structure according to the following formula:
- R a and R & are H.
- R c and R ⁇ are H.
- R e and R h are H.
- the compound has a structure according to the following formula: and .
- R d and R are H.
- R c and R d are H,
- R g and R h are H.
- said compound has a structure according to the following formula:
- R and are H, In an exemplary embodiment, R a and R are H, In an exemplary embodiment, R c and R d are H. In an exemplary embodiment, R g and R h are H. In an exemplary embodiment, said Z is substituted or unsubstituted vinyl.
- said compound is a member selected from
- R d and R are H.
- R c and R d are H.
- R g and R h are H.
- said compound is a member selected from
- said compound is a
- said compound is a member selected from H 2 N and H 2 N-- / r n m exemplary embodiment, said compound is a member selected from
- said Z is substituted or unsubstituted alkyl, and wherein said substituted or unsubstituted alkyl is substituted or unsubstituted alkenyl.
- said Z is substituted or unsubstituted vinyl.
- said Z is substituted or unsubstituted aryl.
- said Z is substituted aryl, and has a structure according to the following formula:
- R ! is a member selected from H, nitro, halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
- said R 1 is a member selected from nitro, halogen, cyano and substituted or unsubstituted alkyl.
- said R ! is a member selected from fluorine, chlorine and bromine.
- said Z is .
- said compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
- said Z is substituted or unsubstituted heteroaryl.
- said Z is a member selected from substituted or unsubstituted 2- pyridinyL substituted or unsubstituted 3-pyridinyl and substituted or unsubstituted 4- pyridinyl.
- said Z is substituted or unsubstituted 3-pyridiny ⁇ .
- said compound is ( NJ
- said R b and R c together with the atoms to which they axe attached, are joined to form a substituted or unsubstituted 4- to 6-membered ring.
- said compound is [0068] In an exemplary embodiment, said compound is a member selected from
- said compound is a member selected from
- said compound is a member selected from
- said compound is a member selected from
- Y and Z together with the atoms to which they are attached, are joined to form a member selected from a 4- to 8- membered ring and a 6- to 12-membered bicyclic ring.
- Y and Z together with the atoms to which they are attached, are joined to form an 8-membered bicyclic ring
- said 8-membered bicyclic ring is unsubstituted.
- the compound is a salt of the compounds described in this section, In an exemplary embodiment, the compound is a pharmaceutically acceptable salt of the compounds described in this section.
- the compounds are produced according to the following scheme:
- the compounds are produced according to the following scheme:
- 2a and 2b can be contacted in order to produce 2c.
- 2c and 2d can be contacted in order to produce 2e.
- 2e and 2f can be contacted in order to produce 2g.
- the compounds are produced according to the following scheme: THF,
- 3a can be reacted under conditions suitable to produce 3b.
- 3b can be contacted with 3c in order to produce 3d.
- 3d can be reacted under conditions suitable to produce 3e.
- the invention provides a compound which has a structure which is a member selected from the following formulae:
- Each R J is a member independently selected from a negative charge, a salt counterion and H.
- each R in each structure is H.
- at least one of said R 3 is a salt counterion.
- at least one of said R 3 is a negative charge.
- the compound is a salt of the compounds described in this section.
- the compound is a pharmaceutically acceptable salt of the compounds described in this section.
- acyclic boronic acids described in this section can be purchased from sources such as Aldrich (St. Louis, MO). TCI America (Portland, OR), Acros Organics (Belgium), Alfa Aesar (Ward Hill, MA) and Lancaster Synthesis (United Kingdom). Acyclic boronic acids can also be synthesized according to the methods described in Boronic Acids: Preparation and Applications in Organic Synthesis and Medicine, Hall, DG, Ed., Wiley-VCH Verlag GmbH & Co., 2005. In addition, the compounds can be produced according to the following scheme:
- the invention provides a compound which has a structure according to the following formula:
- R and R are members independently selected from H, R*. OR*, NR* R**, SR*, - S(O)R*, -S(O) 2 R*, -S(O) 2 NR*R**, nitro, halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.
- R* and R** are members independently selected from H, nitro, halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl. substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.
- R 3 is a member selected from a negative charge, a salt counterion and H
- X is a member selected from O and S. This aspect has the proviso that the compound is not a member selected from
- R 2 is cyclohexyl.
- R 1 is methyl.
- R 2 is a member selected from H, substituted or unsubstituted alky!.
- R" is a member selected from H, methyl, ethyl and isopropyl.
- R 2 is methyl, ⁇ n an exemplary embodiment, X is S.
- the compound is a salt of the compounds described in this section. In an exemplary embodiment, the compound is a pharmaceutically acceptable salt of the compounds described in this section.
- the compounds described in this section can be purchased from sources such as Aldrich (St. Louis, MO). TCI America (Portland, OR), Acros Organics (Belgium), Alfa Aesar (Ward Hill, MA) and Lancaster Synthesis (United Kingdom). In addition, the compounds can be produced according to the following scheme:
- the invention provides a compound which has a structure according to the following formula:
- R a , R b . R c , R d , R e , R 1 are members independently selected from members independently selected from H, OR*, NR*R**, SR*, -S(O)R*, -S(O) 2 R*, -S(O) 2 NR + R**, nitro, halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycioalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
- R* and R** are members independently selected from H, nitro. halogen, cyano, substituted or unsubstituted alky], substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycioalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl .
- R 3 is a member selected from a negative charge, a salt counterion and H. In an exemplary embodiment, there is a proviso that said compound is not a member selected from
- R ⁇ R f are H.
- one of said R a . R , R c , R d , R e and R f is a member selected from bromine, chlorine and fluorine and the remainder of said variables is H.
- the compound has a structure according to Cl .
- the compound is a salt of the compounds described in this section.
- the compound is a pharmaceutically acceptable salt of the compounds described in this section.
- the compounds described in this section can be purchased from sources such as Aldrich (St. Louis, MO), TCI America (Portland, OR), Acros Organics (Belgium). Alfa Aesar (Ward Hill, MA) and Lancaster Synthesis (United Kingdom).
- the compounds can be produced according to the Friendlander synthesis, as well as by the following scheme (McNaughlon et al, Org. Lett., 5: 23. 4257-4259 (2003)):
- the invention provides a compound which has a structure which is a member selected from the following formula:
- R a , R b , R c , R d , R c and R f are members independently selected from members independently selected from H, OR*, NR*R**.
- Each R* and R** are members independently selected from H, nitro, halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
- the compound is not a member selected from
- R a , R b , R c , R d , and R e are H.
- R a , R b , R c , R d , and R c are H.
- R 1 is a member selected from H 5 methyl, substituted or unsubstituted thiazolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted ⁇ - NH
- R r is a member selected from H
- R g , R h and R 1 are members independently selected from H, OR*, NR*R**, SR*, -S(O)R*, -S(O) 2 R*, -S(O) 2 NR*R**, nitro, halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
- Each R* and R** are members independently selected from H, nitro, halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
- R d , R , R c , R , and R c are H and R* is the same as described in the previous sentence.
- R 1 is H 3 C .
- R e is wherein R 1 is a member selected from substituted or unsubstituted alkyl and I— NH q substituted or unsubstituted heteroalkyl and R r is R k wherein R k is a member selected from substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl.
- R e is ⁇ H 3
- R f is methyl.
- the compound is a salt of the compounds described in this section.
- the compound is a pharmaceutically acceptable salt of the compounds described in this section.
- the compounds described in this section can be purchased from sources such as Aldrich (St. Louis, MO), TCI America (Portland, OR), Acros Organics (Belgium), Alfa Aesar (Ward Hill, MA) and Lancaster Synthesis (United Kingdom).
- the compounds can be produced according to one of several syntheses which are known to those of skill in the art.
- One synthesis involves coupling phenylenediamines and carboxylic acids (see Grimmet. M. R. In Comprehensive Heterocyclic Chemistry; Katritzky, A.R., Rees C, W., Eds., 1984; Vol. 5, p. 457; Geratz, Arch Biochem. Biophys. 197: 551-559 (1979)).
- the invention provides a compound which has a structure according to the following formula:
- R a , R b , R c and R d are members independently selected from members independently selected from H, OR*, NR*R**, SR*, -S(O)R*, -S(O) 2 R*, -S(O) 2 NR*R**, nitro, halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryi, and substituted or unsubstituted heteroaryl.
- Each R* and R** are members independently selected from H, nitro.
- X is a member selected from O and S. In an exemplary embodiment, there is a proviso that the compound is not
- X is S.
- R b and R ⁇ are H.
- R a and R ⁇ is a member selected from substituted or unsubstituted alkyl.
- R a and R c are methyl.
- the compound is a salt of the compounds described in this section.
- the compound is a pharmaceutically acceptable salt of the compounds described in this section.
- the compounds described in this section can be purchased from sources such as Aldrich (St. Louis. MO), TCl America (Portland, OR), Acros Organics (Belgium), Alfa Aesar (Ward Hill, MA) and Lancaster Synthesis (United Kingdom).
- the compounds can be produced according to one of several syntheses which are known to those of skill in the art.
- One synthesis involves the following scheme (Katiyar et a!., Bioorg. Med. Chem., 11:4369-4375 (2003))
- the invention provides a compound which has a structure which is a member selected from the following formulae:
- the fungicide is a sordarin.
- the compound is a salt of the compounds described in this section.
- the compound is a pharmaceutically acceptable salt of the compounds described in this section.
- fungicides described in this section are commercially available from sources such as Aldrich (St, Louis, MO), TCI America (Portland. OR), Acros Organics (Belgium), Alfa Aesar (Ward Hill, MA) and Lancaster Synthesis (United Kingdom). //. H. Formulations with keratin
- a compound of the invention described herein When a compound of the invention described herein is applied to a nail component of a human, the compound absorbs or penetrates into the nail.
- the human nail is primarily composed of keratin (i.e. hair keratin or ⁇ -keratin) as well as trace amounts of lipid components. Therefore, in the process of treating a disease of the nail or killing or inhibiting the growth of a microorganism, a formulation comprising a human nail unit and a compound of the invention is formed.
- the invention provides a formulation comprising: (a) a compound which is a member selected from a compound of the invention; and (b) a keratin containing component which is a member selected from a human nail unit, skin and hair.
- the compound of part (a) contacts the component of part (b).
- the keratin containing component is a nail plate of the human nail unit.
- the keratin containing component is a nail bed of the human nail unit.
- the keratin containing component is a proximal nail fold of the human nail unit.
- the keratin containing component is a lateral nail fold of the human nail unit.
- the human nail unit comprises a member selected from keratin and lipid.
- keratin is a member selected from skin keratin and nail/hair keratin.
- lipid is a member selected from cholesterol sulfate, cerebroside, ceramide, free sterol, free fatty acids, triglycerides, sterol esters, wax esters, and squalene.
- the compound is present in the formulation at a concentration which is a member selected from about 0.001%, about 0.01%, about 0.05%, about 0.1%, about 0.5%, about 1%, about 1.5%, about 2%, about 2.5%, about 3%.
- the keratin is present in said formulation at a concentration which is a member selected from about 99.99%, about 99.95%, about 99.90%, about 99.5%, about 99.0%, about 98.5%, about 98.0%, about 97.5% and about 97%.
- the compound is a compound described herein.
- the invention provides a method of forming this formulation, wherein said method comprises applying said compound to a formulation comprising keratin, thereby forming said formulation.
- the formulation comprising keratin is a human nail unit.
- the formulation comprising keratin is a member selected from a nail plate, nail bed, proximal nail fold, and lateral nail fold. Methods of making these formulations are described herein.
- the invention provides a method for inhibiting the growth, or killing, a microorganism, preferably a bacteria, fungus, virus, yeast or parasite, comprising contacting the microorganism with a compound of the invention, such as a compound described by a formula listed herein, under conditions which permit entry of the compound into the organism. Such conditions are known to one skilled in the art and are also described herein.
- This method involves contacting a microbial cell with a therapeutically-effective amount of an editing domain inhibitor to inhibit tRNA synthetase in vivo or in vitro.
- the invention provides a method of inhibiting the growth of a microorganism, or killing a microorganism, or both, comprising contacting the microorganism with a compound described herein.
- Microorganisms are members selected from fungi, yeast, viruses, bacteria and parasites.
- the microorganism is inside, or on the surface of an animal.
- the animal is a member selected from human, cattle, deer, reindeer, goat, honey bee, pig, sheep, horse, cow, bull, dog, guinea pig, gerbil, rabbit, cat, camel, yak, elephant, ostrich, otter, chicken, duck, goose, guinea fowl, pigeon, swan, and turkey.
- the animal is a human.
- the microorganism is a member selected from a fungus and a yeast.
- the fungus or yeast is a member selected from Candida species, Trichophyton species, Microsporium species, Aspergillus species, Cryptococcus species, Blastomyces species, Cocciodiodes species, Histoplasma species, Paracoccidiodes species, Phycomycetes species, Malassezia species, Fusarium species, Epidermophyton species, Scytalidium species, Scopula ⁇ opsis species, Allernaria species, PenicHlium species. Phialophora species, Rhizopus species, Scedosporium species and Zygomycetes class.
- the fungus or yeast is a member selected from Aspergillus fumigatus ⁇ A. fumigatus), Blastomyces dermatitidis, Candida Albicans (C. albicans, both fluconazole sensitive and resistant strains), Candida glabrata (C. glabrata), Candida krusei (C. knisei), Cryptococcus neoformans (C. neoformans), Candida parapsilosis (C. parapsilosis), Candida tropicalis (C tropicalis), Cocciodiodes immitis, Epidermophyton floccosum (E. floccosum), Fusarium solani (F.
- the fungus or yeast is a member selected from Trichophyton concentricum, T. violaceum, T. schoenleinii, T. verrucosum, T. soudanense, Microsporum gypseum, M, equinum, Candida guilUermondii, Malassezia globosa, M. obtuse, M. restricta, M. slooffiae, and Aspergillus flavus.
- the fungus is a member selected from a dermatophyte, Trichophyton species, Microsporium species, Candida species, Aspergillus species and yeasl-like fungus.
- the fungus or yeast is a member selected from dermatophytes, Trichophyton, Microsporum, Epidermophyton and yeast-like fungi.
- the microorganism is a bacteria.
- the bacteria is a gram-positive bacteria.
- the gram-positive bacteria is a member selected from Staphylococcus species, Streptococcus species, Bacillus species, Mycobacterium species, Corynebaclerium species (Propionibacterium species), Clostridium species, Actinomyces species, Enterococcus species and Streptomyces species.
- the bacteria is a gram- negative bacteria.
- the gram -negative bacteria is a member selected from Acinetobacter species, Neisseria species, Pseudomonas species, Brucella species.
- the bacterium is a member selected from Propionibacterium acnes; Staphylococcus aureus:, Staphylococcus epidermidis.
- Staphylococcus saprophytics Streptococcus pyogenes; Streptococcus agalactiae; Streptococcus pneumoniae; Enterococcus faecalis; Enterococcus faecium; Bacillus anthracis; Mycobacterium avium-intracellular e; Mycobacterium tuberculosis, Acinetobacter baumanii; Corynebacterium diphtheria; Clostridium perfringens; Clostridium botulinum; Clostridium tetani; Clostridium difficile; Neisseria gonorrhoeae; Neisseria meningitidis; Pseudomonas aeruginosa; Legionella pneumophila; Escherichia colt; Yersinia pestis; Haemophilus influenzae; Helicobacter pylori; Campylobacter fetus; Campylobacter je
- the microorganism is a bacteria, which is a member selected from acid-fast bacterium, including Mycobacterium species; bacilli, including Bacillus species, Corynebacterium species (also Propionibacterium) and Clostridium species; filamentous bacteria, including Actinomyces species and Streptomyces species; bacilli, such as Pseudomonas species, Brucella species, Agrobacterium species, Bordetella species. Escherichia species, Shigella species, Yersinia species, Salmonella species, Klebsiella species.
- Enterobacter species Haemophilus species, Pasteurella species, and Streptobacillus species; spirochetal species, Campylobacter species, Vibrio species; and intracellular bacteria including Rickettsiae species and Chlamydia species.
- the microorganism is a virus.
- the virus is a member selected from hepatitis A-B, human rhinoviruses, Yellow fever virus, human respiratory coronaviruses. Severe acute respiratory syndrome (SARS), respiratory syncytial virus, influenza viruses, parainfluenza viruses 1-4.
- human immunodeficiency virus 1 HBV-I
- human immunodeficiency virus 2 HMV-2.
- Herpes simplex virus 1 HSV-I
- Herpes simplex virus 2 HS V-2
- HCMV human cytomegalovirus
- HCMV Varicella zoster virus
- Epstein-Barr (EBV) polioviruses.
- the virus is a member selected from picornaviridae, ⁇ aviviridae, coronaviridae, paramyxoviridae, orthomyxoviridae, retroviridae, herpesviridae and hepadnaviridae.
- the virus is a member selected from a virus included in the following table:
- HCV Human respiratory coronavirus
- SAR Severe acute respiratory syndrome
- Bunyavirm - Bunyamwera BUN
- HTN Hantavirus - Hantaan
- CCHF Bimyaviridae Nairevirus - Crimean-Congo hemorrhagic fever
- Herpes simplex virus 1 Herpes simplex virus 1 (HSV-I)
- Herpes simplex virus 2 Herpes simplex virus 2 (HSV-2)
- HCMV Human cytomegalovirus
- VZV Varicella zoster virus
- EBV Epstein-Barr virus
- HHV ⁇ Human herpes virus 6
- Poxviridae Orthopoxvirus is sub-genus for smallpox Virus Category Pertinent Human Infections
- HBV Hepadnaviridae Hepatitis B virus
- HCV Hepatitis C virus
- the microorganism is a parasite.
- the parasite is a member selected from Plasmodium falciparum, P. vivax, P. ovale P. malar iae, P. berghei, Leishmania donovani, L. infantum, L, chagasi, L. mexicana, L. amazonensis, L. venezuelensis, L, tropics, L, major, L, minor, L.
- aethiopica L, Biana braziliensis, L (V.) guyanensis, L (V) panamensis, L (V.) peruviana, Trypanosoma brucei rhodesiense, T. brucei gambiense, T. cruzi, Giardia intestinalis, G. lambda, Toxoplasma gondii, Entamoeba histolytica, Trichomonas vaginalis, Pneumocystis carinii, and Cryptosporidium parvum.
- the invention provides a method of inhibiting the growth of, or killing, a fungus, said method comprising: contacting said fungus with a compound in an amount sufficient to inhibit or kill said fungus wherein said fungus is a member selected from a dermatophyte, Trichophyton species, Microsporium species, Candida species, Aspergillus species and yeast-like fungus, and wherein said compound is described herein,
- the fungus is a member selected from Candida albicans, Candida neoformans, Aspergillus fumigatus, Trichophyton mentagrophytes (T. mentagrophytes) and Trichophyton rubrum (T. rubrum).
- the method has the proviso that the molecular weight of said compound is not greater than a member selected from about 300, about 250, about 225, and about 200. In another exemplary embodiment, the method has the proviso that the c log P o ⁇ said compound is between about 0 and about 2. In another exemplary embodiment, the method has the proviso that the c log P of said compound is between about -5 and about 2, In another exemplary embodiment, the method has the proviso that the c log P of said compound is between about -2 and about 2. In another exemplary embodiment, the method has the proviso that the efficacy coefficient of said compound is greater than about 10.
- the invention provides a method of treating or preventing an infection.
- the method includes administering to the animal a therapeutically effective amount of the compound of the invention, sufficient to treat or prevent said infection.
- the compound is a compound described herein,
- the animal is a member selected from human, cattle, deer, reindeer, goat, honey bee, pig, sheep, horse, cow, bull, dog.
- the animal is a human.
- the animal is a member selected from a human, cattle, goat, pig, sheep, horse, cow, bull, dog, guinea pig, gerbil. rabbit, cat, chicken and turkey.
- the infection is a member selected from a systemic infection, a cutaneous infection, and an ungual, periungual or subungual infection.
- the treatment of a disorder or condition occurs through inhibition of an editing domain of an aminoacyl tRNA synthetase.
- the invention provides a method of treating a disease in a subject, said method comprising administering to said subject a therapeutically effective amount of a compound, thereby treating said diseasewherein said disease is an ungual, periungual or subungual infection; wherein said compound is described herein.
- said disease is onychomycosis.
- the method has the proviso that the molecular weight of said compound is not greater than a member selected from about 300, about 250, about 225. and about 200.
- the method has the proviso that the c log P of said compound is between about 0 and about 2.
- the method has the proviso that the c log P of said compound is between about -5 and about 2. In another exemplary embodiment, the method has the proviso that the c log P of said compound is between about - 2 and about 2. In another exemplary embodiment, the method has the proviso that the efficacy coefficient of said compound is greater than about 10.
- the invention provides a method of treating or preventing an ungual and/or periungual infection.
- the method includes administering to the animal a therapeutically effective amount of a compound or pharmaceutical formulation of the invention, sufficient to treat or prevent said infection.
- the method includes administering the compound or pharmaceutical formulation of the invention at a site which is a member selected from the skin, nail, hair, hoof, claw and the skin surrounding the nail, hair, hoof and claw.
- Onychomycosis is a disease of the nail caused by yeast, dermatophytes, or other molds, and represents approximately 50% of all nail disorders. Toenail infection accounts for approximately 80% of onychomycosis incidence, while fingernails are affected in about 20% of the cases. Dermatophytes are the most frequent cause of nail plate invasion, particularly in toenail onychomycosis. Onychomycosis caused by a dermatophyte is termed Tinea unguium. Trichophyton rubrum is by far the most frequently isolated dermatophyte, followed by T. mentagrophytes.
- Distal subungual onychomycosis is the most common presentation of tinea unguium, with the main site of entry through the hyponychium (the thickened epidermis underneath the free distal end of a nail) progressing in time to involve the nail bed and the nail plate.
- Discoloration, onycholysis, and accumulation of subungual debris and nail plate dystrophy characterize the disease.
- the disease adversely affects the quality of life of its victims, with subject complaints ranging from unsightly nails and discomfort with footwear, to more serious complications including secondary bacterial infections.
- antibiotics e.g., nystatin and amphotericin B
- imidazole anti-fungal agents such as miconazole, clotrimazole, fluconazole, econazole and sulconazole
- non- imidazole fungal agents such as the allylamine derivatives terbinafme and naftifine, and the benzylamine butenafine
- onychomycosis has proven to be resistant to most treatments.
- Nail fungal infections reside in an area difficult to access by conventional topical treatment and anti-fungal drugs cannot readily penetrate the nail plate to reach the infection sites under the nail. Therefore, onychomycosis has traditionally been treated by oral administration of antifungal drugs; however, clearly this is undesirable due to the potential for side effects of such drugs, in particular those caused by the more potent anti-fungal drugs such as itraconazole and ketoconazole.
- An alternative method of treatment of onychomycosis is by removal of the nail before treating with a topically active anti-fungal agent; such a method of treatment is equally undesirable.
- Systemic antimycotic agents require prolonged use and have the potential for significant side effects.
- Topical agents have usually been of little benefit, primarily because of poor penetration of the anti-fungal agents into and through the nail mass.
- the invention provides a method of treating or preventing onychomycosis.
- the method includes administering to a human or an animal a therapeutically effective amount of a compound of the invention, or a pharmaceutical formulation of the invention, sufficient to treat or prevent onychomycosis.
- the method includes administering the pharmaceutical formulation of the invention at a site which is a member selected from the skin, nail, hair, hoof, claw and the skin surrounding the nail, hair, hoof and claw,
- the pharmaceutical formulation includes a compound described herein.
- the invention provides a method of treating or preventing an ungual or periungual infection in an animal (such as a human) or a plant. This method comprising administering to the animal (human) a therapeutically effective amount of a compound of the invention, thereby treating or preventing the ungual or periungual infection.
- the ungual or periungual infection is onychomycosis.
- the ungual or periungual infection is a member selected from: onychomycosis, chloronychia, paronychias, erysipeloid, onychorrhexis, gonorrhea, swimming-pool granuloma, larva migrans, leprosy, Orf nodule, milkers' nodules, herpetic whitlow, acute bacterial perionyxis, chronic perionyxis, sporotrichosis, syphilis, tuberculosis verrucosa cutis, tularemia, tungiasis, peri- and subungual warts, zona, nail dystrophy (trachyonychia), and dermatological diseases with an effect on the nails, such as psoriasis, pustular psoriasis, alopecia aerata, parakeratosis pustulosa, contact dermatosis, Reiter's syndrome,
- the compounds and pharmaceutical formulations of the invention useful for ungual and periungual applications also find application in the cosmetics field, in particular for the treatment of irregularities of the nails, koilonychias, Beau's lines, longitudinal ridging, ingrown nails.
- the infection is of the skin, nail, hair, claw or hoof, hair, ear and eye and is a member selected from Sporotrichosis, Mycotic keratitis, Extension oculomycosis, Endogenous oculomycosis, Lobomycosis, Mycetoma, Piedra, Pityriasis versicolor, Tinea corporis, Tinea cruris, Tinea pedis, Tinea barbae, Tinea capitis, Tinea nigra, Otomycosis, Tinea favosa, Chromomycosis, and Tinea Imbricata.
- the invention provides a method of treating a systemic disease.
- the method involves contacting an animal (human) with a compound of the invention.
- the method of delivery for treatment of systemic disesases can be oral, intravenous, transdermal, inhalation, intraperitoneal, and subcutaneous,
- the infection is systemic and is a member selected from candidiasis, aspergillosis, coccidioidomycosis, cryptococcosis, histoplasmosis, blastomycosis, paracoccidioidomycosis, zygomycosis, phaeohyphomycosis and rhinosporidiosis.
- the compounds of the invention are useful for the treatment of diseases of animals, such as humans, involving viruses
- the disease is a member selected from hepatitis A - B - C, yellow fever, respiratory syncytial, influenza, AIDS, herpes simplex, chicken pox, varicella zoster, and Epstein-Barr disease.
- the compounds of the invention are useful for the treatment of diseases of animals, such as humans, involving parasites.
- the disease is a member selected from malaria, Chagas' disease, Leishmaniasis, African sleeping sickness
- the invention provides a method of killing or inhibiting growth of a microorganism present in a human nail unit, wherein said human nail unit comprises a nail plate.
- the method comprising contacting a dorsal layer of the nail plate with a compound capable of penetrating the nail plate, traveling through the nail plate to a nail bed underlying said nail plate, and contacting said microorganism, under conditions sufficient for said compound to penetrate said nail plate.
- the compound has a molecular weight of between about 100 Da and about 300 Da, a log P value of between about 1.0 and about 2.6, a water solubility greater than about 0.1 mg/mL octanol/saturated water, and an MIC of less than 16 ⁇ g/mL against said microorganism, thereby killing or inhibiting the growth of said microorganism.
- the compound is described herein.
- the invention provides a method of treating a disease caused by a microorganism present in a human nail unit, wherein said human nail unit comprises a nail plate, said method comprising: contacting a dorsal layer of the nail plate with a compound capable of penetrating the nail plate, traveling through the nail plate to a nail bed underlying said nail plate, and contacting said microorganism, under conditions sufficient for said compound to penetrate said nail plate and to treat said disease.
- the compound has a molecular weight of between about 100 Da and about 300 Da; a log P value of between about 1.0 and about 2.6; a water solubility greater than about 0.] mg/mL octanol/saturated water, and an MIC of less than 16 ⁇ g/mL against said microorganism, thereby treating said disease.
- the compound is described herein.
- the invention provides a method of delivering a compound from the dorsal layer of the nail plate to the nail bed.
- This method comprises contacting the cell with a compound capable of penetrating the nail plate, under conditions sufficient to penetrate the nail.
- the compound has a molecular weight of between about 100 and about 300 Da.
- the compound also has a log P value of between about 1.0 and about 2.6.
- the compound additionally has a water solubility between about 0.1 mg/mL and 1 g/mL octanol/saturated water, thereby delivering said compound.
- the compound is described herein.
- the physicochemical properties of the compound of the invention described by quantities predictive for migration of the compound through the nail plate, including, but not limited to. molecular weight, log P and solubility in water, and the like, are effective to provide substantial penetration of the nail plate.
- the compound has a molecular weight of between about 100 Da and about 250 Da. In an exemplary embodiment, the compound has a molecular weight of between about 100 Da and about 225 Da. In an exemplary embodiment, the compound has a molecular weight of between about 100 Da and about 200 Da. In one embodiment of the present invention the compound has a molecular weight of between 130 and 200. In another embodiment of this invention, the compound has a molecular weight of from about 140 to about 210 Da.
- the compound has a molecular weight of from about 170 to about 200 Da. In another embodiment of this invention, the compound has a molecular weight of from about 155 to about 190 Da. In another embodiment of this invention, the compound has a molecular weight of from about 165 to about 185 Da. In another embodiment of this invention, the compound has a molecular weight of from about 145 to about 170 Da. In yet another embodiment the molecular weight is either 151.93 or 168.39 Da.
- the compound has a log P value of between about -3.5 to about 2.5. In another exemplary embodiment, the compound has a log P value of from about -1.0 to about 2.5. In another exemplary embodiment, the compound has a log P value of from about -1.0 to about 2,0. In another exemplary embodiment, the compound has a log P value of from about -0.5 to about 2.5. In another exemplary embodiment, the compound has a log P value of from about -0.5 to about 1.5. In another exemplary embodiment, the compound has a log P value of from about 0.5 to about 2.5. In another exemplary embodiment, the compound has a log P value of from about 1.0 to about 2,5. In yet another exemplary embodiment, the compound has a log P value of 1.9 or 2.3.
- Also contemplated by the present invention is a compound with a log P value less then 2.5, with a molecular weight less than 200 Da, that are still able to penetrate the nail plate.
- the compound has a water solubility between about 0.1 mg/mL to 1 g/mL in octanol saturated water. In one embodiment of the present invention the compound has a water solubility of between 0.1 mg/mL and 100 mg/mL. In another embodiment of this invention, the compound has a water solubility of from about 0.1 mg/mL and 10 mg/mL. In another embodiment of this invention, the compound has a water solubility of from about 0.1 mg/mL and 1 mg/mL. In another embodiment of this invention, the compound has a water solubility of from about 5 mg/mL and 1 g/mL. In another embodiment of this invention, the compound has a water solubility of from about 10 mg/mL and 500 g/mL. In another embodiment of this invention, the compound has a water solubility of from about 80 mg/mL and 250 mg/mL.
- the present invention provides a compound with a log P value selected from a range above, with a molecular weight selected from a range above, that are still able to penetrate the nail plate.
- the present invention provides compounds with a molecular weight selected from a range above, with a water solubility selected from a range above, that are still able to penetrate the nail plate.
- the present invention provides compounds with a log P selected from a range above, with a water solubility selected from a range above, that are still able to penetrate the nail plate.
- the present invention provides compounds with a molecular weight selected from a range above, with a log P selected from a range above, and with a water solubility selected from a range above, that are still able to penetrate the nail plate.
- Penetration of the nail by the active ingredient may be effected by the polarity of the formulation.
- the polarity of the formulation is not expected have as much influence on nail penetration as some of the other factors, such as the molecular weight or the log P of the active ingredient.
- the presence of penetration enhancing agents in the formulation is likely to increase penetration of the active agent when compared to similar formulations containing no penetration enhancing agent.
- Compound 3 below is an example of a compound similar in molecular weight to ciclopirox, and like ciclopirox, penetrates the nail plate poorly.
- the topical formulations including a compound described herein has a total molecular weight of less than 200 Da, has a Log P of less than 2.5, and a minimum inhibitory concentration against Trichophyton ruhrum that is substantially unchanged in the presence of 5% keratin.
- the efficacy coefficient (defined as flux over MIC) of a compound also informs one of skill regarding whether the compound may be effective in killing a microorganism, inhibiting the growth of a microorganism, or treating a disease which is caused by a microorganism present in a human nail unit, wherein said human nail unit comprises a nail plate.
- the method comprises: contacting a dorsal layer of the nail plate with a compound capable of penetrating the nail plate, traveling through the nail plate to a nail bed underlying said nail plate, and contacting said microorganism, under conditions sufficient for said compound to penetrate said nail pjate and to treat said disease, wherein the compound has an efficacy coefficient above 10.
- the compound has an efficacy coefficient between about 10 and about 1000. In an exemplary embodiment, the compound has an efficacy coefficient between about 30 and about 100. In an exemplary embodiment, the compound has an efficacy coefficient between about 100 and about 500. In an exemplary embodiment the compound has an efficacy coefficient between about 25 and about 200.
- This invention is still further directed to methods for treating a fungal infection mediated at least in part by dermatophytes, Trichophyton, Microsporum or Epidermophyion species, or a yeast-like fungi including Candida species, in an animal (such as a human) or a plant, which methods comprise administering to an animal (such as a human) or a plant, that has been diagnosed with said fungal infection or is at risk of developing said fungal infection.
- a pharmaceutical composition comprising a pharmaceutically acceptable diluent and a therapeutically effective amount of a compound described herein or mixtures of one or more of such compounds.
- the infection is onychomycosis.
- Compounds contemplated by the present invention may have broad spectrum antifungal activity and as such may be candidates for use against other cutaneous fungal infections.
- the invention is a pharmaceutical formulation which includes:
- the invention is a pharmaceutical formulation which includes: (a) a pharmaceutically acceptable excipient; and (b) a compound described herein.
- the invention is a pharmaceutical formulation which includes: (a) a pharmaceutically acceptable excipient; and (b) a compound which is a member selected from a boron containing compound described in this document, a Sow molecular weight ciclopirox derivative described in this document, and a fungicide described in this document.
- the invention is a pharmaceutical formulation which includes: (a) a pharmaceutically acceptable excipient; and
- the pharmaceutical formulations of the invention can take a variety of forms adapted to the chosen route of administration. Those skilled in the art will recognize various synthetic methodologies that may be employed to prepare non-toxic pharmaceutical formulations incorporating the compounds described herein. Those skilled in the art will recognize a wide variety of non-toxic pharmaceutically acceptable solvents that may be used to prepare solvates of the compounds of the invention, such as water, ethanol, propylene glycol, mineral oil, vegetable oil and dimethylsulfoxide (DMSO).
- DMSO dimethylsulfoxide
- compositions of the invention may be administered orally, topically, parenterally, by inhalation or spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles, ⁇ t is further understood that the best method of administration may be a combination of methods. Oral administration in the form of a pill, capsule, elixir, syrup, lozenge, troche, or the like is particularly preferred.
- parenteral as used herein includes subcutaneous injections, intradermal, intravascular (e.g., intravenous), intramuscular, spinal, intrathecal injection or like injection or infusion techniques.
- compositions intended for oral use may be prepared according to any method known in the art for the manufacture of pharmaceutical formulations, and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations.
- Tablets may contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipicnts that are suitable for the manufacture of tablets.
- excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia; and lubricating agents, for example magnesium stearate, stearic acid or talc.
- the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
- a time delay material such as glyceryl monostearate or glyceryl distearatc may be employed.
- Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.
- an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
- water or an oil medium for example peanut oil, liquid paraffin or olive oil.
- Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions.
- excipients are suspending agents, for example sodium carboxymethylcelluiose, methylceliulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; and dispersing or wetting agents, which may be a naturally-occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides
- the aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl p-hydroxybenzoate. one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.
- Oily suspensions may be formulated by suspending the active ingredients in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
- the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide palatable oral preparations. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
- Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives.
- a dispersing or wetting agent e.g., glycerol, glycerol, glycerol, glycerol, glycerol, glycerol, glycerin, glycerin, glycerin, glycerin, glycerin, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, glycerol, glycerol, glycerol, glycerol, glycerol, glycerol, glycerol, glycerol, glycerol
- compositions of the invention may also be in the form of oil-in- water emulsions and water-in-oil emulsions.
- the oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these.
- Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth; naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol; anhydrides, for example sorbitan monooleate; and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate.
- the emulsions may also contain sweetening and flavoring agents.
- Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, and flavoring and coloring agents.
- the pharmaceutical formulations may be in the form of a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents, which have been mentioned above.
- the sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example as a solution in 1 ,3-butanediol.
- Suitable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
- sterile, fixed oils are conventionally employed as a solvent or suspending medium.
- any bland fixed oil may be employed including synthetic mono- or diglycerides,
- fatty acids such as oleic acid find use in the preparation of injectables.
- composition of the invention may also be administered in the form of suppositories, e.g., for rectal administration of the drug.
- suppositories e.g., for rectal administration of the drug.
- These compositions can be prepared by mixing the drug with a suitable non-irritating excipient that is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
- suitable non-irritating excipient that is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
- Such materials are cocoa butter and polyethylene glycols.
- compositions can be administered parenterally in a sterile medium.
- the drug depending on the vehicle and concentration used, can either be suspended or dissolved in the vehicle.
- adjuvants such as local anesthetics, preservatives and buffering agents can be dissolved in the vehicle.
- the composition containing the therapeutic compound may be added to the animal's feed or drinking water. Also, it will be convenient to formulate animal feed and drinking water products so that the animal takes in an appropriate quantity of the compound in its diet. It will further be convenient to present the compound in a composition as a premix for addition to the feed or drinking water. The composition can also added as a food or drink supplement for humans.
- the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the condition being treated and the particular mode of administration. Dosage unit forms will generally contain between from about 1 mg to about 500 mg of an active ingredient.
- Frequency of dosage may also vary depending on the compound used and the particular disease treated. However, for treatment of most disorders, a dosage regimen of 4 times daily or less is preferred. It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration and rate of excretion, drug combination and the severity of the particular disease undergoing therapy. [0185] Preferred compounds of the invention will have desirable pharmacological properties that include, but are not limited to, oral bioavailability, low toxicity, low serum protein binding and desirable in vitro and in vivo half-lives. Penetration of the blood brain barrier for compounds used to treat CNS disorders is necessary, while low brain levels of compounds used to treat peripheral disorders are often preferred.
- Assays may be used to predict these desirable pharmacological properties. Assays used to predict bioavailability include transport across human intestinal cell monolayers, including Caco-2 cell monolayers. Toxicity to cultured hepatocyctes may be used to predict compound toxicity. Penetration of the blood brain barrier of a compound in humans may be predicted from the brain levels of laboratory animals that receive the compound intravenously.
- Serum protein binding may be predicted from albumin binding assays. Such assays are described in a review by Oravcova, et al. (Journal of Chromatography B (1996) volume 677, pages 1 -27).
- Compound half-life is inversely proportional to the frequency of dosage of a compound.
- In vitro half-lives of compounds may be predicted from assays of microsomal half-life as described by Kuhnz and Gieschen (Drug Metabolism and Disposition, (1998) volume 26, pages 1 120-1 127).
- compositions required for use in treatment will vary not only with the particular compound selected but also with the route of administration, the nature of the condition being treated and the age and condition of the patient and will ultimately be at the discretion of the attendant physician or clinician.
- the pharmaceutical formulation excipient comprises ethanol and the pharmaceutical formulation compound is a compound described herein.
- the pharmaceutical formulation excipient comprises propylene glycol and the pharmaceutical formulation compound is a compound described herein.
- the pharmaceutical formulation comprises: about 20% propylene glycol; about 70% elhanol; about 10% of a compound described herein.
- the pharmaceutical formulation comprises: about 70% ethanoh about 20% poly(vinyl methyl ether-alt-maleic acid monobutyl ester); about 10% of a compound described herein.
- the pharmaceutical ibrmulalion comprises: about 56% ethanol; about 14% water; about 15% poly(2-hydroxyethyl methacrylate); about 5% di butyl sebacate; about 10% of a compound described herein.
- the pharmaceutical formulation comprises: about 55% ethanol; about 15% ethyl acetate; about 15% polyvinyl acetate); about 5% dibutyl sebacate; about 10% of a compound described herein.
- a compound described herein is present in a pharmaceutical formulation in a concentration which is a member selected from 1 %. 2.5%, 5%, 7.5%, 10% and 15% w/v.
- the pharmaceutical formulation is a lacquer.
- the methods of the invention can be used employed through the topical application of the compounds described herein.
- compositions of the present invention comprises fluid or semi-solid vehicles that may include but are not limited to polymers, thickeners, buffers, neutralizers, chelating agents, preservatives, surfactants or emulsifiers, antioxidants, waxes or oils, emollients, sunscreens, and a solvent or mixed solvent system.
- the solvent or mixed solvent system is important to the formation because it is primarily responsible for dissolving the drug.
- the best solvent or mixed solvent systems are also capable of maintaining clinically relevant levels of the drug in solution despite the addition of a poor solvent to the formulation.
- the topical compositions useful in the subject invention can be made into a wide variety of product types.
- These include, but are not limited to, lotions, creams, gels, sticks, sprays, ointments, pastes, foams, mousses, and cleansers.
- These product types can comprise several types of carrier systems including, but not limited to particles, nanoparticles, and liposomes, if desired, disintegrating agents can be added, such as the cross-linked polyvinyl pyrrolidone, agar or alginic acid or a salt thereof such as sodium alginate. Techniques for formulation and administration can be found in Remington: The Science and Practice of Pharmacy, supra. The formulation can be selected to maximize delivery to a desired target site in the body.
- Lotions which are preparations that are to be applied to the skin, nail, hair, claw or hoof surface without friction, are typically liquid or semi-liquid preparations in which finely divided solid, waxy, or liquid are dispersed. Lotions will typically contain suspending agents to produce better dispersions as well as compounds useful for localizing and holding the active agent in contact with the skin, nail, hair, claw or hoof, e.g.. methylcellulose, sodium carboxymethyl-cellulose, or the like.
- Creams containing the active agent for delivery according to the present invention are viscous liquid or semisolid emulsions, either oil-in- water or water-in-oil.
- Cream bases are water-washable, and contain an oil phase, an emulsifier and an aqueous phase.
- the oil phase is generally comprised of petrolatum or a fatty alcohol, such as cetyl- or stearyl alcohol; the aqueous phase usually, although not necessarily, exceeds the oil phase in volume, and generally contains a humectant.
- the emulsifier in a cream formulation is generally a nonionic, anionic, cationic or amphoteric surfactant.
- Gel formulations can also be used in connection with the present invention, As will be appreciated by those working in the field of topical drug formulation, gels are semisolid. Single-phase gels contain organic macromolecules distributed substantialiy uniformly throughout the carrier liquid, which is typically aqueous, but also may be a solvent or solvent blend,
- Ointments which are semisolid preparations, are typically based on petrolatum or other petroleum derivatives.
- the specific ointment base to be used is one that provides for optimum delivery for the active agent chosen for a given formulation, and, preferably, provides for other desired characteristics as well, e.g., emolliency or the like.
- an ointment base should be inert, stable, nonirritating and non-sensitizing. As explained in Remington: The Science and Practice of Pharmacy, 19th Ed.
- ointment bases may be grouped in four classes: oleaginous bases; emulsifiable bases; emuision bases; and water-soluble bases.
- Oleaginous ointment bases include, for example, vegetable oils, fats obtained from animals, and semisolid hydrocarbons obtained from petroleum.
- Emulsifiable ointment bases also known as absorbent ointment bases, contain little or no water and include, for example, hydroxy stearin sulfate, anhydrous lanolin and hydrophilic petrolatum.
- Emulsion ointment bases are either water-in-oil (W/O) emulsions or oil-in- water (OfW) emulsions, and include, for example, cetyl alcohol, glyceryl monostearate, lanolin and stearic acid.
- W/O water-in-oil
- OfW oil-in- water
- Preferred water-soluble ointment bases are prepared from polyethylene glycols of varying molecular weight; again, reference may be had to Remington: The Science and Practice of Pharmacy, supra, for further information.
- Sprays generally provide the active agent in an aqueous and/or alcoholic solution which can be misted onto the skin, nail, hair, claw or hoof for delivery.
- Such sprays include those formulated to provide for concentration of the active agent solution at the site of administration following delivery, e.g., the spray solution can be primarily composed of alcohol or other like volatile liquid in which the drug or active agent can be dissolved.
- the carrier evaporates, leaving concentrated active agent at the site of administration.
- the topical pharmaceutical compositions may also comprise suitable solid or gel phase carriers.
- suitable solid or gel phase carriers include but are not limited to calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.
- the topical pharmaceutical compositions may also comprise a suitable emulsifier which refers to an agent that enhances or facilitates mixing and suspending oil-in-water or watcr-in-oil.
- a suitable emulsifier which refers to an agent that enhances or facilitates mixing and suspending oil-in-water or watcr-in-oil.
- the emulsifying agent used herein may consist of a single emulsifying agent or may be a nonionic. anionic, cationic or amphoteric surfactant or blend of two or more such surfactants; preferred for use herein are nonionic or anionic emulsifiers.
- Such surface-active agents are described in "McCutcheon ' s Detergent and Emulsifiers," North American Edition, 1980 Annual published by the McCutcheon Division. MC Publishing Company, 175 Rock Road, Glen Rock, N.J. 07452, USA.
- Preferred for use herein are high molecular weight alcohols such as cetearyl alcohol, cetyl alcohol, stearyl alcohol, emulsifying wax, glyceryl monostearate.
- high molecular weight alcohols such as cetearyl alcohol, cetyl alcohol, stearyl alcohol, emulsifying wax, glyceryl monostearate.
- Other examples are ethylene glycol distearate, sorbitan tristearate.
- nonionic emulsifying agents are those with hydrophile- lipophile balances (HLB) of about 3 to 6 for w/o system and 8 to 18 for o/w system as determined by the method described by Paul L. Lindner in “Emulsions and Emulsion' " , edited by Kenneth Lissant, published by Dekker, New York. N.Y., 1974. pages 188-190. More preferred for use herein are one or more nonionic surfactants that produce a system having FILB of about 8 to about 18.
- HLB hydrophile- lipophile balances
- nonionic emulsifiers include but are not limited to "BRIJ 72". the trade name for a polyoxyethylene (2) stearyl ether having an HLB of 4,9; "BRIJ 721 ", the trade name for a polyoxyelhylene (21) stearyl ether having an HLB of 15.5, “Brij 30", the trade name for polyoxyethylene lauryl ether having an HLB of 9.7; "Polawax”, the trade name for emulsifying wax having an HLB of 8.0; "Span 60”, the trade name for sorbitan monostearate having an HLB of 4.7; “Crodesta F- 160”, the trade name for sucrose stearate” having an HLB of 14.5.
- BRIJ 72 the trade name for a polyoxyethylene (2) stearyl ether having an HLB of 4,9
- Brij 30 the trade name for polyoxyethylene lauryl ether having an HLB of 9.7
- Polyawax the trade name for emulsifying wax having an HLB of
- each emulsifying agent is present in amount from about 0.5 to about 2.5 wt%, preferably 0.5 to 2.0%, more preferably 1.0% or 1 ,8%.
- the emulsifying agent comprises a mixture of steareth 21 (at about 1.8 %) and steareth 2 (at about 1.0%).
- the topical pharmaceutical compositions may also comprise suitable emollients.
- Emollients are materials used for the prevention or relief of dryness, as well as for the protection of the skin, nail, hair, claw or hoof.
- Useful emollients include, but are not limited to, cetyl alcohol, isopropyl myristate, stearyl alcohol, and the like.
- suitable emollients are known and can be used herein. See e.g., Sagarin, Cosmetics, Science and Technology, 2nd Edition, Vol. 1 , pp. 32-43 (1972), and U.S. Pat. No. 4,919,934, to Deckner et al., issued Apr. 24, 1990, both of which are incorporated herein by reference in their entirety.
- These materials are available from Ruger Chemical Co, (Irvington, NJ).
- each emollient is present in an amount from about 0.1 to 15%, preferably 0.1 to about 3.0, more preferably 0.5, 1.0, or 2.5 wt%.
- the emollient is a mixture of cetyl alcohol, isopropyl myristate and stearyl alcohol in a 1/5/2 ratio.
- the emollient may also be a mixture of cetyl alcohol and stearyl alcohol in a 1 /2 ratio.
- the topical pharmaceutical compositions may also comprise suitable antioxidants, substances known to inhibit oxidation.
- Antioxidants suitable for use in accordance with the present invention include, but are not limited to, butylated hydroxy toluene, ascorbic acid, sodium ascorbate, calcium ascorbate. ascorbic palmitate, butylated hydroxyanisole, 2,4,5- trihydroxybutyrophenone. 4-hydroxymethyl-2,6-di-fer/-butylphenol, erythorbic acid, gum guaiac, propyl gallate.
- the antioxidant is butylaled hydroxytoluene, butylated hydroxyanisole, propyl gallate, ascorbic acid, pharmaceutically acceptable salts or esters thereof, or mixtures thereof. Most preferably, the antioxidant is butylated hydroxytoluene. These materials are available from Ruger Chemical Co, (Irvinglon. NJ).
- the topical formulations of the present invention contain at least one antioxidant
- the total amount of antioxidant present is from about 0.001 to 0.5 wt%, preferably 0.05 to about 0.5 wt%, more preferably 0.1%.
- the topical pharmaceutical compositions may also comprise suitable preservatives.
- Preservatives are compounds added to a pharmaceutical formulation to act as an anti-microbial agent.
- preservatives known in the art as being effective and acceptable in parenteral formulations are benzalkonium chloride, benzethonium, chlorohexidine, phenol, m-cresol, benzyl alcohol, methylparaben, propylparaben, chlorobutanol, o-cresol, p-cresol, cbJorocresoI, phenylmercuric nitrate, thimerosal, benzoic acid, and various mixtures thereof. See, e.g., Wall Arbitr, K. -H., Develop.
- the preservative is selected from methylparaben, propylparaben and mixtures thereof. These materials are available from Inolex Chemical Co (Philadelphia, PA) or Spectrum Chemicals.
- the topical formulations of the present invention contain at least one preservative
- the total amount of preservative present is from about 0.01 to about 0.5 wt%, preferably from about 0.1 to 0.5%, more preferably from about 0.03 to about 0.15.
- the preservative is a mixture of methylparaben and proplybarben in a 5/1 ratio.
- the amount is usually 15 to 20%.
- the topical pharmaceutical compositions may also comprise suitable chelating agents to form complexes with metal cations that do not cross a lipid bilayer.
- suitable chelating agents include ethylene diamine tetraacetic acid (EDTA). ethylene glycol- bis(beta-aminoethyl ether)-N,N,N', N '-tetraacetic acid (EGTA) and 8-Amino-2-[(2-amino-5- methylphenoxy)methyl]-6-methoxyquinoline-N,N,N',N'-tetraacetic acid, tetrapotassium salt (QUIN-2).
- the chelating agents are EDTA and citric acid. These materials are available from Spectrum Chemicals.
- the total amount of chelating agent present is from about 0.005% to 2.0% by weight, preferably from about 0.05% to about 0.5 wt%, more preferably about 0.1% by weight.
- the topical pharmaceutical compositions may also comprise suitable neutralizing agents used to adjust the pH of the formulation to within a pharmaceutically acceptable range.
- neutralizing agents include but are not limited to trolamine, tromethamine, sodium hydroxide, hydrochloric acid, citric acid, and acetic acid. Such materials are available from are available from Spectrum Chemicals (Gardena, CA).
- the total amount of neutralizing agent present is from about 0.1 wt to about 10 wt %, preferably 0.1 wt % to about 5.0 wt%. and more preferably about 1.0 wt %.
- the neutralizing agent is generally added in whatever amount is required to bring the formulation to the desired pH.
- the topical pharmaceutical compositions may also comprise suitable viscosity increasing agents. These components are diffusible compounds capable of increasing the viscosity of a polymer-containing solution through the interaction of the agent with the polymer.
- CARBOPOL ULTREZ 10 may be used as a viscosity-increasing agent. These materials are available from Noveon Chemicals. Cleveland, OH.
- the total amount of viscosity increasing agent present is from about 0.25% to about 5.0% by weight, preferably from about 0.25% to about 1.0 wt%, and more preferably from about 0.4% to about 0.6% by weight.
- the topical pharmaceutical compositions may also comprise suitable nail penetration enhancers.
- nail penetration enhancers include mercaptan compounds, sulfites and bisulfites, keratolytic agents and surfactants.
- Nail penetration enhancers suitable for use in the invention are described in greater detail in Malhotra et ai, J, Pharm. ScL, 91 :2, 312-323 (2002), which is incorporated herein by reference in its entirety.
- the topical pharmaceutical compositions may also comprise one or more suitable solvents.
- suitable solvents The ability of any solid substance (solute) to dissolve in any liquid substance (solvent) is dependent upon the physical properties of the solute and the solvent. When solutes and solvents have similar physical properties the solubility of the solute in the solvent will be the greatest. This gives rise to the traditional understanding that "like dissolves like.”
- Solvents can be characterized in one extreme as non-polar, lipophilic oils, while in the other extreme as polar hydrophilic solvents. Oily solvents dissolve other non-polar substances by Van der WaIs interactions while water and other hydrophilic solvents dissolve polar substances by ionic, dipole, or hydrogen bonding interactions.
- solvents can be listed along a continuum from the least polar, i.e. hydrocarbons such as decane, to the most polar solvent being water.
- a solute will have its greatest solubility in solvents having equivalent polarity.
- less polar solvents will provide improved solubility with the solvent having polarity nearly equivalent to the solute providing maximum solubility.
- Most drugs have intermediate polarity, and thus experience maximum solubility in solvents such as propylene glycol or ethanol, which are significantly less polar than water.
- the concentration of active ingredient in the formulation may be limited by the solubility of the active ingredient in the chosen solvent and/or carrier.
- Non-lipophilic drugs typically display very low- solubility in pharmaceutically acceptable solvents and/or carriers.
- the solubility of some compounds in the invention in water is less than 0.00025% wt/wt.
- the solubility of the same compounds in the invention can be less than about 2% wt/wt in either propylene glycol or isopropyl myristate.
- diethylene glycol monoethyl ether (DGME) is the solvent used to dissolve the compounds of the invention.
- the compounds in the invention useful in the present formulation are believed to have a solubility of from about 10% wt/wt to about 25% wt/wt in DGME.
- a DGME water cosolvent system is used to dissolve the compounds of the invention.
- the solvent capacity of DGME drops when water is added; however, the DGME/water cosolvent system can be designed to maintain the desired concentration of from about 0.1 % to about 5% wt/wt active ingredient.
- the active ingredient is present from about 0.5 % to about 3% wt/wt. and more preferably at about 1% wt/wt. in the as-applied topical formulations.
- DGME is less volatile than water, as the topical formulation evaporates upon application, the active agent becomes more soluble in the cream formulation. This increased solubility reduces the likelihood of reduced bioavailability caused by the drug precipitating on the surface of the skin, nail, hair, claw or hoof.
- Liquid forms such as lotions suitable for topical administration or suitable for cosmetic application, may include a suitable aqueous or nonaqueous vehicle with buffers, suspending and dispensing agents, thickeners, penetration enhancers, and the like.
- Solid forms such as creams or pastes or the like may include, for example, any of the following ingredients, water, oil, alcohol or grease as a substrate with surfactant, polymers such as polyethylene glycol, thickeners, solids and the like.
- Liquid or solid formulations may include enhanced delivery technologies such as liposomes, microsomes, microsponges and the like.
- the compounds can be delivered using a sustained-release system, such as semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent.
- sustained-release materials have been established and are well known by those skilled in the art.
- Topical treatment regimens according to the practice of this invention comprise applying the composition directly to the skin, nail, hair, claw or hoof at the application site, from one to several times daily.
- Formulations of the present invention can be used to treat, ameliorate or prevent conditions or symptoms associated with bacterial infections, acne, inflammation and the like.
- the pharmaceutical formulation includes a simple solution.
- the simple solution includes an alcohol.
- the simple solution includes alcohol and water.
- the alcohol is ethanol, ethylene glycol, propanol, polypropylene glycol, isopropanol or butanol
- the simple solution is a member selected from about 10% polypropylene glycol and about 90% ethanol; about 20% polypropylene glycol and about 80% ethanol; about 30% polypropylene glycol and about 70% ethanol; about 40% polypropylene glycol and about 60% ethanol; about 50% polypropylene glycol and about 50% ethanol; about 60% polypropylene glycol and about 40% ethanol; about 70% polypropylene glycol and about 30% ethanol; about 80% polypropylene glycol and about 20% ethanol; about 90% polypropylene glycol and about 10% ethanol.
- the pharmaceutical formulation is a lacquer. Please see Remington's, supra, for more information on the production of lacquers.
- the compound is present in said pharmaceutical formulation in a concentration of from about 0,5% to about 15%. In an exemplary embodiment, the compound is present in said pharmaceutical formulation in a concentration of from about 0.1% to about 12.5%. In an exemplary embodiment, the compound is present in said pharmaceutical formulation in a concentration of from about 1% to about 10%. In an exemplary embodiment, the compound is present in said pharmaceutical formulation in a concentration of from about 1% to about 5%. In an exemplary embodiment, the compound is present in said pharmaceutical formulation in a concentration of from about 0.5% to about 5%.
- the compound is present in said pharmaceutical formulation in a concentration of from about 0.5% to about 7.5%, In an exemplary embodiment, the compound is present in said pharmaceutical formulation in a concentration of from about 5% to about 7.5%. In an exemplary embodiment, the compound is present in said pharmaceutical formulation in a concentration of from about 2% to about 8%. In an exemplary embodiment, the compound is present in said pharmaceutical formulation in a concentration of from about 4% to about 9%.
- Anti-inflammatory agents include, but are not limited to, bisabolol, mentholatum, dapsone, aloe, hydrocortisone, and the like.
- Vitamins include, but are not limited to, Vitamin B, Vitamin E, Vitamin A, Vitamin D, and the like and vitamin derivatives such as tazarotene, calcipotriene, tretinoin, adapalene and the like.
- Anti-aging agents include, but are not limited to, niacinamide, retinol and retinoid derivatives, AHA. Ascorbic acid, lipoic acid, coenzyme Q lO, beta hydroxy acids, salicylic acid, copper binding peptides, dimethyl ami noethyl (DAEA), and the like.
- Sunscreens and or sunburn relief agents include, but are not limited to, PABA, jojoba, aloe, padimate-O, methoxycinnamates, proxamine HCl, lidocaine and the like.
- Sunless tanning agents include, but are not limited to, dihydroxyacetone (DHA).
- DHA dihydroxyacetone
- Psoriasis-treating agents and/or acne-treating agents include, but are not limited to, salicylic acid, benzoyl peroxide, coal tar, selenium sulfide, zinc oxide, pyrithione (zinc and/or sodium), tazarotene, calcipotriene, tretinoin, adapalene and the like.
- Agents that are effective to control or modify keratinization including without limitation: tretinoin, tazarotene, and adapalene.
- compositions comprising an compound/active agent of the invention, and optionally at least one of these additional agents, are to be administered topically.
- this leads to the compounds of the invention and any other active agent working upon and treating the skin, nail, hair, claw or hoof.
- any one of the topically applied active agents may also be delivered systemically by transdermal routes.
- an additional cosmetically or pharmaceutically effective agent such as an anti-inflammatory agent, vitamin, anti-aging agent, sunscreen, and/or acne- treating agent, for example, is usually a minor component (from about 0.001 % to about 20% by weight or preferably from about 0.01 % to about 10% by weight) with the remainder being various vehicles or carriers and processing aids helpful for forming the desired dosing form.
- Preferred compounds for use in the present topical formulations will have certain pharmacological properties. Such properties include, but are not limited to, low toxicity, low serum protein binding and desirable in vitro and in vivo half-lives. Assays may be used to predict these desirable pharmacological properties. Assays used to predict bioavailability include transport across human intestinal cell monolayers, including Caco-2 cell monolayers. Serum protein binding may be predicted from albumin binding assays. Such assays are described in a review by Oavcova et al. (1996, J, Chromat. B677: 1-27). Compound half- life is inversely proportional to the frequency of dosage of a compound. In vitro half-lives of compounds may be predicted from assays of microsomal half-life as described by Kuhnz and Gleschen (Drug Metabolism and Disposition, (1998) volume 26, pages 1120-1 127).
- Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED 50 (the dose therapeutically effective in 50% of the population).
- the dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio between LD 50 and ED50.
- Compounds that exhibit high therapeutic indices are preferred.
- the data obtained from these cell culture assays and animal studies can be used in formulating a range of dosage for use in humans.
- the dosage of such compounds lies preferably within a range of circulating concentrations that include the ED S Q with little or no toxicity.
- the dosage can vary within this range depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See, e.g. Fingl el al., 1975, in "The Pharmacological Basis of Therapeutics", Ch
- the therapeutically effective dose can be estimated initially from cell culture assays, as disclosed herein.
- a dose can be formulated in animal models to achieve a circulating concentration range that includes the EC50 (effective dose for 50% increase) as determined in cell culture, i.e., the concentration of the test compound which achieves a half-maximal inhibition of bacterial cell growth.
- EC50 effective dose for 50% increase
- concentration of the test compound which achieves a half-maximal inhibition of bacterial cell growth Such information can be used to more accurately determine useful doses in humans.
- the compounds prepared by the methods, and from the intermediates, described herein will be administered in a therapeutically or cosmetically effective amount by any of the accepted modes of administration for agents that serve similar utilities. It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, and rate of excretion, drug combination, the severity of the particular disease undergoing therapy and the judgment of the prescribing physician.
- the drug can be administered from once or twice a day, or up to 3 or 4 times a day.
- Dosage amount and interval can be adjusted individually to provide plasma levels of the active moiety that are sufficient to maintain bacterial cell growth inhibitory effects.
- Usual patient dosages for systemic administration range from 0.1 to 1000 mg/day, preferably, 1-500 mg/day. more preferably 10 - 200 mg/day, even more preferably 100 - 200 mg/day. Stated in terms of patient body surface areas, usual dosages range from 50-91 mg/m 2 /day.
- the amount of the compound in a formulation can vary within the full range employed by those skilled in the art.
- the formulation will contain, on a weight percent (wt%) basis, from about 0.01-iO wt% of the drag based on the total formulation, with the balance being one or more suitable pharmaceutical excipients.
- the compound is present at a level of about 0.1-3.0 wt%, more preferably, about 1,0 wt%.
- This compound can be synthesized according to the method described in Benkovic el at., J. Med. Chern,, 48: 7468-7476 (2005).
- This compound can be synthesized according to the method described in Brown et al., J, Org. Chem,, 51: 4526-4530 (1986).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Compounds, pharmaceutical compositions, and methods of using either to kill microorganisms are disclosed.
Description
PATENT APPLICATION
MICROORGANISM KILLING COMPOUNDS
CROSS-REFERENCE TO RELATED APPLICATIONS
JOOOl] This application claims priority to United States Provisional Patent Application Serial No. 60/867,065 filed on November 22, 2006 (Attorney Docket No. 064507-5020US). which is herein incorporated by reference in its entirety for all purposes.
BACKGROUND OF THE INVENTION
[0002] There is a need in the art for compounds which can effectively inhibit the growth of. or kill, microorganisms. There is a need in the art for compounds which can effectively penetrate the nail. There is also need in the art for compounds which can effectively treat ungual and/or periungual infections. These and other needs are addressed by the current invention.
BRIEF SUMMARY OF THE INVENTION
|0003] In a first aspect, the invention provides a compound described herein. In an exemplary embodiment, the compound is a salt of a compound of the invention. In an exemplary embodiment, the compound is a pharmaceutically acceptable salt of a compound of the invention. In an exemplary embodiment, the compound has a structure according to the following formula:
wherein Y is a member selected from substituted or unsubstituted vinyl and substituted or unsubstituted aryl. Z, RΛ R , Rc and R are members independently selected from members independently selected from H, OR*, NR*R**, SR*, -S(O)R*. -S(O)2R*, -S(O)2NR*R**, nitro, halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted
heteroaryl. Rb and Rc, together with the atoms to which they are attached, are optionally joined to form a 4- to 8-membered ring. Rd and Re, together with the atoms to which they are attached, are optionally joined to form a 4- to 8-membered ring. Y and Z, together with the atoms to which they are attached, are optionally joined to form a member selected from a 4- to 8- membered ring and a 6- to 12-membered bicyclic ring. Each R* and R** are members independently selected from H, nitro, halogen, cyano, substituted or unsubstituted aikyi, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyi, substituted or unsubstituted heterocycloaikyi, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
[0004] In an exemplary embodiment, said compound has a structure which is a member selected from:
In an exemplary embodiment, said compound has a structure according to the following formula:
In an exemplary embodiment, said Z is substituted or unsubstituted vinyl. In an exemplary embodiment, said compound is a member selected from
In an exemplary embodiment, said compound is a member selected from
In an exemplary embodiment, said Z is substituted or unsubstituted alkyl, and wherein said substituted or unsubstituted alkyl is substituted or unsubstituted alkenyl. In an exemplary embodiment, said Z is substituted or unsubstituted vinyl. In an exemplary embodiment, said Z is substituted or unsubstituted aryl. In an exemplary embodiment, said Z is substituted aryl, and has a structure according to the following formula:
wherein R is a member selected from H, nitro, halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl. substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl. In an exemplary embodiment, said R1 is a member selected from nitro, halogen, cyano and substituted or unsubstituted alkyl. In an exemplary embodiment, said R1 is a member selected from fluorine, chlorine and bromine.
compound is F XJT H2N- . In an exemplary embodiment, said Z is substituted or unsubstituted heteroaryl, In an exemplary embodiment, said Z is a member selected from substituted or unsubstituted 2-pyridinyl, substituted or unsubstituted 3-pyridinyl and substituted or unsubstituted 4-pyridinyI. In an exemplary embodiment, said Z is substituted or unsubstituted 3-pyridinyl. In an exemplary embodiment, said compound is
In an exemplary embodiment, Rb and Rc, together with the atoms to
which they are attached, are joined to form a substituted or unsubstituted 4- to 6-membered
ring. In an exemplary embodiment, said compound i tsc
In an exemplary embodiment, said compound is a member selected from
having a structure according to
. In an exemplary embodiment, said compound is a member selected from
exemplary embodiment, Y and Z, together with the atoms to which they are attached, are joined to form a member selected from a 4- to 8- membered ring and a 6- to 12-membered bicyclic ring. In an exemplary embodiment, Y and Z, together with the atoms to which they are attached, are joined to form an 8-membered bicyclic ring. In an exemplary embodiment, wherein said 8-membered bicyclic ring is unsubstituted. In an exemplary embodiment, the compound has a structure which is a
member selected from
anj
In an exemplary embodiment, the compound has a structure which is a member selected from
has a structure which is a member selected from
and
In an exemplary embodiment, the compound has a structure which is a member selected from
has a structure which is a member selected from
and
[0005] In another aspect, the invention provides a method of inhibiting the growth of, or killing, a fungus, said method comprising: contacting said fungus with a compound of the invention, in an amount sufficient to inhibit or kill said fungus. In an exemplary embodiment, the compound is a salt of a compound of the invention. In an exemplary embodiment, the compound is a pharmaceutically acceptable salt of a compound of the invention. In an exemplary embodiment, said fungus is a member selected from a dermatophyte, Trichophyton species, Microsporium species, Candida species, Aspergillus species and yeast-like fungus. In an exemplary embodiment, the compound is described above. In an exemplary embodiment, wherein said fungus is a member selected from Candida albicans, Candida neoformans, Aspergillus fumigatus, Trichophyton mentagrophytes (T. mentagrophytes) and Trichophyton rubrum (T. rubrum). In an exemplary embodiment, there is a proviso that the molecular weight of said compound is not greater than about 200. In an exemplary embodiment, there is a proviso that the c log P of said compound is between about -2 and about 2. In an exemplary embodiment, there is a proviso that the efficacy coefficient of said compound is greater than about 10. In an exemplary embodiment, the compound has a structure described in section HA '"Boron- Containing Compounds*'. In an exemplary embodiment, the compound has a structure described from paragraph 58 to paragraph 79. In an exemplary embodiment, the compound has a structure described from paragraph 58 to paragraph 72. In an exemplary embodiment, the compound has a structure described in section HB ''Acyclic Boronic Acids". In an exemplary embodiment, the compound has a structure described from paragraph 80 to paragraph 83, In an exemplary embodiment, the compound has a structure described in paragraph 80. In an exemplary embodiment, the compound has a structure described in section OC ''Low MW Pyridone/Pyrithione derivatives". In an exemplary embodiment, the compound has a structure described from paragraph 84 to paragraph 87. In an exemplary embodiment, the compound has a structure described in paragraph 84. In an exemplary embodiment, the compound has a structure described in section HD "Low MW fungicide moiety F. In an exemplary embodiment, the compound has a structure described from paragraph 88 to paragraph 91. In an exemplary embodiment, the compound has a structure described in paragraph 88. In an exemplary embodiment, the compound has a structure described in section HE "Low MW fungicide moiety II". In an exemplary embodiment, the compound has a structure described from paragraph 92 to paragraph 95. In an exemplary embodiment, the compound has a structure described in paragraph 92. In an exemplary embodiment, the compound has a structure described in section HF "Low MW fungicide
moiety III". In an exemplary embodiment, the compound has a structure described from paragraph 96 to paragraph 115. In an exemplary embodiment, the compound has a structure described in paragraph 96. In an exemplary embodiment, the compound has a structure described in section HG "Commercial Fungicides*'. In an exemplary embodiment, the compound has a structure described from paragraph 116 to paragraph 1 17. In an exemplary embodiment, the compound has a structure described in paragraph 1 16.
JΘ006] In another aspect, the invention provides a method of treating a disease in a subject, said method comprising administering to said subject a therapeutically effective amount of a compound, thereby treating said disease. In an exemplary embodiment, the disease is an ungual, periungual or subungual infection, In an exemplary embodiment, the compound is described herein. In an exemplary embodiment, the compound is a salt of a compound of the invention. In an exemplary embodiment, the compound is a pharmaceutically acceptable salt of a compound of the invention. In another exemplary embodiment, the compound is described above. In an exemplary embodiment, the disease is caused by, or involves a fungus is a member selected from Candida albicans, Candida neoformans, Aspergillus fumigatus, Trichophyton mentagrophytes {T. mentagrophytes) and Trichophyton rubrum (T. rubrum). In an exemplary embodiment, said disease is onychomycosis. In an exemplary embodiment, there is a proviso that the molecular weight of said compound is not greater than about 200. In an exemplary embodiment, there is a proviso that the c log P of said compound is between about -2 and about 2. In an exemplary embodiment, there is a proviso that the efficacy coefficient of said compound is greater than about 10. In an exemplary embodiment, the compound has a structure described in section HA '"Boron-Containing Compounds". In an exemplary embodiment, the compound has a structure described from paragraph 58 to paragraph 79. In an exemplary embodiment, the compound has a structure described from paragraph 58 to paragraph 72. In an exemplary embodiment, the compound has a structure described in section OB "Acyclic Boronic Acids". In an exemplary embodiment, the compound has a structure described from paragraph 80 to paragraph 83. In an exemplary embodiment, the compound has a structure described in paragraph 80. In an exemplary embodiment, the compound has a structure described in section HC "Low MW Pyridone/Pyrithione derivatives". In an exemplary embodiment, the compound has a structure described from paragraph 84 to paragraph 87. In an exemplary embodiment, the compound has a structure described in paragraph 84. In an exemplary embodiment, the compound has a structure described in section HD "Low MW fungicide moiety F'. In an exemplary embodiment, the compound has a structure described
from paragraph 88 to paragraph 91. In an exemplary embodiment, the compound has a structure described in paragraph 88. In an exemplary embodiment, the compound has a structure described in section HE "Low MW fungicide moiety II". In an exemplary embodiment, the compound has a structure described from paragraph 92 to paragraph 95. In an exemplary embodiment, the compound has a structure described in paragraph 92. In an exemplary embodiment, the compound has a structure described in section HF "Low MW fungicide moiety III". In an exemplary embodiment, the compound has a structure described from paragraph 96 to paragraph 1 15. In an exemplary embodiment, the compound has a structure described in paragraph 96. In an exemplary embodiment, the compound has a structure described in section HG "Commercial Fungicides". In an exemplary embodiment, the compound has a structure described from paragraph 116 to paragraph 117. In an exemplary embodiment, the compound has a structure described in paragraph 1 16.
[0007] In another aspect, the invention provides a pharmaceutical formulation comprising: a) a pharmaceutically acceptable excipient; and b) a compound of the invention. In an exemplary embodiment, the compound is described above. In an exemplary embodiment, the compound is a salt of a compound of the invention. In an exemplary embodiment, the compound is a pharmaceutically acceptable salt of a compound of the invention, In an exemplary embodiment, there is the proviso that the molecular weight of said compound is not greater than about 200. In an exemplary embodiment, there is the proviso that the c log P of said compound is between about -2 and about 2. In an exemplary embodiment, there is the proviso that the efficacy coefficient of said compound is greater than about 10. In an exemplary embodiment, the compound has a structure described in section HA '"Boron-Containing Compounds"'. In an exemplary embodiment, the compound has a structure described from paragraph 58 to paragraph 79. In an exemplary embodiment, the compound has a structure described from paragraph 58 to paragraph 72. In an exemplary embodiment, the compound has a structure described in section HB "Acyclic Boronic Acids'*. In an exemplary embodiment, the compound has a structure described from paragraph 80 to paragraph 83. In an exemplary embodiment, the compound has a structure described in paragraph 80. In an exemplary embodiment, the compound has a structure described in section HC "Low MW Pyridone/Pyrithione derivatives". In an exemplary embodiment, the compound has a structure described from paragraph 84 to paragraph 87. In an exemplary embodiment, the compound has a structure described in paragraph 84. In an exemplary embodiment, the compound has a structure described in section HD "Low MW fungicide moiety I". In an exemplary embodiment, the compound has a structure described
from paragraph 88 Io paragraph 91. In an exemplary embodiment, the compound has a structure described in paragraph 88. In an exemplary embodiment, the compound has a structure described in section HE "Low MW fungicide moiety II". In an exemplary embodiment, the compound has a structure described from paragraph 92 to paragraph 95. In an exemplary embodiment, the compound has a structure described in paragraph 92. In an exemplary embodiment, the compound has a structure described in section HF '"Low MW fungicide moiety III". In an exemplary embodiment, the compound has a structure described from paragraph 96 to paragraph 115. In an exemplary embodiment, the compound has a structure described in paragraph 96. In an exemplary embodiment, the compound has a structure described in section HG "Commercial Fungicides". In an exemplary embodiment, the compound has a structure described from paragraph 116 to paragraph 117, In an exemplary embodiment, the compound has a structure described in paragraph 1 16.
[0008] In another aspect, the invention provides a formulation comprising: (a) a keratin containing component which is a member selected from a human nail unit, skin and hair; (b) a compound having a structure described herein. In an exemplary embodiment, the compound has a structure described above. In an exemplary embodiment, the compound is a salt of a compound of the invention. In an exemplary embodiment, the compound is a pharmaceutically acceptable salt of a compound of the invention. In an exemplary embodiment, the compound has a structure described in section HA "Boron-Containing Compounds". In an exemplary embodiment, the compound has a structure described from paragraph 58 to paragraph 79. In an exemplary embodiment, the compound has a structure described from paragraph 58 to paragraph 72, In an exemplary embodiment, the compound has a structure described in section IIB "Acyclic Boronic Acids". In an exemplary embodiment, the compound has a structure described from paragraph 80 to paragraph 83, In an exemplary embodiment, the compound has a structure described in paragraph 80. In an exemplary embodiment, the compound has a structure described in section HC "Low MW Pyridone/Pyrithione derivatives". In an exemplary embodiment, the compound has a structure described from paragraph 84 to paragraph 87. In an exemplary embodiment, the compound has a structure described in paragraph 84. In an exemplary embodiment, the compound has a structure described in section IID "Low MW fungicide moiety I". In an exemplary embodiment, the compound has a structure described from paragraph 88 to paragraph 91. In an exemplary embodiment, the compound has a structure described in paragraph 88. In an exemplary embodiment, the compound has a structure described in section HE
"Low MW fungicide moiety II"'. In an exemplary embodiment, the compound has a structure described from paragraph 92 to paragraph 95, In an exemplary embodiment, the compound has a structure described in paragraph 92. In an exemplary embodiment. the compound has a structure described in section HF "'Low MW fungicide moiety III". In an exemplary embodiment, the compound has a structure described from paragraph 96 to paragraph 1 15. In an exemplary embodiment, the compound has a structure described in paragraph 96. In an exemplary embodiment, the compound has a structure described in section HG "'Commercial Fungicides''. In an exemplary embodiment, the compound has a structure described from paragraph 1 16 to paragraph 117. In an exemplary embodiment, the compound has a structure described in paragraph 116.
[0009] In another aspect, the invention provides a method of inhibiting the growth of, or killing, a microorganism present in a human nail unit, wherein said human nail unit comprises a nail plate, comprising: contacting a dorsal layer of the nail plate with a compound capable of penetrating the nail plate, traveling through the nail plate to a nail bed underlying said nail plate, and contacting said microorganism, under conditions sufficient for said compound to penetrate said nail plate, wherein said compound has a structure described herein. In an exemplary embodiment, the compound has a structure described above. In an exemplary embodiment, the compound is a salt of a compound of the invention. In an exemplary embodiment, the compound is a pharmaceutically acceptable salt of a compound of the invention. In an exemplary embodiment, said microorganism is a member selected from a bacteria, a fungus, a virus, a parasite, and a yeast. In an exemplary embodiment, said microorganism is a fungus, and said fungus is a member selected from a dermatophyte, Trichophyton species. Microsporium species, Candida species, Aspergillus species and yeast-like fungus. In an exemplary embodiment, said fungus is a member selected from Candida albicans, Candida neoformans, Aspergillus fumigatus. Trichophyton mentagrophytes (T. mentagrophyles) and Trichophyton rubrwn (T rubruni). In an exemplary embodiment, there is the proviso that the molecular weight of said compound is not greater than about 200. In an exemplary embodiment, there is the proviso that the c log P of said compound is between about -2 and about 2. In an exemplary embodiment, there is the proviso that the efficacy coefficient of said compound is greater than about 10. In an exemplary embodiment, the compound has a structure described in section HA "Boron-Containing Compounds", In an exemplary embodiment, the compound has a structure described from paragraph 58 to paragraph 79. In an exemplary embodiment, the compound has a structure described
from paragraph 58 to paragraph 72. In an exemplary embodiment, the compound has a structure described in section HB "Acyclic Boronic Acids". In an exemplary embodiment, the compound has a structure described from paragraph 80 to paragraph 83. In an exemplary embodiment, the compound has a structure described in paragraph 80. In an exemplary embodiment, the compound has a structure described in section OC "Low MW Pyridone/Pyrithione derivatives". In an exemplary embodiment, the compound has a structure described from paragraph 84 to paragraph 87. In an exemplary embodiment, the compound has a structure described in paragraph 84. In an exemplary embodiment, the compound has a structure described in section IID "Low MW fungicide moiety I". In an exemplary embodiment, the compound has a structure described from paragraph 88 to paragraph 91. In an exemplary embodiment, the compound has a structure described in paragraph 88. In an exemplary embodiment, the compound has a structure described in section OE "Low MW fungicide moiety II"'. In an exemplary embodiment, the compound has a structure described from paragraph 92 to paragraph 95. In an exemplary embodiment, the compound has a structure described in paragraph 92. In an exemplary embodiment, the compound has a structure described in section IfF "Low MW fungicide moiety IH''. In an exemplary embodiment, the compound has a structure described from paragraph 96 to paragraph 1 15. In an exemplary embodiment, the compound has a structure described in paragraph 96. In an exemplary embodiment, the compound has a structure described in section HG "Commercial Fungicides". In an exemplary embodiment, the compound has a structure described from paragraph 116 to paragraph 1 17. In an exemplary embodiment, the compound has a structure described in paragraph 1 16.
[001 OJ In another aspect, the invention provides a method of inhibiting the growth of, or killing, a fungus, said method comprising: contacting said fungus with a compound in an amount sufficient to inhibit or kill said fungus, wherein said fungus is a member selected from a dermatophyte, Trichophyton species, Microsporhtm species, Candida species, Aspergillus species and yeast-like fungus. In an exemplary embodiment, the compound is described herein. In an exemplary embodiment, the compound is a salt of a compound of the invention. In an exemplary embodiment, the compound is a pharmaceutically acceptable salt of a compound of the invention. In an exemplary embodiment, the compound is provided above. In an exemplary embodiment, the compound has a structure described in section ΪIA "Boron-Containing Compounds". In an exemplary embodiment, the compound has a structure described from paragraph 58 to
paragraph 79. In an exemplary embodiment, the compound has a structure described from paragraph 58 to paragraph 72. In an exemplary embodiment, the compound has a structure described in section HB "Acyclic Boronic Acids". In an exemplary embodiment, the compound has a structure described from paragraph 80 to paragraph 83. In an exemplary embodiment, the compound has a structure described in paragraph 80. In an exemplary embodiment, the compound has a structure described in section HC "Low MW Pyridone/Pyrithione derivatives". In an exemplary embodiment, the compound has a structure described from paragraph 84 to paragraph 87. In an exemplary embodiment, the compound has a structure described in paragraph 84. In an exemplary embodiment, the compound has a structure described in section HD "Low MW fungicide moiety I'\ In an exemplary embodiment, the compound has a structure described from paragraph 88 to paragraph 91. In an exemplary embodiment, the compound has a structure described in paragraph 88. In an exemplary embodiment, the compound has a structure described in section HE ''Low MW fungicide moiety II". In an exemplary embodiment, the compound has a structure described from paragraph 92 to paragraph 95. In an exemplary embodiment, the compound has a structure described in paragraph 92, In an exemplary embodiment, the compound has a structure described in section IIP ''Low MW fungicide moiety HI", In an exemplary embodiment, the compound has a structure described from paragraph 96 to paragraph 1 15. In an exemplary embodiment, the compound has a structure described in paragraph 96. In an exemplary embodiment, the compound has a structure described in section HG "Commercial Fungicides". In an exemplary embodiment, the compound has a structure described from paragraph 1 16 to paragraph 1 17. In an exemplary embodiment, the compound has a structure described in paragraph 1 16.
(0011] In another aspect, the invention provides a method of treating a disease in a subject, said method comprising administering to said subject a therapeutically effective amount of a compound, thereby treating said disease; wherein said disease is an ungual. periungual or subungual infection. In an exemplary embodiment, the compound is described herein. In an exemplary embodiment, the compound is a salt of a compound of the invention. In an exemplary embodiment, the compound is a pharmaceutically acceptable salt of a compound of the invention. In an exemplary embodiment, the compound is provided above. In an exemplary embodiment, the compound has a structure described in section HA "Boron- Containing Compounds". In an exemplary embodiment, the compound has a structure described from paragraph 58 to paragraph 79. In an exemplary embodiment, the
compound has a structure described from paragraph 58 to paragraph 72. In an exemplary embodiment, the compound has a structure described in section HB "Acyclic Boronic Acids". In an exemplary embodiment, the compound has a structure described from paragraph 80 to paragraph 83. 3n an exemplary embodiment, the compound has a structure described in paragraph 80. In an exemplary embodiment, the compound has a structure described in section HC "Low MW Pyridone/Pyrithione derivatives". In an exemplary embodiment, the compound has a structure described from paragraph 84 to paragraph 87. In an exemplary embodiment, the compound has a structure described in paragraph 84. In an exemplary embodiment, the compound has a structure described in section HD '"Low MW fungicide moiety I". In an exemplary embodiment, the compound has a structure described from paragraph 88 to paragraph 91. In an exemplary embodiment, the compound has a structure described in paragraph 88. In an exemplary embodiment, the compound has a structure described in section HE "Low MW fungicide moiety II". In an exemplary embodiment, the compound has a structure described from paragraph 92 to paragraph 95. In an exemplary embodiment, the compound has a structure described in paragraph 92. In an exemplary embodiment, the compound has a structure described in section HF "Low MW fungicide moiety III". In an exemplary embodiment, the compound has a structure described from paragraph 96 to paragraph 1 15. In an exemplary embodiment, the compound has a structure described in paragraph 96. In an exemplary embodiment, the compound has a structure described in section HG '"Commercial Fungicides". In an exemplary embodiment, the compound has a structure described from paragraph 116 to paragraph 1 17. In an exemplary embodiment, the compound has a structure described in paragraph 1 16.
[0012) In another aspect, the invention provides a pharmaceutical formulation comprising: a) a pharmaceutically acceptable excipient; and b) a compound of the invention. In an exemplary embodiment, the compound is a salt of a compound of the invention. In an exemplary embodiment, the compound is a pharmaceutically acceptable salt of a compound of the invention. In an exemplary embodiment, the compound has a structure described in section HA "Boron- Containing Compounds", In an exemplary embodiment, the compound has a structure described in section HA "Boron-Containing Compounds". In an exemplary embodiment, the compound has a structure described from paragraph 58 to paragraph 79. In an exemplary embodiment, the compound has a structure described from paragraph 58 to paragraph 72. In an exemplary embodiment, the compound has a structure described in section HB "Acyclic Boronic Acids". In an exemplary embodiment, the compound has a structure described from paragraph 80 to paragraph 83. In an exemplary embodiment, the
compound has a structure described in paragraph 80. In an exemplary embodiment, the compound has a structure described in section HC "Low MW Pyridone/Pyrithione derivatives". In an exemplary embodiment, the compound has a structure described from paragraph 84 to paragraph 87. In an exemplary embodiment, the compound has a structure described in paragraph 84. In an exemplary embodiment, the compound has a structure described in section UD "Low MW fungicide moiety I". In an exemplary embodiment, the compound has a structure described from paragraph 88 to paragraph 91. In an exemplary embodiment, the compound has a structure described in paragraph 88. In an exemplary embodiment, the compound has a structure described in section HE "Low MW fungicide moiety II". In an exemplary embodiment, the compound has a structure described from paragraph 92 to paragraph 95, In an exemplary embodiment, the compound has a structure described in paragraph 92. In an exemplary embodiment, the compound has a structure described in section OF '"Low MW fungicide moiety III". In an exemplary embodiment, the compound has a structure described from paragraph 96 to paragraph 1 15. In an exemplary embodiment, the compound has a structure described in paragraph 96. In an exemplary embodiment, the compound has a structure described in section HG "Commercial Fungicides". In an exemplary embodiment, the compound has a structure described from paragraph 116 to paragraph 1 17. In an exemplary embodiment, the compound has a structure described in paragraph 1 16.
(0013] In another aspect, the invention provides a formulation comprising: (a) a keratin containing component which is a member selected from a human nail unit, skin and hair; (b) a compound of the invention. In an exemplary embodiment, the compound is a salt of a compound of the invention. In an exemplary embodiment, the compound is a pharmaceutically acceptable salt of a compound of the invention. In an exemplary embodiment, the compound has a structure described in section HA "Boron-Containing Compounds". In an exemplary embodiment, the compound has a structure described from paragraph 58 to paragraph 79. In an exemplary embodiment, the compound has a structure described from paragraph 58 to paragraph 72. In an exemplary embodiment, the compound has a structure described in section HB "Acyclic Boronic Acids*'. In an exemplary embodiment, the compound has a structure described from paragraph 80 to paragraph 83. In an exemplary embodiment, the compound has a structure described in paragraph 80. In an exemplary embodiment, the compound has a structure described in section HC "Low MW Pyridone/Pyrithione derivatives". In an exemplary embodiment, the compound has a structure described from paragraph 84 to paragraph 87. In an
exemplary embodiment, the compound has a structure described in paragraph 84. In an exemplary embodiment, the compound has a structure described in section HD "Low MW fungicide moiety I". In an exemplary embodiment, the compound has a structure described from paragraph 88 to paragraph 91. In an exemplary embodiment, the compound has a structure described in paragraph 88. In an exemplary embodiment, the compound has a structure described in section HE "Low MW fungicide moiety II". In an exemplary embodiment, the compound has a structure described from paragraph 92 to paragraph 95. In an exemplar}' embodiment, the compound has a structure described in paragraph 92. In an exemplary embodiment, the compound has a structure described in section HF '"Low MW fungicide moiety IH''. In an exemplary embodiment, the compound has a structure described from paragraph 96 to paragraph 1 15. In an exemplary embodiment, the compound has a structure described in paragraph 96. In an exemplary embodiment, the compound has a structure described in section HG "Commercial Fungicides". In an exemplary embodiment, the compound has a structure described from paragraph 1 16 to paragraph 117. In an exemplary embodiment, the compound has a structure described in paragraph 1 16.
[0014] In another aspect, the invention provides a method of inhibiting the growth of, or killing, a microorganism present in a human nail unit, wherein said human nail unit comprises a nail plate, comprising: contacting a dorsal layer of the nail plate with a compound capable of penetrating the nail plate, traveling through the nail plate to a nail bed underlying said nail plate, and contacting said microorganism, under conditions sufficient for said compound to penetrate said nail plate. In an exemplary embodiment, the compound is described herein. In an exemplary embodiment, the compound is a salt of a compound of the invention. In an exemplary embodiment, the compound is a pharmaceutical] y acceptable salt of a compound of the invention. In an exemplary embodiment, the compound has a structure described in section HA "Boron-Containing Compounds". In an exemplary embodiment, the compound has a structure described from paragraph 58 to paragraph 79. In an exemplary embodiment, the compound has a structure described from paragraph 58 to paragraph 72. In an exemplary embodiment, the compound has a structure described in section HB "Acyclic Boronic Acids". In an exemplary embodiment, the compound has a structure described from paragraph 80 to paragraph 83. In an exemplary embodiment, the compound has a structure described in paragraph 80. In an exemplary embodiment, the compound has a structure described in section HC "Low MW Pyridone/Pyrithione derivatives". In an exemplary embodiment,
the compound has a structure described from paragraph 84 to paragraph 87. In an exemplary embodiment, the compound has a structure described in paragraph 84. In an exemplary embodiment, the compound has a structure described in section HD "Low MW fungicide moiety I". In an exemplary embodiment, the compound has a structure described from paragraph 88 to paragraph 91. In an exemplary embodiment, the compound has a structure described in paragraph 88, In an exemplary embodiment, the compound has a structure described in section HE "Low MW fungicide moiety II'". In an exemplary embodiment, the compound has a structure described from paragraph 92 to paragraph 95. In an exemplary embodiment, the compound has a structure described in paragraph 92. In an exemplary embodiment, the compound has a structure described in section HF "Low MW fungicide moiety III". In an exemplary embodiment, the compound has a structure described from paragraph 96 to paragraph 115. In an exemplary embodiment, the compound has a structure described in paragraph 96. In an exemplary embodiment, the compound has a structure described in section HG "Commercial Fungicides". In an exemplary embodiment, the compound has a structure described from paragraph 116 to paragraph 1 17. In an exemplary embodiment, the compound has a structure described in paragraph 116,
BRIEF DESCRIPTION OF THE DRAWINGS
[0015] FIG. 1 shows selected compounds of the invention and MlC data against various microorganisms.
DETAILED DESCRIPTION OF THE INVENTION
Definitions and Abbreviations
[0016] The abbreviations used herein generally have their conventional meaning within the chemical and biological arts.
[0017] "Compound of the invention" and "exemplary compounds of use in methods of the invention," are used interchangeably and refer to the compounds discussed herein, and pharmaceutically acceptable salts and prodrugs of these compounds.
[0018] Where substituent groups are specified by their conventional chemical formulae, written from left to right, they equally encompass the chemically identical substituents, which would result from writing the structure from right to left, e.g., -CH2O- is intended to also recite -OCH2-.
[0019] The term "poly" as used herein means at least 2. For example, a polyvalent metal ion is a metal ion having a valency of at least 2,
[0020} "Moiety" refers to the radical of a molecule that is attached to another moiety.
10021 ] The symbol ~sw^ , whether utilized as a bond or displayed perpendicular to a bond, indicates the point at which the displayed moiety is attached to the remainder of the molecule.
[0022J The term "'alkyl." by itself or as part of another substituent, means, unless otherwise stated, a straight or branched chain, or cyclic hydrocarbon radical, or combination thereof, which may be fully saturated, mono- or polyunsaturated and can include di- and multivalent radicals, having the number of carbon atoms designated (Le. C|-Cιo means one to ten carbons). Examples of saturated hydrocarbon radicals include, but are not limited to, groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl. sec-butyl, cyclohexyl, (cyclohexyl)methyl. cyclopropylmethyl, homoiogs and isomers of, for example, n-pentyl, n- hexyl, n-heptyl, n-octyl, and the like. An unsaturated aikyl group is one having one or more double bonds or triple bonds. Examples of unsaturated alkyl groups include, but are not limited to, vinyl, 2-propenyl, crotyl. 2-isopentenyl, 2-(butadienyl), 2,4-pentadienyl, 3 -(1.4- pentadienyl), ethynyl, 1- and 3-propynyl, 3-butynyl, and the higher homoiogs and isomers. The term "alkyl," unless otherwise noted, is also meant to include those derivatives of alkyl defined in more detail below, such as "heteroaikyl." Alkyi groups that are limited to hydrocarbon groups are termed "homoalkyl".
[0023] The term "alkyiene" by itself or as part of another substituent means a divalent radical derived from an alkane, as exemplified, but not limited, by -CH2CH2CH2CH2-, and further includes those groups described below as "heteroalkylene." Typically, an alkyi (or alkyiene) group will have from 1 to 24 carbon atoms, with those groups having 10 or fewer carbon atoms being preferred in the present invention. A "lower alkyl" or "lower alkyiene" is a shorter chain alkyi or alkyiene group, generally having eight or fewer carbon atoms.
[0024] The terms "alkoxy," "alkylamino" and "alkylthio" (or thioalkoxy) are used in their conventional sense, and refer to those alkyl groups attached to the remainder of the molecule via an oxygen atom, an amino group, or a sulfur atom, respectively.
[0025] The term "heteroalkyl," by itself or in combination with another term, means, unless otherwise stated, a stable straight or branched chain, or cyclic hydrocarbon radical, or combinations thereof, consisting of the stated number of carbon atoms and at least one
heteroatom. In an exemplary embodiment, the heteroatoms can be selected from the group consisting of B, O, N and S. and wherein the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized. The heteroatom(s) B, O. N and S may be placed at any interior position of the heteroalkyl group or at the position at which the alkyl group is attached to the remainder of the molecule. Examples include, but are not limited to, -CH2-CH2-O-CH3, -CH2-CH2-NH-CH3, -CH2-CH2-N (CH3J-CH3, -CH2-S- CII2-CH3, -CH2-CH^-S(O)-CII3. -CH2-CH2-S(O)2-CH3, -CH-CH-O-CH3, -CH2-CH=N- OCH3, and -CH=CH-N(CH3)-CH3. Up to two heteroatoms may be consecutive, such as, for example, -CH2-NH-OCH3. Similarly, the term "heteroalkylene" by itself or as part of another substituent means a divalent radical derived from heteroalkyl, as exemplified, but not limited by, -CH2-CH2-S-CH2-CH2- and -CH2-S-CH2-CH2-NH-CH2-. For heteroalkylene groups, heteroatoms can also occupy either or both of the chain termini (e g , alkyleneoxy, alkylenedioxy, alkyleneamino, alkylenediarnino. and the like). Still further, for alkylene and heteroalkylene linking groups, no orientation of the linking group is implied by the direction in which the formula of the linking group is written. For example, the formula -C(O)2R'- represents both -C(O)2R'- and -R-C(O)2-.
[0026] The terms "cycloalkyl" and ''heterocycloalkyl". by themselves or in combination with other terms, represent, unless otherwise stated, cyclic versions of "alkyl" and "heteroalkyl", respectively. Additionally, for heterocycloalkyl, a heteroatom can occupy the position at which the heterocycle is attached to the remainder of the molecule. Examples of cycloalkyl include, but are not limited to, cyclopentyl, cyclohexyl, 1 -cyclohexenyl. 3- cyclohexeny], cycloheptyl, and the like. Examples of heterocycloalkyl include, but are not limited to, 1 ~(l,2.5,6-tetrahydropyridyl), 1 -piperidinyl, 2-piperidinyl, 3-piperidinyl, 4- morpholinyl, 3-morpholinyl. tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, 1 -piperazinyl, 2-piperazinyl, and the like.
[0027] The terms "'halo" or "halogen,'" by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom. Additionally, terms such as "haloalkyl," are meant to include monohaloalkyl and polyhaloalkyl. For example, the term *'halo(Ci-C4)alkyr is mean to include, but not be limited to, trifluoromethyl, 2,2,2-trifluoroethyI, 4-chlorobutyl, 3-bromopropyl, and the like.
[0028] The term "aryl" means, unless otherwise stated, a polyunsaturated, aromatic, substituent that can be a single ring or multiple rings (preferably from 1 to 3 rings), which are fused together or linked covalently. The term "heteroaryl" refers to aryl groups (or rings)
I i
that contain from one to four heteroatoms. In an exemplary embodiment, the heteroatom is selected from B, N, O, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized. A heteroaryl group can be attached to the remainder of the molecule through a heteroatom. Non-limiting examples of aryl and heteroaryl groups include phenyl, 1-naphthyl, 2-naphthyl, 4-biphenyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 2-imidazolyl, 4-imidazolyl. pyrazjnyl, 2-oxazolyl, 4-oxazolyl, 2- phenyl-4-oxazolyl. 5-oxazolyl. 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-thiazolyl, 4- thiazolyl, 5-thiazolyl, 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2- pyrimidyl. 4-pyrimidyl, 5-benzothiazolyl, purinyl, 2-benzimidazolyl, 5-jndolyl, 1- isoquinolyl, 5-isoquinolyl, 2-quinoxalinyl, 5-quinoxalinyl, 3-quinolyl, and 6-quinolyl. Substituents for each of the above noted aryl and heteroaryl ring systems are selected from the group of acceptable substituents described below.
[0029] For brevity, the term "'aryl" when used in combination with other terms (e.g., aryloxy. arylthJoxy. arylalkyl) includes both aryl and heteroaryl rings as defined above. Thus, the term ''arylalkyl'' is meant to include those radicals in which an aryl group is attached to an alkyl group (e.g., benzyl, phenethyl, pyridylmethyl and the like) including those alky! groups in which a carbon atom (e.g., a methylene group) has been replaced by, for example, an oxygen atom (e.g., phenoxymethyl, 2-pyridyloxymethyl. 3-(l- naphthyloxy)propyl, and the like).
[0030] Each of the above terms (e.g., "alkyl," ''heteroalkyl," "aryl" and -'heteroaryP') are meant to include both substituted and unsubstituted forms of the indicated radical. Preferred substituents for each type of radical are provided below.
[0031] Substituents for the alkyl and heteroalkyl radicals (including those groups often referred to as alkylene, alkenyl, heteroalkylene, heteroalkenyl, alkynyi, cycloalkyl, heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl) are generically referred to as "alkyl group substituents," and they can be one or more of a variety of groups selected from, but not limited to: -OR', =0, =NR', -N-OR', -NR5R". -SR', -halogen, -OC(O)R', -C(O)R', -CO2R', -CONR'R", -OC(O)NR7R", -NRX(O)R', -NR'-C(0)NR"'R'"5 -NRX(O)2R', -NR- C(NR'R"R'")=NR"". -NR-C(NR*R")=NR*", -S(O)R'. -S(O)2R', -S(O)2NR1R", -NRSO2R'. - CN and -NO2 in a number ranging from zero to (2m '+I), where m' is the total number of carbon atoms in such radical. R", R", R'" and R"" each preferably independently refer to hydrogen, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, e.g. , aryl substituted with 1-3 halogens, substituted or unsubstituted alkyl, alkoxy or thioalkoxy
groups, or arylalky] groups. When a compound of the invention includes more than one R group, for example, each of the R groups is independently selected as are each R', R", R"* and R'"" groups when more than one of these groups is present. When R' and R" are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring. For example, -NR'R" is meant to include, but not be limited to. 1 -pyrrolidinyl and 4-morpholinyl. From the above discussion of substituents, one of skill in the art will understand that the term "alkyl" is meant to include groups including carbon atoms bound to groups other than hydrogen groups, such as haloalkyl {e.g., -CF3 and ~ CH2CF3) and acyl (e g , -C(O)CH3, -C(O)CF3, -C(O)CH2OCH3, and the like).
[0032] Similar to the substituents described for the alkyl radical, substituents for the aryl and heteroaryl groups are generkally referred to as "aryl group substituents." The substituents are selected from, for example: halogen, -OR', =0, =NR\ =N-0R", -NR'R*', - SR'. -halogen. -OC(O)R", -C(O)R', -CO2R', -CONR'R", -OC(O)NR5R", -NR"C(O)R\ -NR*-C(O)NR"R"\ -NR"C(0)2R\ -NR-C(NR'R"R'")=NR'"\ -NR-C(NR'R")=NR"\ - S(O)R', -S(O)2R', -S(O)2NR5R", -NRSO2R', -CN and -NO2, -R', -N3, -CH(Ph)2, fluoro(Cr C4)alkoxy. and fluoro(Ci-C4)alkyL in a number ranging from zero to the total number of open valences on the aromatic ring system; and where R', R", R'" and R'"" are preferably independently selected from hydrogen, substituted or unsubslituted alkyl, substituted or unsubstituted heteroalkyi, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl. When a compound of the invention includes more than one R group, for example, each of the R groups is independently selected as are each R', R", R'" and R'"" groups when more than one of these groups is present.
[0033] Two of the substituenls on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -T-C(O)-(CRR^q-U-, wherein T and U are independently -NR-, -0-, -CRR'- or a single bond, and q is an integer of from O to 3. Alternatively, two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula -A-(CH2VB-, wherein A and B are independently -CRR'-, -O-, -NR-. -S-, -S(O)-. -S(O)2-, -S(O)2NR'- or a single bond, and r is an integer of from 1 to 4. One of the single bonds of the new ring so formed may optionally be replaced with a double bond. Alternatively, two of the substituents on adjacent atoms of the aryl or heteroaryl ring may optionally be replaced with a substituent of the formula - (CRR')s-X-(CR"R"')d-, where s and d are independently integers of from O to 3, and X is -O- , -NR'-. -S-, -S(O)-, -S(O)2-. or -S(O)2NR'-. The substituents R, R% R" and R'"' are
preferably independently selected from hydrogen or substituted or unsubstituted (Q- C6)alkyl.
[0034] "Ring"' as used herein means a substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, A ring optionally includes fused ring moieties. Substituents on the ring may be optionally joined to form additional ring systems (bicyclic or tricyclic ring systems, for example). The number of atoms in a ring is typically defined by the number of members in the ring. For example, a "5- to 7-membered ring" means there are 5 to 7 atoms in the encircling arrangement. The ring optionally included a heteroatom. Thus, the term "5- to 7-membered ring"' includes, for example pyridinyl and pipcridinyl. The term "'ring'' further includes a ring system comprising more than one "'ring", wherein each "ring"' is independently defined as above.
[0035] As used herein, the term "heteroatom" includes atoms other than carbon (C) and hydrogen (H). Examples include oxygen (O). nitrogen (N) sulfur (S), silicon (Si), germanium (Ge), aluminum (Al) and boron (B).
[0036] The symbol "R" is a general abbreviation that represents a substituent group that is selected from substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl. substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl and substituted or unsubstituted heterocycloalkyl groups.
[0037] By "'effective" amount of a drug, formulation, or permeant is meant a sufficient amount of a active agent to provide the desired local or systemic effect. A "Topically effective," "'Cosmetically effective," "pharmaceutically effective," or "therapeutically effective" amount refers to the amount of drug needed to effect the desired therapeutic result.
[0038] "Topically effective" refers to a material that, when applied to the skin, nail, hair, claw or hoof produces a desired pharmacological result cither locally at the place of application or systemically as a result of transdermal passage of an active ingredient in the material,
[0039] "Cosmetically effective" refers to a material that, when applied to the skin, nail, hair, claw or hoof, produces a desired cosmetic result locally at the place of application of an active ingredient in the material.
[0040] The term "pharmaceutically acceptable salts" is meant to include salts of the compounds of the invention which are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein. When compounds of the present invention contain relatively acidic functionalities, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt. When compounds of the present invention contain relatively basic functionalities, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic. phthalic, benzene sulfonic, p-tolylsulfonic, citric, tartaric, methanesulfonic, and the like. Also included are salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, for example, Berge el al.. Journal of Pharmaceutical Science 66: 1-19 (1977)). Certain specific compounds of the present invention contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.
[0041] The neutral forms of the compounds are preferably regenerated by contacting the salt with a base or acid and isolating the parent compounds in the conventional manner. The parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents.
[0042] In addition to salt forms, the present invention provides compounds which are in a prodrug form. Prodrugs of the compounds or complexes described herein readily undergo chemical changes under physiological conditions to provide the compounds of the present invention. Additionally, prodrugs can be converted to the compounds of the present invention by chemical or biochemical methods in an ex vivo environment.
[0043] Certain compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to
unsolvated forms and are encompassed within the scope of the present invention. Certain compounds of the present invention may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present invention and are intended to be within the scope of the present invention.
[0044] Certain compounds of the present invention possess asymmetric carbon atoms (optical centers) or double bonds; the racemates, diastereomers, geometric isomers and individual isomers are encompassed within the scope of the present invention.
J0045] The compounds of the present invention may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, the compounds may be radiolabeled with radioactive isotopes, such as for example tritium (1H), iodine- 125 (123I) or carbon- 14 (14C). All isotopic variations of the compounds of the present invention, whether radioactive or not, are intended to be encompassed within the scope of the present invention.
[0046] The term ''pharmaceutically acceptable carrier" or "pharmaceutically acceptable vehicle" refers to any formulation or carrier medium that provides the appropriate delivery of an effective amount of a active agent as defined herein, does not interfere with the effectiveness of the biological activity of the active agent, and that is sufficiently non-toxic to the host or patient. Representative carriers include water, oils, both vegetable and mineral, cream bases, lotion bases, ointment bases and the like. These bases include suspending agents, thickeners, penetration enhancers, and the like. Their formulation is well known to those in the art of cosmetics and topical pharmaceuticals. Additional information concerning carriers can be found in Remington: The Science and Practice of Pharmacy, 21st Ed., Lippincott, Williams & Wilkins (2005) which is incorporated herein by reference.
[0047] "Pharmaceutically acceptable topical carrier"' and equivalent terms refer to pharmaceutically acceptable carriers, as described herein above, suitable for topical application. An inactive liquid or cream vehicle capable of suspending or dissolving the active agent(s), and having the properties of being nontoxic and non-inflammatory when applied to the skin, nail, hair, claw or hoof is an example of a pharmaceutically-acceptable topical carrier. This term is specifically intended to encompass carrier materials approved for use in topical cosmetics as well.
[0048] The term ''pharmaceutically acceptable additive" refers to preservatives, antioxidants, fragrances, emulsifiers, dyes and excipients known or used in the field of drug
formulation and that do not unduly interfere with the effectiveness of the biological activity of the active agent, and that is sufficiently non-toxic to the host or patient. Additives for topical formulations are well-known in the art, and may be added to the topical composition. as long as they are pharmaceutically acceptable and not deleterious to the epithelial cells or their function. Further, they should not cause deterioration in the stability of the composition. For example, inert fillers, anti- irritants, tackifiers, excipients, fragrances, opacifiers, antioxidants, gelling agents, stabilizers, surfactant, emollients, coloring agents, preservatives, buffering agents, other permeation enhancers, and other conventional components of topical or transdermal delivery formulations as are known in the art.
[0049] The terms "enhancement." "penetration enhancement" or "permeation enhancement" relate to an increase in the permeability of the skin, nail, hair, claw or hoof to a drug, so as to increase the rate at which the drug permeates through the skin, nail, hair, claw or hoof. The enhanced permeation effected through the use of such enhancers can be observed, for example, by measuring the rate of diffusion of the drug through animal or human skin, nail, hair, claw or hoof using a diffusion cell apparatus. A diffusion cell is described by Merritt et al, J of Controlled Release, 1 : 161 - 162 ( 1984). The term "permeation enhancer" or "penetration enhancer" intends an agent or a mixture of agents, which, alone or in combination, act to increase the permeability of the skin, nail, hair or hoof to a drug.
{0050] The term "excipients" is conventionally known to mean carriers, diluents and/or vehicles used in formulating drug compositions effective for the desired use.
[0051 J The term ''topical administration" refers to the application of a pharmaceutical agent to the external surface of the skin, nail, hair, claw or hoof, such that the agent crosses the external surface of the skin, nail, hair, claw or hoof and enters the underlying tissues. Topical administration includes application of the composition to intact skin, nail, hair, claw or hoof, or to a broken, raw or open wound of skin, nail, hair, claw or hoof. Topical administration of a pharmaceutical agent can result in a limited distribution of the agent to the skin and surrounding tissues or, when the agent is removed from the treatment area by the bloodstream, can result in systemic distribution of the agent.
J0052] The term "transdermal delivery" refers to the diffusion of an agent across the barrier of the skin, nail, hair, claw or hoof resulting from topical administration or other application of a composition. The stratum corneum acts as a barrier and few pharmaceutical agents are able to penetrate intact skin. In contrast, the epidermis and dermis are permeable to many
solutes and absorption of drugs therefore occurs more readily through skin, nail, hair, claw or hoof that is abraded or otherwise stripped of the stratum corneum to expose the epidermis. Transdermal delivery includes injection or other delivery through any portion of the skin, nail, hair, claw or hoof or mucous membrane and absorption or permeation through the remaining portion. Absorption through intact skin, nail, hair, claw or hoof can be enhanced by placing the active agent in an appropriate pharmaceutically acceptable vehicle before application to the skin, nail, hair, claw or hoof. Passive topical administration may consist of applying the active agent directly to the treatment site in combination with emollients or penetration enhancers. As used herein, transdermal delivery is intended to include delivery by permeation through or past the integument, i.e. skin, nail, hair, claw or hoof.
[0053] The term "microbial infection" refers to any infection of a host tissue by an infectious agent including, but not limited to, viruses, bacteria, mycobacteria, fungus and parasites (see, e.g., Harrison's Principles of Internal Medicine, pp. 93-98 (Wilson et ah, eds.. 12th ed. 1991 ); Williams et al., J. of Medicinal Chern. 42: 1481 -1485 (1999), herein each incorporated by reference in their entirety).
[0054] "Biological medium," as used herein refers to both in vitro and in vivo biological milieus. Exemplary in vitro "biological media" include, but are not limited to, cell culture, tissue culture, homogenates, plasma and blood. In vivo applications are generally performed in mammals, preferably humans.
[0055] MIC, or minimum inhibitory concentration, is the point where compound stops more than 90% of cell growth relative to an untreated control.
[0056] "Inhibiting'1 and "blocking," are used interchangeably herein to refer to the partial or full blockade of an editing domain of a tRNA synthetase.
/. Introduction
[0057] The present invention provides compounds which are capable of inhibiting the growth of, or killing, microorganisms and/or treating diseases in an animal (such as a human) or a plant. These compounds may be included within a pharmaceutical formulation,
JI- The Compounds
II. A, Boron-containing compounds
[0058] In a first aspect, the invention provides a compound which has a structure which is a member selected from the following formulae:
wherein Y is a member selected from substituted or unsubstituted vinyl and substituted or unsubstituted aryi, Z, Ra, Rb, Rϋ and Rd are members independently selected from members independently selected from H, OR*, NR*R**. SR*, -S(O)R*, -S(O)2R*, -S(O)2NR*R**, nitro, halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl. substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyc Io alkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl. Rb and Rc, together with the atoms to which they are attached, are optionally joined to form a 4- to 8-membered ring. Rά and Re, together with the atoms to which they are attached, are optionally joined to form a 4- to 8-membered ring. Y and Z, together with the atoms to which they are attached, are optionally joined to form a member selected from a 4- to 8- membered ring and a 6- to 12-membered bicyclic ring. Substituents on the ring may be optionally joined to form additional ring systems, for example
. Each R* and R** are members independently selected from H, nitro, halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl. substituted or unsubstituted heterocycloalkyl. substituted or unsubslituted aryl, and substituted or unsubstituted heteroaryl, and pharmaceutically acceptable salts thereof.
(0059] In an exemplary embodiment, said compound has a structure according to the following formula:
In an exemplary embodiment, Ra and R& are H. In an exemplary embodiment, Rc and Rα are H. In an exemplary embodiment, Re and Rh are H.
In an exemplary embodiment, the compound has a structure according to the following formula:
and . In an exemplary embodiment, Rd and R are H. In an exemplary embodiment, Rc and Rd are H, In an exemplary embodiment, Rg and Rh are H.
[0060] In an exemplary embodiment, said compound has a structure according to the following formula:
R and . In an exemplary embodiment, Ra and R are H, In an exemplary embodiment, Rc and Rd are H. In an exemplary embodiment, Rg and Rh are H. In an exemplary embodiment, said Z is substituted or unsubstituted vinyl.
[0061] In an exemplary embodiment, said compound is a member selected from
and . In an exemplary embodiment, Rd and R are H. In an exemplary embodiment, Rc and Rd are H. In an exemplary embodiment, Rg and Rh are H.
[0062] In an exemplary embodiment, said compound is a member selected from
member selected from H2N and H2N--/ rn m exemplary embodiment, said compound is a member selected from
2?
[0063] In an exemplary embodiment, said Z is substituted or unsubstituted alkyl, and wherein said substituted or unsubstituted alkyl is substituted or unsubstituted alkenyl. In an exemplary embodiment, said Z is substituted or unsubstituted vinyl. In an exemplary embodiment, said Z is substituted or unsubstituted aryl. In an exemplary embodiment, said Z is substituted aryl, and has a structure according to the following formula:
wherein R! is a member selected from H, nitro, halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
[0064] In an exemplary embodiment, said R1 is a member selected from nitro, halogen, cyano and substituted or unsubstituted alkyl. In an exemplary embodiment, said R! is a member selected from fluorine, chlorine and bromine.
[0066] In an exemplary embodiment, said Z is substituted or unsubstituted heteroaryl. In an exemplary embodiment, said Z is a member selected from substituted or unsubstituted 2- pyridinyL substituted or unsubstituted 3-pyridinyl and substituted or unsubstituted 4- pyridinyl. In an exemplary embodiment, said Z is substituted or unsubstituted 3-pyridinyϊ.
[0067] In an exemplary embodiment, said Rb and Rc, together with the atoms to which they axe attached, are joined to form a substituted or unsubstituted 4- to 6-membered ring. In
an exemplary embodiment, said compound is
[0068] In an exemplary embodiment, said compound is a member selected from
[0069] In an exemplary embodiment, said compound is a member selected from
[0070] In an exemplary embodiment, said compound is a member selected from
[0071] In an exemplary embodiment, wherein Y and Z, together with the atoms to which they are attached, are joined to form a member selected from a 4- to 8- membered ring and a 6- to 12-membered bicyclic ring. In an exemplary embodiment, wherein Y and Z, together with the atoms to which they are attached, are joined to form an 8-membered bicyclic ring, In an exemplary embodiment, said 8-membered bicyclic ring is unsubstituted.
[0072] In an exemplary embodiment, having a structure which is a member selected from
In an exemplary embodiment, having a structure which is a member selected from
In an exemplary embodiment, having a structure which is a member selected from
and m an exemplary embodiment, the compound is a salt of the compounds described in this section, In an exemplary embodiment, the compound is a pharmaceutically acceptable salt of the compounds described in this section.
Preparation of boron-containing compounds
[0073] The following exemplary schemes illustrate methods of preparing the compounds of the invention. These methods are not limited to producing the compounds shown, but can be used to prepare a variety of molecules such as the compounds and complexes described herein. The compounds of the invention can also be synthesized by methods not explicitly illustrated in the schemes but are well within the skill of one in the art. The compounds can be prepared using readily available materials of known intermediates. In the following schemes, 'Ar" can be a substitued or unsubstituted aryl or heteroaryl moiety.
[0075] According to Scheme 1, Ia and Ib are contacted in order to produce Ic. Ic is contacted with Id in order to produce Ie.
[0076] In an exemplary embodiment, the compounds are produced according to the following scheme:
2g
[0077] According to Scheme 2, 2a and 2b can be contacted in order to produce 2c. 2c and 2d can be contacted in order to produce 2e. 2e and 2f can be contacted in order to produce 2g.
[0078] In an exemplary embodiment, the compounds are produced according to the following scheme:
THF,
3a . MgCI
Addition@0°C, Ar' 3b
- Br
Ar r t. 1 h
MgCI )
[0079] According to Scheme 3, 3a can be reacted under conditions suitable to produce 3b. 3b can be contacted with 3c in order to produce 3d. 3d can be reacted under conditions suitable to produce 3e.
//. B. Acyclic boronic acids
[0080] In another aspect, the invention provides a compound which has a structure which is a member selected from the following formulae:
Each RJ is a member independently selected from a negative charge, a salt counterion and H. In an exemplary embodiment, each R in each structure is H. In an exemplary embodiment, at least one of said R3 is a salt counterion. In an exemplary embodiment, at least one of said R3 is a negative charge. In an exemplary embodiment, the compound is a salt of the compounds described in this section. In an exemplary embodiment, the compound is a pharmaceutically acceptable salt of the compounds described in this section.
Preparation of acyclic boronic acids
[0081] The following exemplar)- schemes illustrate methods of preparing the compounds of the invention. These methods are not limited to producing the compounds shown, but can be used to prepare a variety of molecules such as the compounds and complexes described
herein. The compounds of the present invention can also be synthesized by methods not explicitly illustrated in the schemes but are well within the skill of one in the art. The compounds can be prepared using readily available materials of known intermediates.
[0082] The acyclic boronic acids described in this section can be purchased from sources such as Aldrich (St. Louis, MO). TCI America (Portland, OR), Acros Organics (Belgium), Alfa Aesar (Ward Hill, MA) and Lancaster Synthesis (United Kingdom). Acyclic boronic acids can also be synthesized according to the methods described in Boronic Acids: Preparation and Applications in Organic Synthesis and Medicine, Hall, DG, Ed., Wiley-VCH Verlag GmbH & Co., 2005. In addition, the compounds can be produced according to the following scheme:
4a 4b 4c
[0083] According to Scheme 4, 4a and 4b can be contacted under conditions suitable to produce 4c.
//. C. Low MW Pyndone/PyrUhione derivatives
[0084] In another aspect, the invention provides a compound which has a structure according to the following formula:
wherein R and R are members independently selected from H, R*. OR*, NR* R**, SR*, - S(O)R*, -S(O)2R*, -S(O)2NR*R**, nitro, halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl. Each R* and R** are members independently selected from H, nitro, halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl. substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl. R3 is a member selected from a negative charge, a salt counterion and H, X is a member selected from O and S. This aspect has the proviso that the compound is not a member selected from
In an exemplary embodiment, R2 is cyclohexyl. In an exemplary embodiment, R1 is methyl. In an exemplary embodiment, R2 is a member selected from H, substituted or unsubstituted alky!. In an exemplary embodiment, R" is a member selected from H, methyl, ethyl and isopropyl. In an exemplary embodiment, R2 is methyl, ϊn an exemplary embodiment, X is S. In an exemplary embodiment, the compound is a salt of the compounds described in this section. In an exemplary embodiment, the compound is a pharmaceutically acceptable salt of the compounds described in this section.
Preparation of low MW Pyridone/Pyrithione derivatives [0085] The following exemplary schemes illustrate methods of preparing pyridone/pyrithione molecules of the invention. These methods are not limited to producing the compounds shown, but can be used to prepare a variety of molecules such as the compounds and complexes described herein. The compounds of the invention can also be synthesized by methods not explicitly illustrated in the schemes but are well within the skill of one in the art. The compounds can be prepared using readily available materials of known intermediates.
[0086] The compounds described in this section can be purchased from sources such as Aldrich (St. Louis, MO). TCI America (Portland, OR), Acros Organics (Belgium), Alfa Aesar (Ward Hill, MA) and Lancaster Synthesis (United Kingdom). In addition, the compounds can be produced according to the following scheme:
2-aminopyπdine 7O0C 3 days, N2
[0087] According to Scheme 5, 5a can be reacted with an excess of hydroxylamine in order to produce 5b.
II- D- Low MW fungicide moiety I
[0088] In another aspect, the invention provides a compound which has a structure according to the following formula:
wherein Ra, Rb. Rc, Rd, Re, R1 are members independently selected from members independently selected from H, OR*, NR*R**, SR*, -S(O)R*, -S(O)2R*, -S(O)2NR+R**, nitro, halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycioalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl. Each R* and R** are members independently selected from H, nitro. halogen, cyano, substituted or unsubstituted alky], substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycioalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl . R3 is a member selected from a negative charge, a salt counterion and H. In an exemplary embodiment, there is a proviso that said compound is not a member selected from
In an exemplary embodiment, there is a proviso that said compound is not
R\ Rf are H. In another exemplary embodiment, one of said Ra. R , Rc, Rd, Re and Rf is a member selected from bromine, chlorine and fluorine and the remainder of said variables is H. In another
exemplary embodiment, the compound has a structure according to Cl . In an exemplary embodiment, the compound is a salt of the compounds described in this section.
In an exemplary embodiment, the compound is a pharmaceutically acceptable salt of the compounds described in this section.
Preparation of Low MW fungicide I
[0089] The following exemplary schemes illustrate methods of preparing fungicides of the invention. These methods are not limited to producing the compounds shown, but can be used to prepare a variety of molecules such as the compounds and complexes described herein. The compounds of the invention can also be synthesized by methods not explicitly illustrated in the schemes but are well within the skill of one in the art. The compounds can be prepared using readily available materials of known intermediates.
f0090] The compounds described in this section can be purchased from sources such as Aldrich (St. Louis, MO), TCI America (Portland, OR), Acros Organics (Belgium). Alfa Aesar (Ward Hill, MA) and Lancaster Synthesis (United Kingdom). In addition, the compounds can be produced according to the Friendlander synthesis, as well as by the following scheme (McNaughlon et al, Org. Lett., 5: 23. 4257-4259 (2003)):
[0091J According to Scheme 5, Sa can be reacted with 5b in order to produce 5c.
//. E. Low MW fungicide moiety II
[0092] In another aspect, the invention provides a compound which has a structure which is a member selected from the following formula:
wherein Ra, Rb, Rc, Rd, Rc and Rf are members independently selected from members independently selected from H, OR*, NR*R**. SR*, -S(O)R*, -S(O)2R*, -S(O)2NR*R**, nitro, halogen, cyano, substituted or unsubstituted alky], substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl. Each R* and R** are members independently selected from H, nitro, halogen,
cyano, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl. In an exemplary embodiment, there is a proviso that the compound is not a member selected from
In an exemplary embodiment, Ra, Rb, Rc, Rd, and Re are H. In an exemplary embodiment, Ra, Rb, Rc, Rd, and Rc are H. and R1 is a member selected from H5 methyl, substituted or unsubstituted thiazolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted ^- NH
pyrazolyl, and CH3 [n an exemplary embodiment, Rr is a member selected from H,
unsubstituted thiazolyl,
, wherein Rg, Rh and R1 are members independently selected from H, OR*, NR*R**, SR*, -S(O)R*, -S(O)2R*, -S(O)2NR*R**, nitro, halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl. Each R* and R** are members independently selected from H, nitro, halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl. In an exemplary embodiment, Rd, R , Rc, R , and Rc are H and R* is the same as described in the previous sentence.
In an exemplary embodiment, R1 is H3C . In another exemplary embodiment, Re is
wherein R1 is a member selected from substituted or unsubstituted alkyl and
I— NH q substituted or unsubstituted heteroalkyl and Rr is Rk wherein Rk is a member selected from substituted or unsubstituted alkyl and substituted or unsubstituted heteroalkyl. In
I— MH z0 <CH2)3 another exemplary embodiment. Re is ^H3 In another exemplary embodiment, Rf is methyl. In an exemplary embodiment, the compound is a salt of the compounds described in this section. In an exemplary embodiment, the compound is a pharmaceutically acceptable salt of the compounds described in this section.
Preparation of Low MW fungicide H
[0093] The following exemplary schemes illustrate methods of preparing fungicides of the invention. These methods are not limited to producing the compounds shown, but can be used to prepare a variety of molecules such as the compounds and complexes described herein. The compounds of the invention can also be synthesized by methods not explicitly illustrated in the schemes but are well within the skill of one in the art. The compounds can be prepared using readily available materials of known intermediates.
[0094] The compounds described in this section can be purchased from sources such as Aldrich (St. Louis, MO), TCI America (Portland, OR), Acros Organics (Belgium), Alfa Aesar (Ward Hill, MA) and Lancaster Synthesis (United Kingdom). In addition, the compounds can be produced according to one of several syntheses which are known to those of skill in the art. One synthesis involves coupling phenylenediamines and carboxylic acids (see Grimmet. M. R. In Comprehensive Heterocyclic Chemistry; Katritzky, A.R., Rees C, W., Eds., 1984; Vol. 5, p. 457; Geratz, Arch Biochem. Biophys. 197: 551-559 (1979)). An additional synthesis involves a two-step procedure that includes the oxidative cyclo- dehydrogenation of aniline Schiff s bases, which are often generated in situ from the condensation of phenylenediamines and aldehydes (Dubey et at., Indian J. Chem. B 18: 428 (1979)). An additional synthesis is presented in the following scheme: (Lin, S et at., TeL Lett., 46: 4315-4319 (2005)):
[0095J According to Scheme 6, 6a can be reacted with 6b in order to produce 6c,
//. F. Low MW fungicide moiety III
[0096] In another aspect, the invention provides a compound which has a structure according to the following formula:
wherein Ra, Rb, Rc and Rd are members independently selected from members independently selected from H, OR*, NR*R**, SR*, -S(O)R*, -S(O)2R*, -S(O)2NR*R**, nitro, halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryi, and substituted or unsubstituted heteroaryl. Each R* and R** are members independently selected from H, nitro. halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl. substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl. X is a member selected from O and S. In an exemplary embodiment, there is a proviso that the compound is not
In an exemplary embodiment, X is S. In an exemplary embodiment, Rb and Rύ are H. In an exemplary embodiment, Ra and Rς is a member selected from substituted or unsubstituted alkyl. In an exemplary embodiment, Ra and Rc are methyl. In an exemplary embodiment, the compound is a salt of the compounds described in this section. In an exemplary embodiment, the compound is a pharmaceutically acceptable salt of the compounds described in this section.
Preparation of Low MW fungicide moiety III
[0097] The following exemplary schemes illustrate methods of preparing fungicides of the invention. These methods are not limited to producing the compounds shown, but can be used to prepare a variety of molecules such as the compounds and complexes described herein. The compounds of the invention can also be synthesized by methods not explicitly illustrated in the schemes but are well within the skill of one in the art. The compounds can be prepared using readily available materials of known intermediates.
[0098] The compounds described in this section can be purchased from sources such as Aldrich (St. Louis. MO), TCl America (Portland, OR), Acros Organics (Belgium), Alfa Aesar (Ward Hill, MA) and Lancaster Synthesis (United Kingdom). In addition, the compounds can be produced according to one of several syntheses which are known to those of skill in the art. One synthesis involves the following scheme (Katiyar et a!., Bioorg. Med. Chem., 11:4369-4375 (2003))
[0099] According to Scheme 7, 7a can be reacted with CS2. followed by formaldehyde, in order to produce 7b,
[0100] Another synthesis involves the following:
[0101] According to Scheme 8, 8a can be reacted with a first isothiocyanate 8b in order to produce 8c, followed by a reaction with a second isothiocyanate 8d, in order to produce 8e.
[0102] Another synthesis is described below, as well as in Coburn, R. A. et α/.. J Med. Chem. 25:481 (1982):
[0103] According to Scheme 9, 9a can be reacted with 9b in order to produce 9c.
(0104] Another synthesis is described below, as well as in Vovk, M. V. et al, Russ. J. Org. Chem. 30:456 (1994):
(0105] According to Scheme 10. 10a can be reacted with 10b in order to produce 10c.
[0106| Another synthesis is described below, as well as in Tsuge, O. et al., Asahϊ Garasu Kogyo Gijidsu Shoreikai Kenkyu Ilokoku, 26: 101 (1975); Tsuge, O. et al., Bull. Chem. Soc, Jpn., 45:3591 (1972); Tsuge, O. et al, Bull Chem. Soc. Jpn., 45:1534 (1972); Tsuge, O. et al, Bull Chem. Soc. Jpn.. 45:2877 (1972).
[0107] According to Scheme 1 1, lla can be reacted with lib in order to produce lie.
[0108] Another synthesis is described below, as well as in Burluenga, J. et al., Synlett. 1991, 93; Chem. Abstr. 1 15, 8743h (1991):
[0109] According to Scheme 12, 12a can be reacted with 12b in order to produce 12c.
[0110] Another synthesis is described below, as well as in Goerdeler, J. et al,
[Oil 1] According to Scheme 13, two equivalents of 13a can be reacted in order to produce 13b.
[0112] Another synthesis is described below, as well as in Goerdeler. J. et ai, J. Chem. Ber., 118:4196 (1985):
[0113] According to Scheme 14, two equivalents of 14a can be reacted in order to produce 14b.
[0114] Another synthesis is described below, as well as in Giordano. C. et ai., Tetrahedreon Lett. 1537 (1979):
[0115] According to Scheme 15, two equivalents of 15a can be reacted in order to produce 15c.
II' G. Commercial fungicides
[θl 16] In another aspect, the invention provides a compound which has a structure which is a member selected from the following formulae:
In an exemplary embodiment, the fungicide is a sordarin. In an exemplary embodiment, the compound is a salt of the compounds described in this section. In an exemplary embodiment, the compound is a pharmaceutically acceptable salt of the compounds described in this section.
Preparation of Commercial fungicides
[0117] The fungicides described in this section are commercially available from sources such as Aldrich (St, Louis, MO), TCI America (Portland. OR), Acros Organics (Belgium), Alfa Aesar (Ward Hill, MA) and Lancaster Synthesis (United Kingdom).
//. H. Formulations with keratin
[0118] When a compound of the invention described herein is applied to a nail component of a human, the compound absorbs or penetrates into the nail. The human nail is primarily composed of keratin (i.e. hair keratin or α-keratin) as well as trace amounts of lipid components. Therefore, in the process of treating a disease of the nail or killing or inhibiting the growth of a microorganism, a formulation comprising a human nail unit and a compound of the invention is formed.
10119) In another aspect, the invention provides a formulation comprising: (a) a compound which is a member selected from a compound of the invention; and (b) a keratin containing component which is a member selected from a human nail unit, skin and hair. In an exemplary embodiment, the compound of part (a) contacts the component of part (b). In an exemplary embodiment, the keratin containing component is a nail plate of the human nail unit. In an exemplary embodiment, the keratin containing component is a nail bed of the human nail unit. In an exemplary embodiment, the keratin containing component is a proximal nail fold of the human nail unit. In an exemplary embodiment, the keratin containing component is a lateral nail fold of the human nail unit. In another exemplary embodiment, the human nail unit comprises a member selected from keratin and lipid. In another exemplary embodiment, keratin is a member selected from skin keratin and nail/hair keratin. In another exemplary embodiment, lipid is a member selected from cholesterol sulfate, cerebroside, ceramide, free sterol, free fatty acids, triglycerides, sterol esters, wax esters, and squalene.
[0120] In an exemplary embodiment, the compound is present in the formulation at a concentration which is a member selected from about 0.001%, about 0.01%, about 0.05%, about 0.1%, about 0.5%, about 1%, about 1.5%, about 2%, about 2.5%, about 3%. In another exemplary embodiment, the keratin is present in said formulation at a concentration which is a member selected from about 99.99%, about 99.95%, about 99.90%, about 99.5%, about 99.0%, about 98.5%, about 98.0%, about 97.5% and about 97%. In another exemplary embodiment, the compound is a compound described herein.
[0121 J In another aspect, the invention provides a method of forming this formulation, wherein said method comprises applying said compound to a formulation comprising keratin, thereby forming said formulation. In an exemplary embodiment, the formulation comprising keratin is a human nail unit. In an exemplary embodiment, the formulation comprising
keratin is a member selected from a nail plate, nail bed, proximal nail fold, and lateral nail fold. Methods of making these formulations are described herein.
///. Methods of Inhibiting Microorganism Growth or Killing Microorganisms [0122] In a further aspect, the invention provides a method for inhibiting the growth, or killing, a microorganism, preferably a bacteria, fungus, virus, yeast or parasite, comprising contacting the microorganism with a compound of the invention, such as a compound described by a formula listed herein, under conditions which permit entry of the compound into the organism. Such conditions are known to one skilled in the art and are also described herein. This method involves contacting a microbial cell with a therapeutically-effective amount of an editing domain inhibitor to inhibit tRNA synthetase in vivo or in vitro.
[0123] In another aspect, the invention provides a method of inhibiting the growth of a microorganism, or killing a microorganism, or both, comprising contacting the microorganism with a compound described herein. Microorganisms are members selected from fungi, yeast, viruses, bacteria and parasites. In another exemplary embodiment, the microorganism is inside, or on the surface of an animal. In an exemplary embodiment, the animal is a member selected from human, cattle, deer, reindeer, goat, honey bee, pig, sheep, horse, cow, bull, dog, guinea pig, gerbil, rabbit, cat, camel, yak, elephant, ostrich, otter, chicken, duck, goose, guinea fowl, pigeon, swan, and turkey. In another exemplary embodiment, the animal is a human.
[0124] In an exemplary embodiment, the microorganism is a member selected from a fungus and a yeast. In another exemplary embodiment, the fungus or yeast is a member selected from Candida species, Trichophyton species, Microsporium species, Aspergillus species, Cryptococcus species, Blastomyces species, Cocciodiodes species, Histoplasma species, Paracoccidiodes species, Phycomycetes species, Malassezia species, Fusarium species, Epidermophyton species, Scytalidium species, Scopulaήopsis species, Allernaria species, PenicHlium species. Phialophora species, Rhizopus species, Scedosporium species and Zygomycetes class. In another exemplary embodiment, the fungus or yeast is a member selected from Aspergillus fumigatus {A. fumigatus), Blastomyces dermatitidis, Candida Albicans (C. albicans, both fluconazole sensitive and resistant strains), Candida glabrata (C. glabrata), Candida krusei (C. knisei), Cryptococcus neoformans (C. neoformans), Candida parapsilosis (C. parapsilosis), Candida tropicalis (C tropicalis), Cocciodiodes immitis, Epidermophyton floccosum (E. floccosum), Fusarium solani (F. solanϊ), Histoplasma capsulatυm, Malassezia furfur (M. furfur), Malassezia pachydermatis (M. pachydermatis),
Malassezia sympodialis (M sympodialis), Microsporum audouinii (M, audouinii), Microsporum canis (M canis), Microsporum gypseum (M gypseum), Paracoccidiodes brasilϊensis and Phycomycetes spp. Trichophyton meniagrophytes (T, mentagrophytes), Trichophyton rubrum (T. rubrutn). Trichophyton tonsurans (T. tonsurans). In another exemplary embodiment, the fungus or yeast is a member selected from Trichophyton concentricum, T. violaceum, T. schoenleinii, T. verrucosum, T. soudanense, Microsporum gypseum, M, equinum, Candida guilUermondii, Malassezia globosa, M. obtuse, M. restricta, M. slooffiae, and Aspergillus flavus. In another exemplary embodiment, the fungus is a member selected from a dermatophyte, Trichophyton species, Microsporium species, Candida species, Aspergillus species and yeasl-like fungus. In another exemplary embodiment, the fungus or yeast is a member selected from dermatophytes, Trichophyton, Microsporum, Epidermophyton and yeast-like fungi.
[0125] In an exemplary embodiment, the microorganism is a bacteria. In an exemplary embodiment, the bacteria is a gram-positive bacteria. In another exemplary embodiment, the gram-positive bacteria is a member selected from Staphylococcus species, Streptococcus species, Bacillus species, Mycobacterium species, Corynebaclerium species (Propionibacterium species), Clostridium species, Actinomyces species, Enterococcus species and Streptomyces species. In another exemplary embodiment, the bacteria is a gram- negative bacteria. In another exemplary embodiment, the gram -negative bacteria is a member selected from Acinetobacter species, Neisseria species, Pseudomonas species, Brucella species. Agrobacterium species, Bordetella species, Escherichia species, Shigella species, Yersinia species, Salmonella species. Klebsiella species, Enterobacier species, Haemophilus species. Pasteurella species, Streptobacillus species, spirochetal species, Campylobacter species, Vibrio species and Helicobacter species. In another exemplary embodiment, the bacterium is a member selected from Propionibacterium acnes; Staphylococcus aureus:, Staphylococcus epidermidis. Staphylococcus saprophytics; Streptococcus pyogenes; Streptococcus agalactiae; Streptococcus pneumoniae; Enterococcus faecalis; Enterococcus faecium; Bacillus anthracis; Mycobacterium avium-intracellular e; Mycobacterium tuberculosis, Acinetobacter baumanii; Corynebacterium diphtheria; Clostridium perfringens; Clostridium botulinum; Clostridium tetani; Clostridium difficile; Neisseria gonorrhoeae; Neisseria meningitidis; Pseudomonas aeruginosa; Legionella pneumophila; Escherichia colt; Yersinia pestis; Haemophilus influenzae; Helicobacter pylori; Campylobacter fetus; Campylobacter jejuni; Vibrio cholerae; Vibrio parahemolyticus; Trepomena pallidum; Actinomyces israelii; Rickettsia prowazekii;
Rickettsia rickettsii; Chlamydia trachomatis; Chlamydia psitlaci; Brucella abortus; Agrobacterium tumefaciens; and Francisella tularensis.
[0126] In an exemplary embodiment, the microorganism is a bacteria, which is a member selected from acid-fast bacterium, including Mycobacterium species; bacilli, including Bacillus species, Corynebacterium species (also Propionibacterium) and Clostridium species; filamentous bacteria, including Actinomyces species and Streptomyces species; bacilli, such as Pseudomonas species, Brucella species, Agrobacterium species, Bordetella species. Escherichia species, Shigella species, Yersinia species, Salmonella species, Klebsiella species. Enterobacter species, Haemophilus species, Pasteurella species, and Streptobacillus species; spirochetal species, Campylobacter species, Vibrio species; and intracellular bacteria including Rickettsiae species and Chlamydia species.
[0127] In an exemplary embodiment, the microorganism is a virus. In an exemplary embodiment, the virus is a member selected from hepatitis A-B, human rhinoviruses, Yellow fever virus, human respiratory coronaviruses. Severe acute respiratory syndrome (SARS), respiratory syncytial virus, influenza viruses, parainfluenza viruses 1-4. human immunodeficiency virus 1 (HIV-I), human immunodeficiency virus 2 (HIV-2). Herpes simplex virus 1 (HSV-I), Herpes simplex virus 2 (HS V-2), human cytomegalovirus (HCMV), Varicella zoster virus, Epstein-Barr (EBV), polioviruses. coxsackieviruses, echoviruses, rubella virus, neuroderma-tropic virus, variola virus, papoviruses, rabies virus, dengue virus, West Nile virus and SARS virus. In another exemplary embodiment, the virus is a member selected from picornaviridae, βaviviridae, coronaviridae, paramyxoviridae, orthomyxoviridae, retroviridae, herpesviridae and hepadnaviridae. In another exemplary embodiment, the virus is a member selected from a virus included in the following table:
Table A. Viruses
Virus Category Pertinent Human Infections
RNA Viruses
Polio
Picomaviridae Human hepatitis A
Human rhinovirus
Togaviridae and Rubella — German measles
Flaviviridae
Yellow fever
Coronaviridae Human respiratory coronavirus (HCV)
Severe acute respiratory syndrome (SAR)
Virus Category Pertinent Human Infections
Rhabdoviridae Lyssavirus - Rabies
Paramyxovirus - Mumps
Paramyxoviήdae Morbillvirus - measles
Pneumovirus - respiratory syncytial virus
Orthomyxoviridae Influenza A-C
Bunyavirm - Bunyamwera (BUN) Hantavirus - Hantaan (HTN)
Bimyaviridae Nairevirus - Crimean-Congo hemorrhagic fever (CCHF)
Phlebovirus - Sandfly fever (SFN) Uuknvirus - Uukuniemi (UUK) Rift Valley Fever (RVFN)
Junin - Argentine hemorrhagic fever
Arenaviridae Machiφo - Bolivian hemorrhagic fever
Lassa - Lassa fever
LCM- aseptic lymphocytic choriomeningitis
Rotavirus
Reoviridae Reovirus
Orbivirus
Human immunodeficiency virus 1
(HIV-I)
Retroviridae Human immunodeficiency virus 2
(HIV-2)
Simian immunodeficiency virus (SIV)
DNA Viruses
Papovaviridae Pediatric viruses that reside in kidney
Adenoviridae Human respiratory distress and some deep-seated eye infections
Parvoviridae Human gastro- intestinal distress
(Norwalk Virus)
Herpes simplex virus 1 (HSV-I) Herpes simplex virus 2 (HSV-2)
Herpesviridae Human cytomegalovirus (HCMV) Varicella zoster virus (VZV) Epstein-Barr virus (EBV) Human herpes virus 6 (HHVό)
Poxviridae Orthopoxvirus is sub-genus for smallpox
Virus Category Pertinent Human Infections
Hepadnaviridae Hepatitis B virus (HBV)
Hepatitis C virus (HCV)
[0128] In another exemplary embodiment, the microorganism is a parasite. In an exemplary embodiment, the parasite is a member selected from Plasmodium falciparum, P. vivax, P. ovale P. malar iae, P. berghei, Leishmania donovani, L. infantum, L, chagasi, L. mexicana, L. amazonensis, L. venezuelensis, L, tropics, L, major, L, minor, L. aethiopica, L, Biana braziliensis, L (V.) guyanensis, L (V) panamensis, L (V.) peruviana, Trypanosoma brucei rhodesiense, T. brucei gambiense, T. cruzi, Giardia intestinalis, G. lambda, Toxoplasma gondii, Entamoeba histolytica, Trichomonas vaginalis, Pneumocystis carinii, and Cryptosporidium parvum.
[0129] In an exemplary embodiment, the invention provides a method of inhibiting the growth of, or killing, a fungus, said method comprising: contacting said fungus with a compound in an amount sufficient to inhibit or kill said fungus wherein said fungus is a member selected from a dermatophyte, Trichophyton species, Microsporium species, Candida species, Aspergillus species and yeast-like fungus, and wherein said compound is described herein, In an exemplary embodiment, the fungus is a member selected from Candida albicans, Candida neoformans, Aspergillus fumigatus, Trichophyton mentagrophytes (T. mentagrophytes) and Trichophyton rubrum (T. rubrum). In another exemplary embodiment, the method has the proviso that the molecular weight of said compound is not greater than a member selected from about 300, about 250, about 225, and about 200. In another exemplary embodiment, the method has the proviso that the c log P oϊ said compound is between about 0 and about 2. In another exemplary embodiment, the method has the proviso that the c log P of said compound is between about -5 and about 2, In another exemplary embodiment, the method has the proviso that the c log P of said compound is between about -2 and about 2. In another exemplary embodiment, the method has the proviso that the efficacy coefficient of said compound is greater than about 10.
IV, Methods of Treating or Preventing Infections
[0130] In another aspect, the invention provides a method of treating or preventing an infection. The method includes administering to the animal a therapeutically effective amount of the compound of the invention, sufficient to treat or prevent said infection. In an exemplary embodiment, the compound is a compound described herein, In another exemplary embodiment, the animal is a member selected from human, cattle, deer, reindeer,
goat, honey bee, pig, sheep, horse, cow, bull, dog. guinea pig, gerbil, rabbit, cat, camel, yak, elephant, ostrich, otter, chicken, duck, goose, guinea fowl, pigeon, swan, and turkey. In another exemplary embodiment, the animal is a human. In another exemplary embodiment, the animal is a member selected from a human, cattle, goat, pig, sheep, horse, cow, bull, dog, guinea pig, gerbil. rabbit, cat, chicken and turkey. In another exemplary embodiment, the infection is a member selected from a systemic infection, a cutaneous infection, and an ungual, periungual or subungual infection.
[0131] In another exemplary embodiment, the treatment of a disorder or condition occurs through inhibition of an editing domain of an aminoacyl tRNA synthetase.
[0132] In an exemplary embodiment, the invention provides a method of treating a disease in a subject, said method comprising administering to said subject a therapeutically effective amount of a compound, thereby treating said diseasewherein said disease is an ungual, periungual or subungual infection; wherein said compound is described herein. In another exemplary embodiment, said disease is onychomycosis. In another exemplary embodiment, the method has the proviso that the molecular weight of said compound is not greater than a member selected from about 300, about 250, about 225. and about 200. In another exemplary embodiment, the method has the proviso that the c log P of said compound is between about 0 and about 2. In another exemplary embodiment, the method has the proviso that the c log P of said compound is between about -5 and about 2. In another exemplary embodiment, the method has the proviso that the c log P of said compound is between about - 2 and about 2. In another exemplary embodiment, the method has the proviso that the efficacy coefficient of said compound is greater than about 10.
V, a) Methods of Treating of Preventing Ungual and/or Periungual Infections
[0133] In another aspect, the invention provides a method of treating or preventing an ungual and/or periungual infection. The method includes administering to the animal a therapeutically effective amount of a compound or pharmaceutical formulation of the invention, sufficient to treat or prevent said infection. In another exemplary embodiment, the method includes administering the compound or pharmaceutical formulation of the invention at a site which is a member selected from the skin, nail, hair, hoof, claw and the skin surrounding the nail, hair, hoof and claw.
V. a) 1) Onychomycosis
[0134] Onychomycosis is a disease of the nail caused by yeast, dermatophytes, or other molds, and represents approximately 50% of all nail disorders. Toenail infection accounts for approximately 80% of onychomycosis incidence, while fingernails are affected in about 20% of the cases. Dermatophytes are the most frequent cause of nail plate invasion, particularly in toenail onychomycosis. Onychomycosis caused by a dermatophyte is termed Tinea unguium. Trichophyton rubrum is by far the most frequently isolated dermatophyte, followed by T. mentagrophytes. Distal subungual onychomycosis is the most common presentation of tinea unguium, with the main site of entry through the hyponychium (the thickened epidermis underneath the free distal end of a nail) progressing in time to involve the nail bed and the nail plate. Discoloration, onycholysis, and accumulation of subungual debris and nail plate dystrophy characterize the disease. The disease adversely affects the quality of life of its victims, with subject complaints ranging from unsightly nails and discomfort with footwear, to more serious complications including secondary bacterial infections.
[0135] Many methods are known for the treatment of fungal infections, including the oral and topical use of antibiotics (e.g., nystatin and amphotericin B), imidazole anti-fungal agents such as miconazole, clotrimazole, fluconazole, econazole and sulconazole, and non- imidazole fungal agents such as the allylamine derivatives terbinafme and naftifine, and the benzylamine butenafine,
[0136] However, onychomycosis has proven to be resistant to most treatments. Nail fungal infections reside in an area difficult to access by conventional topical treatment and anti-fungal drugs cannot readily penetrate the nail plate to reach the infection sites under the nail. Therefore, onychomycosis has traditionally been treated by oral administration of antifungal drugs; however, clearly this is undesirable due to the potential for side effects of such drugs, in particular those caused by the more potent anti-fungal drugs such as itraconazole and ketoconazole. An alternative method of treatment of onychomycosis is by removal of the nail before treating with a topically active anti-fungal agent; such a method of treatment is equally undesirable. Systemic antimycotic agents require prolonged use and have the potential for significant side effects. Topical agents have usually been of little benefit, primarily because of poor penetration of the anti-fungal agents into and through the nail mass.
(0137 ( In an exemplary embodiment, the invention provides a method of treating or preventing onychomycosis. The method includes administering to a human or an animal a therapeutically effective amount of a compound of the invention, or a pharmaceutical formulation of the invention, sufficient to treat or prevent onychomycosis. In another exemplary embodiment, the method includes administering the pharmaceutical formulation of the invention at a site which is a member selected from the skin, nail, hair, hoof, claw and the skin surrounding the nail, hair, hoof and claw, In another exemplary embodiment, the pharmaceutical formulation includes a compound described herein.
V. a) 2) Other Unugal and Periungual Infections
[0138{ In a*1 exemplary embodiment, the invention provides a method of treating or preventing an ungual or periungual infection in an animal (such as a human) or a plant. This method comprising administering to the animal (human) a therapeutically effective amount of a compound of the invention, thereby treating or preventing the ungual or periungual infection. In an exemplary embodiment, the ungual or periungual infection is onychomycosis. In an exemplary embodiment, the ungual or periungual infection is a member selected from: onychomycosis, chloronychia, paronychias, erysipeloid, onychorrhexis, gonorrhea, swimming-pool granuloma, larva migrans, leprosy, Orf nodule, milkers' nodules, herpetic whitlow, acute bacterial perionyxis, chronic perionyxis, sporotrichosis, syphilis, tuberculosis verrucosa cutis, tularemia, tungiasis, peri- and subungual warts, zona, nail dystrophy (trachyonychia), and dermatological diseases with an effect on the nails, such as psoriasis, pustular psoriasis, alopecia aerata, parakeratosis pustulosa, contact dermatosis, Reiter's syndrome, psoriasiform acral dermatitis, lichen planus, idiopathy atrophy in the nails, lichin nitidus, lichen striatus, inflammatory linear verrucous epidermal naevus (ILVEN), alopecia, pemphigus, bullous pemphigoid, acquired epidermolysis bullosa, Darier's disease, pityriasis rubra pilaris, palmoplanar keratoderma, contact eczema, polymorphic erythema, scabies, Bazex syndrome, systemic scleroderma, systemic lupus erythematosus, chronic lupus erythematosus, dermatomyositus.
[0139] The compounds and pharmaceutical formulations of the invention useful for ungual and periungual applications also find application in the cosmetics field, in particular for the treatment of irregularities of the nails, koilonychias, Beau's lines, longitudinal ridging, ingrown nails.
[0140] In an exemplary embodiment, the infection is of the skin, nail, hair, claw or hoof, hair, ear and eye and is a member selected from Sporotrichosis, Mycotic keratitis, Extension
oculomycosis, Endogenous oculomycosis, Lobomycosis, Mycetoma, Piedra, Pityriasis versicolor, Tinea corporis, Tinea cruris, Tinea pedis, Tinea barbae, Tinea capitis, Tinea nigra, Otomycosis, Tinea favosa, Chromomycosis, and Tinea Imbricata.
V. b) Methods of Treating Systemic Diseases
[0141] In another aspect, the invention provides a method of treating a systemic disease. The method involves contacting an animal (human) with a compound of the invention. The method of delivery for treatment of systemic disesases can be oral, intravenous, transdermal, inhalation, intraperitoneal, and subcutaneous,
[0142] In an exemplary embodiment, the infection is systemic and is a member selected from candidiasis, aspergillosis, coccidioidomycosis, cryptococcosis, histoplasmosis, blastomycosis, paracoccidioidomycosis, zygomycosis, phaeohyphomycosis and rhinosporidiosis.
V. c) Methods of Treating Diseases Involving Viruses
[0143] The compounds of the invention are useful for the treatment of diseases of animals, such as humans, involving viruses, In an exemplary embodiment, the disease is a member selected from hepatitis A - B - C, yellow fever, respiratory syncytial, influenza, AIDS, herpes simplex, chicken pox, varicella zoster, and Epstein-Barr disease.
V. d) Methods of Treating Diseases Involving Parasites
[0144] The compounds of the invention are useful for the treatment of diseases of animals, such as humans, involving parasites. In an exemplary embodiment, the disease is a member selected from malaria, Chagas' disease, Leishmaniasis, African sleeping sickness
(African human trypanosomiasis), giardiasis, toxoplasmosis, amebiasis and cryptosporidiosis.
VI- Methods of Nail Penetration
[0145] It is believed that poor penetration of the active agent through the hoof or nail plate and/or excessive binding to keratin, (the major protein in nails and hair) are the reasons for the poor efficacy of 8% ciclopirox w/w in commercial lacquer and other topical treatments that have failed in clinical trials. In mild cases of onychomycosis, the pathogenic fungi reside in the nail plate only. In moderate to severe cases the pathogenic fungi establish a presence in the nail plate and in the nail bed. If the infection is cleared from the nail plate but not from the nail bed, the fungal pathogen can re-infect the nail plate. Therefore, to
effectively treat onychomycosis, the infection must be eliminated from the nail plate and the nail bed. To do this, the active agent must penetrate and disseminate substantially throughout the nail plate and nail bed.
[0146] It is believed that in order for an active agent to be effective once disseminated throughout the infected area, it must be bioavailable to the fungal pathogen and cannot be so tightly bound to keratin that the drug cannot inhibit growth or kill the infecting fungi.
[0147] An understanding of the morphology of the nail plate suggests certain physicochemical properties of an active agent that would facilitate penetration of the nail plate. The desired physicochemicai properties are described throughout. The tested compounds of the present invention are able to penetrate the nail plate and were also active against Trichophyton rubrum and mentagrophytes and other species. In addition, the tested compounds are also active against Trichophyton rubrum in the presence of 5% keratin powder.
[0148] In an exemplary embodiment, the invention provides a method of killing or inhibiting growth of a microorganism present in a human nail unit, wherein said human nail unit comprises a nail plate. The method comprising contacting a dorsal layer of the nail plate with a compound capable of penetrating the nail plate, traveling through the nail plate to a nail bed underlying said nail plate, and contacting said microorganism, under conditions sufficient for said compound to penetrate said nail plate. In this embodiment, the compound has a molecular weight of between about 100 Da and about 300 Da, a log P value of between about 1.0 and about 2.6, a water solubility greater than about 0.1 mg/mL octanol/saturated water, and an MIC of less than 16 μg/mL against said microorganism, thereby killing or inhibiting the growth of said microorganism. In an exemplary embodiment, the compound is described herein.
[0149] In another exemplary embodiment, the invention provides a method of treating a disease caused by a microorganism present in a human nail unit, wherein said human nail unit comprises a nail plate, said method comprising: contacting a dorsal layer of the nail plate with a compound capable of penetrating the nail plate, traveling through the nail plate to a nail bed underlying said nail plate, and contacting said microorganism, under conditions sufficient for said compound to penetrate said nail plate and to treat said disease. In this embodiment, the compound has a molecular weight of between about 100 Da and about 300 Da; a log P value of between about 1.0 and about 2.6; a water solubility greater than about
0.] mg/mL octanol/saturated water, and an MIC of less than 16 μg/mL against said microorganism, thereby treating said disease. In an exemplary embodiment, the compound is described herein.
[0150] In another aspect, the invention provides a method of delivering a compound from the dorsal layer of the nail plate to the nail bed. This method comprises contacting the cell with a compound capable of penetrating the nail plate, under conditions sufficient to penetrate the nail. The compound has a molecular weight of between about 100 and about 300 Da. The compound also has a log P value of between about 1.0 and about 2.6. The compound additionally has a water solubility between about 0.1 mg/mL and 1 g/mL octanol/saturated water, thereby delivering said compound. In an exemplary embodiment, the compound is described herein.
[0151] In a preferred embodiment, the physicochemical properties of the compound of the invention, described by quantities predictive for migration of the compound through the nail plate, including, but not limited to. molecular weight, log P and solubility in water, and the like, are effective to provide substantial penetration of the nail plate.
[0152J Compounds with a molecular weight of less than 300 Da penetrate the nail plate in a manner superior to the commercially available treatment for onychomycosis. In an exemplary embodiment, the compound has a molecular weight of between about 100 Da and about 250 Da. In an exemplary embodiment, the compound has a molecular weight of between about 100 Da and about 225 Da. In an exemplary embodiment, the compound has a molecular weight of between about 100 Da and about 200 Da. In one embodiment of the present invention the compound has a molecular weight of between 130 and 200. In another embodiment of this invention, the compound has a molecular weight of from about 140 to about 210 Da. In another embodiment of this invention, the compound has a molecular weight of from about 170 to about 200 Da. In another embodiment of this invention, the compound has a molecular weight of from about 155 to about 190 Da. In another embodiment of this invention, the compound has a molecular weight of from about 165 to about 185 Da. In another embodiment of this invention, the compound has a molecular weight of from about 145 to about 170 Da. In yet another embodiment the molecular weight is either 151.93 or 168.39 Da.
[0153] In one embodiment of the present invention the compound has a log P value of between about -3.5 to about 2.5. In another exemplary embodiment, the compound has a log
P value of from about -1.0 to about 2.5. In another exemplary embodiment, the compound has a log P value of from about -1.0 to about 2,0. In another exemplary embodiment, the compound has a log P value of from about -0.5 to about 2.5. In another exemplary embodiment, the compound has a log P value of from about -0.5 to about 1.5. In another exemplary embodiment, the compound has a log P value of from about 0.5 to about 2.5. In another exemplary embodiment, the compound has a log P value of from about 1.0 to about 2,5. In yet another exemplary embodiment, the compound has a log P value of 1.9 or 2.3.
[0154] Also contemplated by the present invention is a compound with a log P value less then 2.5, with a molecular weight less than 200 Da, that are still able to penetrate the nail plate.
[0155] In one embodiment of the present invention the compound has a water solubility between about 0.1 mg/mL to 1 g/mL in octanol saturated water. In one embodiment of the present invention the compound has a water solubility of between 0.1 mg/mL and 100 mg/mL. In another embodiment of this invention, the compound has a water solubility of from about 0.1 mg/mL and 10 mg/mL. In another embodiment of this invention, the compound has a water solubility of from about 0.1 mg/mL and 1 mg/mL. In another embodiment of this invention, the compound has a water solubility of from about 5 mg/mL and 1 g/mL. In another embodiment of this invention, the compound has a water solubility of from about 10 mg/mL and 500 g/mL. In another embodiment of this invention, the compound has a water solubility of from about 80 mg/mL and 250 mg/mL.
[0156] In an exemplary embodiment, the present invention provides a compound with a log P value selected from a range above, with a molecular weight selected from a range above, that are still able to penetrate the nail plate.
[0157] In an exemplary embodiment, the present invention provides compounds with a molecular weight selected from a range above, with a water solubility selected from a range above, that are still able to penetrate the nail plate.
[0158] In an exemplary embodiment, the present invention provides compounds with a log P selected from a range above, with a water solubility selected from a range above, that are still able to penetrate the nail plate.
[0159] In an exemplary embodiment, the present invention provides compounds with a molecular weight selected from a range above, with a log P selected from a range above, and
with a water solubility selected from a range above, that are still able to penetrate the nail plate.
[0160] Penetration of the nail by the active ingredient may be effected by the polarity of the formulation. However, the polarity of the formulation is not expected have as much influence on nail penetration as some of the other factors, such as the molecular weight or the log P of the active ingredient. The presence of penetration enhancing agents in the formulation is likely to increase penetration of the active agent when compared to similar formulations containing no penetration enhancing agent.
[0161] Some examples of molecules with optimal physicochemical properties are given in the table below.
[0162] Compound 3 below is an example of a compound similar in molecular weight to ciclopirox, and like ciclopirox, penetrates the nail plate poorly.
[0163] ϊn a preferred embodiment the topical formulations including a compound described herein has a total molecular weight of less than 200 Da, has a Log P of less than
2.5, and a minimum inhibitory concentration against Trichophyton ruhrum that is substantially unchanged in the presence of 5% keratin.
[0164] The efficacy coefficient (defined as flux over MIC) of a compound also informs one of skill regarding whether the compound may be effective in killing a microorganism, inhibiting the growth of a microorganism, or treating a disease which is caused by a microorganism present in a human nail unit, wherein said human nail unit comprises a nail plate. The method comprises: contacting a dorsal layer of the nail plate with a compound capable of penetrating the nail plate, traveling through the nail plate to a nail bed underlying said nail plate, and contacting said microorganism, under conditions sufficient for said compound to penetrate said nail pjate and to treat said disease, wherein the compound has an efficacy coefficient above 10.
fO165] In an exemplary embodiment, the compound has an efficacy coefficient between about 10 and about 1000. In an exemplary embodiment, the compound has an efficacy coefficient between about 30 and about 100. In an exemplary embodiment, the compound has an efficacy coefficient between about 100 and about 500. In an exemplary embodiment the compound has an efficacy coefficient between about 25 and about 200.
[0166J This invention is still further directed to methods for treating a fungal infection mediated at least in part by dermatophytes, Trichophyton, Microsporum or Epidermophyion species, or a yeast-like fungi including Candida species, in an animal (such as a human) or a plant, which methods comprise administering to an animal (such as a human) or a plant, that has been diagnosed with said fungal infection or is at risk of developing said fungal infection. a pharmaceutical composition comprising a pharmaceutically acceptable diluent and a therapeutically effective amount of a compound described herein or mixtures of one or more of such compounds. In one embodiment the infection is onychomycosis.
[0167] Compounds contemplated by the present invention may have broad spectrum antifungal activity and as such may be candidates for use against other cutaneous fungal infections.
[0168] The methods provided in this aspect of the invention are useful in the penetration of nails and hoofs, as well as the treatment of ungual and periungual conditions.
VJl. Pharmaceutical Formulations
[0169] In another aspect, the invention is a pharmaceutical formulation which includes:
(a) a pharmaceutically acceptable excipient; and (b) a compound of the invention. In another aspect, the invention is a pharmaceutical formulation which includes: (a) a pharmaceutically acceptable excipient; and (b) a compound described herein. In another aspect, the invention is a pharmaceutical formulation which includes: (a) a pharmaceutically acceptable excipient; and (b) a compound which is a member selected from a boron containing compound described in this document, a Sow molecular weight ciclopirox derivative described in this document, and a fungicide described in this document. In another aspect, the invention is a pharmaceutical formulation which includes: (a) a pharmaceutically acceptable excipient; and
(b) a compound which is described in 'The Compounds" section and/or the "Examples"' section of this document.
[0170] The pharmaceutical formulations of the invention can take a variety of forms adapted to the chosen route of administration. Those skilled in the art will recognize various synthetic methodologies that may be employed to prepare non-toxic pharmaceutical formulations incorporating the compounds described herein. Those skilled in the art will recognize a wide variety of non-toxic pharmaceutically acceptable solvents that may be used to prepare solvates of the compounds of the invention, such as water, ethanol, propylene glycol, mineral oil, vegetable oil and dimethylsulfoxide (DMSO).
[0171] The compositions of the invention may be administered orally, topically, parenterally, by inhalation or spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles, ϊt is further understood that the best method of administration may be a combination of methods. Oral administration in the form of a pill, capsule, elixir, syrup, lozenge, troche, or the like is particularly preferred. The term parenteral as used herein includes subcutaneous injections, intradermal, intravascular (e.g., intravenous), intramuscular, spinal, intrathecal injection or like injection or infusion techniques.
[0172] The pharmaceutical formulations containing compounds of the invention are preferably in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, or syrups or elixirs.
[0173] Compositions intended for oral use may be prepared according to any method known in the art for the manufacture of pharmaceutical formulations, and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets may contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipicnts that are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia; and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearatc may be employed.
[0174] Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.
[0175] Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcelluiose, methylceliulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; and dispersing or wetting agents, which may be a naturally-occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl p-hydroxybenzoate. one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.
[0176] Oily suspensions may be formulated by suspending the active ingredients in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide palatable oral preparations. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
[0177] Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.
|0178] Pharmaceutical formulations of the invention may also be in the form of oil-in- water emulsions and water-in-oil emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth; naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol; anhydrides, for example sorbitan monooleate; and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavoring agents.
[0179] Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, and flavoring and coloring agents. The pharmaceutical formulations may be in the form of a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents, which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example as a solution in 1 ,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland
fixed oil may be employed including synthetic mono- or diglycerides, In addition, fatty acids such as oleic acid find use in the preparation of injectables.
[0180] The composition of the invention may also be administered in the form of suppositories, e.g., for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient that is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.
[0181] Alternatively, the compositions can be administered parenterally in a sterile medium. The drug, depending on the vehicle and concentration used, can either be suspended or dissolved in the vehicle. Advantageously, adjuvants such as local anesthetics, preservatives and buffering agents can be dissolved in the vehicle.
[0182] for administration to non-human animals, the composition containing the therapeutic compound may be added to the animal's feed or drinking water. Also, it will be convenient to formulate animal feed and drinking water products so that the animal takes in an appropriate quantity of the compound in its diet. It will further be convenient to present the compound in a composition as a premix for addition to the feed or drinking water. The composition can also added as a food or drink supplement for humans.
[0183] Dosage levels of the order of from about 5 mg to about 250 mg per kilogram of body weight per day and more preferably from about 25 mg to about 150 mg per kilogram of body weight per day, are useful in the treatment of the above-indicated conditions. The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the condition being treated and the particular mode of administration. Dosage unit forms will generally contain between from about 1 mg to about 500 mg of an active ingredient.
[0184] Frequency of dosage may also vary depending on the compound used and the particular disease treated. However, for treatment of most disorders, a dosage regimen of 4 times daily or less is preferred. It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration and rate of excretion, drug combination and the severity of the particular disease undergoing therapy.
[0185] Preferred compounds of the invention will have desirable pharmacological properties that include, but are not limited to, oral bioavailability, low toxicity, low serum protein binding and desirable in vitro and in vivo half-lives. Penetration of the blood brain barrier for compounds used to treat CNS disorders is necessary, while low brain levels of compounds used to treat peripheral disorders are often preferred.
[0186] Assays may be used to predict these desirable pharmacological properties. Assays used to predict bioavailability include transport across human intestinal cell monolayers, including Caco-2 cell monolayers. Toxicity to cultured hepatocyctes may be used to predict compound toxicity. Penetration of the blood brain barrier of a compound in humans may be predicted from the brain levels of laboratory animals that receive the compound intravenously.
[0187] Serum protein binding may be predicted from albumin binding assays. Such assays are described in a review by Oravcova, et al. (Journal of Chromatography B (1996) volume 677, pages 1 -27).
[0188] Compound half-life is inversely proportional to the frequency of dosage of a compound. In vitro half-lives of compounds may be predicted from assays of microsomal half-life as described by Kuhnz and Gieschen (Drug Metabolism and Disposition, (1998) volume 26, pages 1 120-1 127).
[0189] The amount of the composition required for use in treatment will vary not only with the particular compound selected but also with the route of administration, the nature of the condition being treated and the age and condition of the patient and will ultimately be at the discretion of the attendant physician or clinician.
[0190] In an exemplary embodiment, the pharmaceutical formulation excipient comprises ethanol and the pharmaceutical formulation compound is a compound described herein. In another exemplary embodiment, the pharmaceutical formulation excipient comprises propylene glycol and the pharmaceutical formulation compound is a compound described herein. In an exemplary embodiment the pharmaceutical formulation comprises: about 20% propylene glycol; about 70% elhanol; about 10% of a compound described herein. In an exemplary embodiment the pharmaceutical formulation comprises: about 70% ethanoh about 20% poly(vinyl methyl ether-alt-maleic acid monobutyl ester); about 10% of a compound described herein. In an exemplary embodiment the pharmaceutical ibrmulalion comprises: about 56% ethanol; about 14% water; about 15% poly(2-hydroxyethyl
methacrylate); about 5% di butyl sebacate; about 10% of a compound described herein. In an exemplary embodiment the pharmaceutical formulation comprises: about 55% ethanol; about 15% ethyl acetate; about 15% polyvinyl acetate); about 5% dibutyl sebacate; about 10% of a compound described herein. In another exemplary embodiment, a compound described herein is present in a pharmaceutical formulation in a concentration which is a member selected from 1 %. 2.5%, 5%, 7.5%, 10% and 15% w/v. In another exemplary embodiment, the pharmaceutical formulation is a lacquer.
VIh a) Topical formulations
[0191] In a preferred embodiment, the methods of the invention can be used employed through the topical application of the compounds described herein.
|0192] The compositions of the present invention comprises fluid or semi-solid vehicles that may include but are not limited to polymers, thickeners, buffers, neutralizers, chelating agents, preservatives, surfactants or emulsifiers, antioxidants, waxes or oils, emollients, sunscreens, and a solvent or mixed solvent system. The solvent or mixed solvent system is important to the formation because it is primarily responsible for dissolving the drug. The best solvent or mixed solvent systems are also capable of maintaining clinically relevant levels of the drug in solution despite the addition of a poor solvent to the formulation. The topical compositions useful in the subject invention can be made into a wide variety of product types. These include, but are not limited to, lotions, creams, gels, sticks, sprays, ointments, pastes, foams, mousses, and cleansers. These product types can comprise several types of carrier systems including, but not limited to particles, nanoparticles, and liposomes, if desired, disintegrating agents can be added, such as the cross-linked polyvinyl pyrrolidone, agar or alginic acid or a salt thereof such as sodium alginate. Techniques for formulation and administration can be found in Remington: The Science and Practice of Pharmacy, supra. The formulation can be selected to maximize delivery to a desired target site in the body.
|0193] Lotions, which are preparations that are to be applied to the skin, nail, hair, claw or hoof surface without friction, are typically liquid or semi-liquid preparations in which finely divided solid, waxy, or liquid are dispersed. Lotions will typically contain suspending agents to produce better dispersions as well as compounds useful for localizing and holding the active agent in contact with the skin, nail, hair, claw or hoof, e.g.. methylcellulose, sodium carboxymethyl-cellulose, or the like.
[0194] Creams containing the active agent for delivery according to the present invention are viscous liquid or semisolid emulsions, either oil-in- water or water-in-oil. Cream bases are water-washable, and contain an oil phase, an emulsifier and an aqueous phase. The oil phase is generally comprised of petrolatum or a fatty alcohol, such as cetyl- or stearyl alcohol; the aqueous phase usually, although not necessarily, exceeds the oil phase in volume, and generally contains a humectant. The emulsifier in a cream formulation, as explained in Remington: The Science and Practice of Pharmacy, supra, is generally a nonionic, anionic, cationic or amphoteric surfactant.
[0195] Gel formulations can also be used in connection with the present invention, As will be appreciated by those working in the field of topical drug formulation, gels are semisolid. Single-phase gels contain organic macromolecules distributed substantialiy uniformly throughout the carrier liquid, which is typically aqueous, but also may be a solvent or solvent blend,
[0196] Ointments, which are semisolid preparations, are typically based on petrolatum or other petroleum derivatives. As will be appreciated by the ordinarily skilled artisan, the specific ointment base to be used is one that provides for optimum delivery for the active agent chosen for a given formulation, and, preferably, provides for other desired characteristics as well, e.g., emolliency or the like. As with other carriers or vehicles, an ointment base should be inert, stable, nonirritating and non-sensitizing. As explained in Remington: The Science and Practice of Pharmacy, 19th Ed. (Easton, Pa.: Mack Publishing Co., 1995), at pages 1399-1404, ointment bases may be grouped in four classes: oleaginous bases; emulsifiable bases; emuision bases; and water-soluble bases. Oleaginous ointment bases include, for example, vegetable oils, fats obtained from animals, and semisolid hydrocarbons obtained from petroleum. Emulsifiable ointment bases, also known as absorbent ointment bases, contain little or no water and include, for example, hydroxy stearin sulfate, anhydrous lanolin and hydrophilic petrolatum. Emulsion ointment bases are either water-in-oil (W/O) emulsions or oil-in- water (OfW) emulsions, and include, for example, cetyl alcohol, glyceryl monostearate, lanolin and stearic acid. Preferred water-soluble ointment bases are prepared from polyethylene glycols of varying molecular weight; again, reference may be had to Remington: The Science and Practice of Pharmacy, supra, for further information.
[0197] Useful formulations of the invention also encompass sprays. Sprays generally provide the active agent in an aqueous and/or alcoholic solution which can be misted onto the
skin, nail, hair, claw or hoof for delivery. Such sprays include those formulated to provide for concentration of the active agent solution at the site of administration following delivery, e.g., the spray solution can be primarily composed of alcohol or other like volatile liquid in which the drug or active agent can be dissolved. Upon delivery to the skin, nail, hair, claw or hoof, the carrier evaporates, leaving concentrated active agent at the site of administration.
[0198] The topical pharmaceutical compositions may also comprise suitable solid or gel phase carriers. Examples of such carriers include but are not limited to calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.
[0199] The topical pharmaceutical compositions may also comprise a suitable emulsifier which refers to an agent that enhances or facilitates mixing and suspending oil-in-water or watcr-in-oil. The emulsifying agent used herein may consist of a single emulsifying agent or may be a nonionic. anionic, cationic or amphoteric surfactant or blend of two or more such surfactants; preferred for use herein are nonionic or anionic emulsifiers. Such surface-active agents are described in "McCutcheon's Detergent and Emulsifiers," North American Edition, 1980 Annual published by the McCutcheon Division. MC Publishing Company, 175 Rock Road, Glen Rock, N.J. 07452, USA.
[0200] Preferred for use herein are high molecular weight alcohols such as cetearyl alcohol, cetyl alcohol, stearyl alcohol, emulsifying wax, glyceryl monostearate. Other examples are ethylene glycol distearate, sorbitan tristearate. propylene glycol monostearate, sorbitan monooleate, sorbitan monostearate (SPAN 60), diethyiene glycol monolaurate, sorbitan monopalmitate, sucrose dioleate, sucrose stearate (CRODESTA F-160), polyoxyethylene lauryl ether (BRlJ 30), polyoxyethylene (2) stearyl ether (BRIJ 72), polyoxyethylene (21) stearyl ether (BRIJ 721 ), polyoxyethylene monostearate (Myrj 45), polyoxyethylene sorbitan monostearate (TWEEN 60), polyoxyethylene sorbitan monooleate (TWEEN 80), polyoxyethylene sorbitan monolaurate (TWEEN 20) and sodium oleate. Cholesterol and cholesterol derivatives may also be employed in externally used emulsions and promote w/o emulsions.
]0201] Especially suitable nonionic emulsifying agents are those with hydrophile- lipophile balances (HLB) of about 3 to 6 for w/o system and 8 to 18 for o/w system as determined by the method described by Paul L. Lindner in "Emulsions and Emulsion'", edited by Kenneth Lissant, published by Dekker, New York. N.Y., 1974. pages 188-190. More
preferred for use herein are one or more nonionic surfactants that produce a system having FILB of about 8 to about 18.
[0202] Examples of such nonionic emulsifiers include but are not limited to "BRIJ 72". the trade name for a polyoxyethylene (2) stearyl ether having an HLB of 4,9; "BRIJ 721 ", the trade name for a polyoxyelhylene (21) stearyl ether having an HLB of 15.5, "Brij 30", the trade name for polyoxyethylene lauryl ether having an HLB of 9.7; "Polawax", the trade name for emulsifying wax having an HLB of 8.0; "Span 60", the trade name for sorbitan monostearate having an HLB of 4.7; "Crodesta F- 160", the trade name for sucrose stearate" having an HLB of 14.5. All of these materials are available from Ruger Chemicals Inc.; Croda; ICI Americas, Inc.; Spectrum Chemicals; and BASF. When the topical formulations of the present invention contain at least one emulsifying agent, each emulsifying agent is present in amount from about 0.5 to about 2.5 wt%, preferably 0.5 to 2.0%, more preferably 1.0% or 1 ,8%. Preferably the emulsifying agent comprises a mixture of steareth 21 (at about 1.8 %) and steareth 2 (at about 1.0%).
[0203] The topical pharmaceutical compositions may also comprise suitable emollients. Emollients are materials used for the prevention or relief of dryness, as well as for the protection of the skin, nail, hair, claw or hoof. Useful emollients include, but are not limited to, cetyl alcohol, isopropyl myristate, stearyl alcohol, and the like. A wide variety of suitable emollients are known and can be used herein. See e.g., Sagarin, Cosmetics, Science and Technology, 2nd Edition, Vol. 1 , pp. 32-43 (1972), and U.S. Pat. No. 4,919,934, to Deckner et al., issued Apr. 24, 1990, both of which are incorporated herein by reference in their entirety. These materials are available from Ruger Chemical Co, (Irvington, NJ).
[0204] When the topical formulations of the present invention contain at least one emollient, each emollient is present in an amount from about 0.1 to 15%, preferably 0.1 to about 3.0, more preferably 0.5, 1.0, or 2.5 wt%. Preferably the emollient is a mixture of cetyl alcohol, isopropyl myristate and stearyl alcohol in a 1/5/2 ratio. The emollient may also be a mixture of cetyl alcohol and stearyl alcohol in a 1 /2 ratio.
[0205] The topical pharmaceutical compositions may also comprise suitable antioxidants, substances known to inhibit oxidation. Antioxidants suitable for use in accordance with the present invention include, but are not limited to, butylated hydroxy toluene, ascorbic acid, sodium ascorbate, calcium ascorbate. ascorbic palmitate, butylated hydroxyanisole, 2,4,5- trihydroxybutyrophenone. 4-hydroxymethyl-2,6-di-fer/-butylphenol, erythorbic acid, gum
guaiac, propyl gallate. thiodiprop ionic acid, dilauryl thiodipropionate, tert-butylhydroquinone and tocopherols such as vitamin E, and the like, including pharmaceutically acceptable salts and esters of these compounds. Preferably, the antioxidant is butylaled hydroxytoluene, butylated hydroxyanisole, propyl gallate, ascorbic acid, pharmaceutically acceptable salts or esters thereof, or mixtures thereof. Most preferably, the antioxidant is butylated hydroxytoluene. These materials are available from Ruger Chemical Co, (Irvinglon. NJ).
[0206] When the topical formulations of the present invention contain at least one antioxidant, the total amount of antioxidant present is from about 0.001 to 0.5 wt%, preferably 0.05 to about 0.5 wt%, more preferably 0.1%.
[0207] The topical pharmaceutical compositions may also comprise suitable preservatives. Preservatives are compounds added to a pharmaceutical formulation to act as an anti-microbial agent. Among preservatives known in the art as being effective and acceptable in parenteral formulations are benzalkonium chloride, benzethonium, chlorohexidine, phenol, m-cresol, benzyl alcohol, methylparaben, propylparaben, chlorobutanol, o-cresol, p-cresol, cbJorocresoI, phenylmercuric nitrate, thimerosal, benzoic acid, and various mixtures thereof. See, e.g., Wallhausser, K. -H., Develop. Biol. Standard, 24:9-28 (1974) (S. Krager, Basel). Preferably, the preservative is selected from methylparaben, propylparaben and mixtures thereof. These materials are available from Inolex Chemical Co (Philadelphia, PA) or Spectrum Chemicals.
[0208] When the topical formulations of the present invention contain at least one preservative, the total amount of preservative present is from about 0.01 to about 0.5 wt%, preferably from about 0.1 to 0.5%, more preferably from about 0.03 to about 0.15. Preferably the preservative is a mixture of methylparaben and proplybarben in a 5/1 ratio. When alcohol is used as a preservative, the amount is usually 15 to 20%.
[0209J The topical pharmaceutical compositions may also comprise suitable chelating agents to form complexes with metal cations that do not cross a lipid bilayer. Examples of suitable chelating agents include ethylene diamine tetraacetic acid (EDTA). ethylene glycol- bis(beta-aminoethyl ether)-N,N,N', N '-tetraacetic acid (EGTA) and 8-Amino-2-[(2-amino-5- methylphenoxy)methyl]-6-methoxyquinoline-N,N,N',N'-tetraacetic acid, tetrapotassium salt (QUIN-2). Preferably the chelating agents are EDTA and citric acid. These materials are available from Spectrum Chemicals.
[0210J When the topical formulations of the present invention contain at least one chelating agent, the total amount of chelating agent present is from about 0.005% to 2.0% by weight, preferably from about 0.05% to about 0.5 wt%, more preferably about 0.1% by weight.
[0211 ] The topical pharmaceutical compositions may also comprise suitable neutralizing agents used to adjust the pH of the formulation to within a pharmaceutically acceptable range. Examples of neutralizing agents include but are not limited to trolamine, tromethamine, sodium hydroxide, hydrochloric acid, citric acid, and acetic acid. Such materials are available from are available from Spectrum Chemicals (Gardena, CA).
[0212] When the topical formulations of the present invention contain at least one neutralizing agent, the total amount of neutralizing agent present is from about 0.1 wt to about 10 wt %, preferably 0.1 wt % to about 5.0 wt%. and more preferably about 1.0 wt %. The neutralizing agent is generally added in whatever amount is required to bring the formulation to the desired pH.
[0213] The topical pharmaceutical compositions may also comprise suitable viscosity increasing agents. These components are diffusible compounds capable of increasing the viscosity of a polymer-containing solution through the interaction of the agent with the polymer. CARBOPOL ULTREZ 10 may be used as a viscosity-increasing agent. These materials are available from Noveon Chemicals. Cleveland, OH.
[0214] When the topical formulations of the present invention contain at least one viscosity increasing agent, the total amount of viscosity increasing agent present is from about 0.25% to about 5.0% by weight, preferably from about 0.25% to about 1.0 wt%, and more preferably from about 0.4% to about 0.6% by weight.
[0215] The topical pharmaceutical compositions may also comprise suitable nail penetration enhancers. Examples of nail penetration enhancers include mercaptan compounds, sulfites and bisulfites, keratolytic agents and surfactants. Nail penetration enhancers suitable for use in the invention are described in greater detail in Malhotra et ai, J, Pharm. ScL, 91 :2, 312-323 (2002), which is incorporated herein by reference in its entirety.
[0216] The topical pharmaceutical compositions may also comprise one or more suitable solvents. The ability of any solid substance (solute) to dissolve in any liquid substance (solvent) is dependent upon the physical properties of the solute and the solvent. When solutes and solvents have similar physical properties the solubility of the solute in the solvent
will be the greatest. This gives rise to the traditional understanding that "like dissolves like." Solvents can be characterized in one extreme as non-polar, lipophilic oils, while in the other extreme as polar hydrophilic solvents. Oily solvents dissolve other non-polar substances by Van der WaIs interactions while water and other hydrophilic solvents dissolve polar substances by ionic, dipole, or hydrogen bonding interactions. All solvents can be listed along a continuum from the least polar, i.e. hydrocarbons such as decane, to the most polar solvent being water. A solute will have its greatest solubility in solvents having equivalent polarity. Thus, for drugs having minimal solubility in water, less polar solvents will provide improved solubility with the solvent having polarity nearly equivalent to the solute providing maximum solubility. Most drugs have intermediate polarity, and thus experience maximum solubility in solvents such as propylene glycol or ethanol, which are significantly less polar than water. If the drug has greater solubility in propylene glycol (for example 8% (w/w)) than in water (for example 0.1 % (w/w)), then addition of water to propylene glycol should decrease the maximum amount of drug solubility for the solvent mixture compared with pure propylene glycol. Addition of a poor solvent to an excellent solvent will decrease the maximum solubility for the blend compared with the maximum solubility in the excellent solvent.
[0217J When compounds are incorporated into topical formulations the concentration of active ingredient in the formulation may be limited by the solubility of the active ingredient in the chosen solvent and/or carrier. Non-lipophilic drugs typically display very low- solubility in pharmaceutically acceptable solvents and/or carriers. For example, the solubility of some compounds in the invention in water is less than 0.00025% wt/wt. The solubility of the same compounds in the invention can be less than about 2% wt/wt in either propylene glycol or isopropyl myristate. In one embodiment of the present invention, diethylene glycol monoethyl ether (DGME) is the solvent used to dissolve the compounds of the invention. The compounds in the invention useful in the present formulation are believed to have a solubility of from about 10% wt/wt to about 25% wt/wt in DGME. In another embodiment a DGME water cosolvent system is used to dissolve the compounds of the invention. The solvent capacity of DGME drops when water is added; however, the DGME/water cosolvent system can be designed to maintain the desired concentration of from about 0.1 % to about 5% wt/wt active ingredient. Preferably the active ingredient is present from about 0.5 % to about 3% wt/wt. and more preferably at about 1% wt/wt. in the as-applied topical formulations. Because DGME is less volatile than water, as the topical formulation evaporates upon application, the active agent becomes more soluble in the cream
formulation. This increased solubility reduces the likelihood of reduced bioavailability caused by the drug precipitating on the surface of the skin, nail, hair, claw or hoof.
[0218] Liquid forms, such as lotions suitable for topical administration or suitable for cosmetic application, may include a suitable aqueous or nonaqueous vehicle with buffers, suspending and dispensing agents, thickeners, penetration enhancers, and the like. Solid forms such as creams or pastes or the like may include, for example, any of the following ingredients, water, oil, alcohol or grease as a substrate with surfactant, polymers such as polyethylene glycol, thickeners, solids and the like. Liquid or solid formulations may include enhanced delivery technologies such as liposomes, microsomes, microsponges and the like.
[0219] Additionally, the compounds can be delivered using a sustained-release system, such as semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent. Various sustained-release materials have been established and are well known by those skilled in the art.
[0220] Topical treatment regimens according to the practice of this invention comprise applying the composition directly to the skin, nail, hair, claw or hoof at the application site, from one to several times daily.
[0221] Formulations of the present invention can be used to treat, ameliorate or prevent conditions or symptoms associated with bacterial infections, acne, inflammation and the like.
[0222] In an exemplary embodiment, the pharmaceutical formulation includes a simple solution. In an exemplary embodiment, the simple solution includes an alcohol. In an exemplary embodiment the simple solution includes alcohol and water. In an exemplary embodiment, the alcohol is ethanol, ethylene glycol, propanol, polypropylene glycol, isopropanol or butanol, In another exemplary embodiment, the simple solution is a member selected from about 10% polypropylene glycol and about 90% ethanol; about 20% polypropylene glycol and about 80% ethanol; about 30% polypropylene glycol and about 70% ethanol; about 40% polypropylene glycol and about 60% ethanol; about 50% polypropylene glycol and about 50% ethanol; about 60% polypropylene glycol and about 40% ethanol; about 70% polypropylene glycol and about 30% ethanol; about 80% polypropylene glycol and about 20% ethanol; about 90% polypropylene glycol and about 10% ethanol.
[0223] In an exemplary embodiment, the pharmaceutical formulation is a lacquer. Please see Remington's, supra, for more information on the production of lacquers.
[0224] In an exemplary embodiment, the compound is present in said pharmaceutical formulation in a concentration of from about 0,5% to about 15%. In an exemplary embodiment, the compound is present in said pharmaceutical formulation in a concentration of from about 0.1% to about 12.5%. In an exemplary embodiment, the compound is present in said pharmaceutical formulation in a concentration of from about 1% to about 10%. In an exemplary embodiment, the compound is present in said pharmaceutical formulation in a concentration of from about 1% to about 5%. In an exemplary embodiment, the compound is present in said pharmaceutical formulation in a concentration of from about 0.5% to about 5%. ϊn an exemplary embodiment, the compound is present in said pharmaceutical formulation in a concentration of from about 0.5% to about 7.5%, In an exemplary embodiment, the compound is present in said pharmaceutical formulation in a concentration of from about 5% to about 7.5%. In an exemplary embodiment, the compound is present in said pharmaceutical formulation in a concentration of from about 2% to about 8%. In an exemplary embodiment, the compound is present in said pharmaceutical formulation in a concentration of from about 4% to about 9%.
VlL b) Additional Active Agents
[0225] The following are examples of the cosmetic and pharmaceutical agents that can be added to the topical pharmaceutical formulations of the present invention. The following agents are known compounds and are readily available commercially.
[0226] Anti-inflammatory agents include, but are not limited to, bisabolol, mentholatum, dapsone, aloe, hydrocortisone, and the like.
[0227] Vitamins include, but are not limited to, Vitamin B, Vitamin E, Vitamin A, Vitamin D, and the like and vitamin derivatives such as tazarotene, calcipotriene, tretinoin, adapalene and the like.
[0228] Anti-aging agents include, but are not limited to, niacinamide, retinol and retinoid derivatives, AHA. Ascorbic acid, lipoic acid, coenzyme Q lO, beta hydroxy acids, salicylic acid, copper binding peptides, dimethyl ami noethyl (DAEA), and the like.
[0229] Sunscreens and or sunburn relief agents include, but are not limited to, PABA, jojoba, aloe, padimate-O, methoxycinnamates, proxamine HCl, lidocaine and the like. Sunless tanning agents include, but are not limited to, dihydroxyacetone (DHA).
[0230] Psoriasis-treating agents and/or acne-treating agents include, but are not limited to, salicylic acid, benzoyl peroxide, coal tar, selenium sulfide, zinc oxide, pyrithione (zinc and/or sodium), tazarotene, calcipotriene, tretinoin, adapalene and the like.
[0231 J Agents that are effective to control or modify keratinization. including without limitation: tretinoin, tazarotene, and adapalene.
[0232] The compositions comprising an compound/active agent of the invention, and optionally at least one of these additional agents, are to be administered topically. In a primary application, this leads to the compounds of the invention and any other active agent working upon and treating the skin, nail, hair, claw or hoof. Alternatively, any one of the topically applied active agents may also be delivered systemically by transdermal routes.
[0233] In such compositions an additional cosmetically or pharmaceutically effective agent, such as an anti-inflammatory agent, vitamin, anti-aging agent, sunscreen, and/or acne- treating agent, for example, is usually a minor component (from about 0.001 % to about 20% by weight or preferably from about 0.01 % to about 10% by weight) with the remainder being various vehicles or carriers and processing aids helpful for forming the desired dosing form.
VH. c) Testing
[0234] Preferred compounds for use in the present topical formulations will have certain pharmacological properties. Such properties include, but are not limited to, low toxicity, low serum protein binding and desirable in vitro and in vivo half-lives. Assays may be used to predict these desirable pharmacological properties. Assays used to predict bioavailability include transport across human intestinal cell monolayers, including Caco-2 cell monolayers. Serum protein binding may be predicted from albumin binding assays. Such assays are described in a review by Oavcova et al. (1996, J, Chromat. B677: 1-27). Compound half- life is inversely proportional to the frequency of dosage of a compound. In vitro half-lives of compounds may be predicted from assays of microsomal half-life as described by Kuhnz and Gleschen (Drug Metabolism and Disposition, (1998) volume 26, pages 1120-1 127).
[0235] Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio between LD50
and ED50. Compounds that exhibit high therapeutic indices are preferred. The data obtained from these cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the EDSQ with little or no toxicity. The dosage can vary within this range depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See, e.g. Fingl el al., 1975, in "The Pharmacological Basis of Therapeutics", Ch. 1, p. 1).
VH. d) A dministration
J0236J For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays, as disclosed herein. For example, a dose can be formulated in animal models to achieve a circulating concentration range that includes the EC50 (effective dose for 50% increase) as determined in cell culture, i.e., the concentration of the test compound which achieves a half-maximal inhibition of bacterial cell growth. Such information can be used to more accurately determine useful doses in humans.
[0237] In general, the compounds prepared by the methods, and from the intermediates, described herein will be administered in a therapeutically or cosmetically effective amount by any of the accepted modes of administration for agents that serve similar utilities. It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, and rate of excretion, drug combination, the severity of the particular disease undergoing therapy and the judgment of the prescribing physician. The drug can be administered from once or twice a day, or up to 3 or 4 times a day.
[0238] Dosage amount and interval can be adjusted individually to provide plasma levels of the active moiety that are sufficient to maintain bacterial cell growth inhibitory effects. Usual patient dosages for systemic administration range from 0.1 to 1000 mg/day, preferably, 1-500 mg/day. more preferably 10 - 200 mg/day, even more preferably 100 - 200 mg/day. Stated in terms of patient body surface areas, usual dosages range from 50-91 mg/m2/day.
[0239] The amount of the compound in a formulation can vary within the full range employed by those skilled in the art. Typically, the formulation will contain, on a weight
percent (wt%) basis, from about 0.01-iO wt% of the drag based on the total formulation, with the balance being one or more suitable pharmaceutical excipients. Preferably, the compound is present at a level of about 0.1-3.0 wt%, more preferably, about 1,0 wt%.
[0240] The invention is further illustrated by the Examples that follow. The Examples are not intended to define or limit the scope of the invention.
EXAMPLES
[0241] General: Melting points were obtained using a Mel-Temp-0 melting point apparatus and are uncorrected. 1H NMR spectra were recorded on Oxford 300 (300 MHz) spectrometer (Varian). Mass spectra were determined on API 3000 (Applied Biosystems). Purity by HPLC (relative area) was determined using ProStar Model 330 (PDA detector, Varian), Model 210 (pump, Varian), and a BetaBasic-18 4.6 x 150 mm column (Thermo Electron Corporation) with a linear gradient of 0 to 100% MeCN in 0.01 % H3PO4 over 10 min followed by 100% MeCN for another 1 Omin at 220 nm.
EXAMPLE 1
Synthesis of 2-(Divinγlboryloxy)ethanaminc
1 , THF, -780C -780C to r.t 2 h
[0242J To a solution of vinylmagnesium bromide (23 mL 1 .0 M THF, 23 mmol) in anhydrous THF (50 mL) at -780C was added trimethyl borate (1.11 mL, 10 mmol) under nitrogen atmosphere. After the cooling bath was removed, the reaction mixture was stirred for 2 h and then a water bath was placed with stirring for additional 2 h. Hydrochloric acid (6 N) was used to adjust the pH value of the solution to 7-8 and the aqueous layer was removed from the flask with a pipet. Ethanolamine (0.61 g. 10 mmol) was added to the THF solution and the mixture was stirred for 10 min before rotary evaporation. The residue was mixed with methylene chloride and dried with anhydrous MgSO4, then filtered. The filtrate was evaporated and pumped under high vacuum to give the desired title compound as an off- white solid (0.73 g, yield 58.4%). 1H NMR (DMSO-d6, 300 MHz): δ= 5.94 (dd. J= 19.2 & 13.5 Hz, 2H), 5.45 (br. s, 2H), 5.21 (dd, J= 13.5 & 4.8 Hz, 2H), 5.12 (dd, J= 19.5 & 4.8 Hz,
2H), 3.60 (t, J= 6.3 Hz, 2H), 2.69 (t. J= 6.6 Hz, 2H) ppm; MS: m/z = 126 (M+ 1 , ESI+) and 124 (M-I 7 ESI-).
EXAMPLE 2 f2-fPyridin-3-yl(vinyI)borγloxyjpheny|}methanamine
CH2=CHB(OBu)2, THF O0C, r t 16 h H2O pH 9-10
[0243] To a solution of 3-bromopyridine (4.74 g. 30 mmol) in anhydrous THF (90 mL) at O0C was added isopropylmagnesium chloride (15 mL 2.0 M THF, 30 mmol) in one portion and the mixture was stirred for Ih at room temperature. The mixture was cooled again with ice bath and vinylboronic acid dibutyl ester (6.95 mL, 31.5 mmol) was added in one portion. The reaction mixture was stirred overnight at room temperature and brine was added. The pH of the mixture was adjusted to 9-10 with 6N HC3 solution and extracted with THF (3 x 80 mL), dried and filtered. Evaporation of the filtrate gave brown oil (6.65 g) that was dissolved in ethanol (100 mL). Half of the solution was mixed with 2-(aminomethyl)phenol (1.29 g, 10.5 mmol) and stirred for 15 min before rotary evaporation. The residue was mixed with hexane and then rotary evaporated. Isopropyl ether was added and the mixture was sonicated for a while to give a brown solid (2.4 g) with 90% purity. The solid was mixed with diethyl ether and then filtered. The filtrate was rotary evaporated and pumped under high vacuum affording the desired title compound (0.92 g, yield 25.8%). 1H NMR (DMSOd6, 300 MHz): S= 8.56 (s, IH), 8.29 (d, J= 4.8 Hz, I H), 7.74 (d, J= 7.5 Hz, I H), 7.17 (dd, J= 7.5 & 5.1 Hz, IH). 7.07 (t, J = 7.5 Hz, I H), 6.91 (d, J = 7.2 Hz, IH), 6.82 (d, J = 7.8 Hz. IH). 6.63 (t. J = 7.2 Hz, III), 6.53 (br. s, IH), 6.44 (br. s, IH), 6.1 1 (dd, J= 18.9 & 13.5 Hz, IH), 5.30 (dd, J = 13.5 & 4.5 Hz, IH). 5.15 (dd, J= 19.5 & 4.5 Hz, IH), 3.89-3.82 (m, I H), 3.66-3.60 (m, IH) ppm; MS: m/z = 239 (M+ 1, ESI+).
EXAMPLE 3
[0244] This compound can be synthesized according to the method described in Benkovic el at., J. Med. Chern,, 48: 7468-7476 (2005).
EXAMPLE 4
[0245] This compound can be synthesized according to the method described in Brown et al., J, Org. Chem,, 51: 4526-4530 (1986).
EXAMPLE 5
(2-Aminoethoxy)(4-fluorophenyi)vinylborane
[0246] To a solution of 4-fluorophenylboronic acid ethylene glycol ester (3.32 g, 20.0 mmol) in THF (20 mL) was added vinylmagnesium bromide (1.0 mol/L solution in THF; 24 mL) at -780C under nitrogen atmosphere, and the mixture was stirred for 2 h while being allowed to warm to room temperature. The reaction was quenched with 1 mol/L HCl, and extracted with ethyl acetate. The organic layer was washed with brine and dried on anhydrous sodium sulfate. Then the solvent was removed under reduced pressure. To a solution of the residue in EtOH (50 mL) was added 8-hydroxyquinoline (2.03 g, 14.0 mmol), and the solvent was removed under reduced pressure. The residue was purified by silica gel column chromatography (3:1 hexane/ethyl acetate) to give (4-fluorophenyl)(quinolin-8- oxy)vinylborane (3.24 g, 58%). 1H-NMR (300 MHz, DMS(M?) δ ppm 5.19 (dd, J= 19.3, 4.1 Hz, IH), 5.43 (dd, J= 13.5, 4.1 Hz, IH), 6.42 (dd, J= 19.3, 13.5 Hz, IH), 7.00 (dd, J = 9.7, 8.8 Hz. 2H), 7.12 (d, J = 7.6 Hz, IH), 7.3-7.5 (m, 3H), 7.68 (t, J= 8.2 Hz, IH), 7.86 (dd, J= 8.2. 5.0 Hz, IH), 8.73 (d, J- 8.5 Hz, IH), 8.90 (d, J= 5.0 Hz, IH).
[0247] A solution of (4-fluorophenyl)(quinoIin-8-oxy)vinylborane (2.73 g, 9.86 mmol) in ether (100 mL) was washed successively with 6 mol/L HCl twice, water, and brine. Then the
solution was dried on anhydrous sodium sulfate followed by filtration. To the solution was added ethanolamine (0.596 mL, 9.86 mL), and the solution was removed under reduced pressure to give the title compound (1.64 g, 86%). 1H-NMR (300 MHz, DMSO-ofc) δ ppni 2.6-2.9 (m. 2H), 3.6-3.8 (m, 2H), 5.11 (dd, J = 19.3, 4.7 Hz. IH). 5.22 (dd, J- 13.4, 4.7 Hz, IH), 5.64 (br s, IH), 5.83 (br s. I H), 6.07 (dd, J = 19.7. 13.4 Hz, IH), 6.92 (dd, J= 9.7, 8.8 Hz, 2H), 7.32 (dd, J= 7.9, 6.7 Hz, 2H).
EXAMPLE 6
[0248] 9.OmL of N-methyl-1-phenylmethanamine (79.0 mmol) and 1 1.8mL of N.N,N',N' tetramethylethylencdiamine (leq) were dissolved in 10OmL of tetrahydrofuran and cooled to O0C under N2. 10OmL of 1,63V! n-butyl lithium (2eq) was added drop-wise from an addition funnel over 30min then the reaction was allowed to warm to rt and stirred overnight. The following day, the reaction was cooled to -780C then 12.3mL of trimethyl borate (1 ,4eq) was added via syringe. The reaction was then allowed to warm to rt and stirred again overnight. Solvent was then removed under vacuum and the residue suspended in dichloromethane. filtered and washed 3x with additional dichloromethane. Combined washes were distilled under reduced pressure and fractions were collected between 70-900C, One fraction was hydrolyzed in aqueous methanol and evaporated to 1.3g of white solid. 1H NMR (DMSO-Cl6, 300 MHz): S= 1 AA-I Al (m. IH), 7.19-7.11 (m, 3H), 4.88 (s, 2H), 3.97 (broad s, I H)5 2.50 (s, 3H). Mp 179-1860C.
EXAMPLE 7 l-Hγdroxy-4,6-Dimethyipyridin-2(i//)-one
[0249] A literature procedure (G. Lohaus and W. Dittmar, "'Chemistry of Antimicrobially Active 1 -hydroxy-2-pyridones", Ar∑neimittel-Forschung, 1981, 3_I (8A), 1311-1316) was adapted for the preparation of the title compound. In a 500-mL flask, a mixture of 4,6- dJmethy]-2H-pyran-2-one (10.6 g, 85.39 mmol), hydroxylamine HCl salt (15 g, 0.216 mol)
and 2-aminopyridine (50 g, 0.531 mol, m.p.54°C) under nitrogen was heated with a magnetic stirring at 7O0C. Additional hydroxylamine HCl salts were added in three hours (2.5 g) and in five hours (2.5 g), and the resulting mixture was stirred at 7O0C during a weekend. Then more hydroxylamine HCl salt (2.5 g) was added and the mixture was heated at the same temperature for 5 h more. The mixture was cooled with ice bath and methylene chloride (200 mL) was added. The mixture was added to HCl solution and made the final pH 1. The organic layer was separated, dried and evaporated. The yellow solid residue was sonicated with EtOAc to give the pure title compound (2.2 g, yield 18.5%) as a cream solid. 1H NMR (DMSOd6, 300 MHz): S= 11.19 (br. s, IH), 6.16 (s, IH), 5.97 (s, IH), 2.25 (s, 3H), 2.07 (s, 3H) ppm; HPLC: 98.3% at 220 nm and 100% at 254 nm; MS: m/z - 140 (M+ 1, ESl+) and 138 (M-I5 ESI-).
EXAMPLE 8
Antifungal MJC Testing
[0250] All MlC testing followed the National Committee for Clinical Laboratory Standards (NCCLS) guidelines for antimicrobial testing of yeasts (M27-A2 NCCLS) and filamentous fungi (Pfaller et a!.. NCCLS publication M38-A - Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi; Approved Standard. Wayne, PA: NCCLS; 2002 (Vol. 22, No. 16) except the Maϊasse∑ia species which was incubated in a urea broth (Nakamura et al> Antimicrobial Agents And Chemotherapy, 2000, 44(8) p. 2185-2186). Results of the MIC testing is provided in FIG.l.
Claims
WHAT IS CLAIMED IS:
1. A compound having a structure according to the following formula:
Y is a member selected from substituted or iinsubstituted vinyl and substituted or unsubstituted aryl;
Z, Ra, Rb, Rc and Rd are members independently selected from members independently selected from H, OR*, NR*R**, SR*, -S(O)R*, -S(O)2R*, - S(O)2NR*R**, nitro, halogen, cyano, substituted or unsubstituted alkyl, substituted or imsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or iinsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; wherein Rb and Rc. together with the atoms to which they are attached, are optionally joined to form a 4- to 8-membered ring; wherein Rd and Rc, together with the atoms to which they are attached, are optionally joined to form a 4- to 8-membered ring; wherein Y and Z, together with the atoms to which they are attached, are optionally joined to form a member selected from a 4- to 8- membered ring and a 6- to 12-membered bieycHc ring; wherein each R* and R** are members independently selected from H5 nitro, halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl and salts thereof.
2. The compound of claim 1, wherein said compound has a structure according to the following formula:
3. The compound of claim 2, wherein said compound has a structure according to the following formula:
4. The compound of claim 3, wherein said Z is substituted or unsubstituted vinyl.
5. The compound of claim 4, wherein said compound is a member selected from
The compound of claim 4, wherein said compound is a member selected from
8. The compound of claim 1, wherein said compound is a member selected from
9. The compound of claim 1, wherein said 2 is substituted or unsubstituted alkyl, and wherein said substituted or unsubstitυted alkyl is substituted or unsubstituted alkenyl.
10. The compound of claim 1, wherein said Z is substituted or unsubstituted vinyl.
11. The compound of claim 1, wherein said Z is substituted or unsubstituted aryl,
12. The compound of claim 1, wherein said Z is substituted aryl, and has a structure according to the following formula:
wherein R is a member selected from H, nitro, halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubslituted heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl.
13. The compound of claim 12, wherein said R1 is a member selected from nitro. halogen, cyano and substituted or unsubstituted alkyl.
14. The compound of claim 12, wherein said R1 is a member selected from fluorine, chlorine and bromine.
16. The compound of claim 12. wherein said compound is
17. The compound of claim 1, wherein said Z is substituted or unsubstituted heteroaryl.
18. The compound of claim 17, wherein said Z is a member selected from substituted or unsubstituted 2-pyridinyl, substituted or unsubstituted 3-pyridinyl and substituted or unsubstituted 4-pyridinyl.
19. The compound of claim 18, wherein said Z is substituted or unsubstituted 3-pyridinyl.
20. The compound of claim 19, wherein said compound is
21. The compound of claim 1, wherein Rb and Rc, together with the atoms to which they are attached, are joined to form a substituted or unsubstituted 4- to 6- membered ring.
22. The compound of claim 21. wherein said compound is
25, The compound of claim 24, wherein said compound is a member selected from
26. The compound of claim 25, having a structure according to
27. The compound of claim 1. wherein said compound is a member selected from
28. The compound of claim 1, wherein Y and Z, together with the atoms to which they are attached, are joined to form a member selected from a 4- to 8- membered ring and a 6- to 12-membered bicyclic ring,
29. The compound of claim 1, wherein Y and Z, together with the atoms to which they are attached, are joined to form an 8-membered bicyclic ring.
30. The compound of claim 29, wherein said 8-membered bicyclic ring is unsubstituted.
31. The compound of claim 30, having a structure which is a member
32. The compound of claim 31, having a structure which is a member
33. The compound of claim 32, having a structure which is a member
34. The compound of claim 31, having a structure which is a member
35. The compound of claim 34, having a structure which is a member
36. A method of inhibiting the growth of, or killing, a fungus, said method comprising:
contacting said fungus with a compound in an amount sufficient to inhibit or kill said fungus wherein said fungus is a member selected from a dermatophyte, Trichophyton species, Microsporium species, Candida species, Aspergillus species and yeast-like fungus; wherein said compound has a structure according to claim 1.
37. A method of treating a disease in a subject, said method comprising administering to said subject a therapeutically effective amount of a compound, thereby treating said disease wherein said disease is an ungual, periungual or subungual infection; wherein said compound has a structure according claim 1.
38. A pharmaceutical formulation comprising: a) a pharmaceutically acceptable excipient; and b) a compound having a structure according to claim 1.
39. A formulation comprising: (a) a keratin containing component which is a member selected from a human nail unit, skin and hair; (b) a compound having a structure according to claim 1.
40. A method of inhibiting the growth of, or killing, a microorganism present in a human nail unit, wherein said human nail unit comprises a nail plate, comprising: contacting a dorsal layer of the nail plate with a compound capable of penetrating the nail plate, traveling through the nail plate to a nail bed underlying said nail plate, and contacting said microorganism, under conditions sufficient for said compound to penetrate said nail plate, wherein said compound has a structure according to claim 1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07868837A EP2069370A4 (en) | 2006-11-22 | 2007-11-21 | Microorganism killing compounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86706506P | 2006-11-22 | 2006-11-22 | |
US60/867,065 | 2006-11-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008064345A2 true WO2008064345A2 (en) | 2008-05-29 |
WO2008064345A3 WO2008064345A3 (en) | 2008-12-18 |
Family
ID=39430608
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/085448 WO2008064345A2 (en) | 2006-11-22 | 2007-11-21 | Microorganism killing compounds |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP2069370A4 (en) |
WO (1) | WO2008064345A2 (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012137164A1 (en) * | 2011-04-07 | 2012-10-11 | Biolinerx Ltd. | Antimicrobial compositions, antibiofilm compositions and uses thereof |
US8778365B1 (en) | 2013-01-31 | 2014-07-15 | Merz Pharmaceuticals, Llc | Topical compositions and methods for making and using same |
US9138002B2 (en) | 2013-01-30 | 2015-09-22 | Agrofresh Inc. | Compounds and compositions |
US9426996B2 (en) | 2013-01-30 | 2016-08-30 | Agrofresh Inc. | Use of benzoxaboroles as volatile antimicrobial agents on meats, plants, or plant parts |
US9433680B2 (en) | 2013-01-31 | 2016-09-06 | Merz Pharmaceuticals, Llc | Topical compositions and methods for making and using same |
US9446131B2 (en) | 2013-01-31 | 2016-09-20 | Merz Pharmaceuticals, Llc | Topical compositions and methods for making and using same |
US9452173B2 (en) | 2013-01-31 | 2016-09-27 | Merz Pharmaceuticals, Llc | Topical compositions and methods for making and using same |
US9585396B2 (en) | 2013-01-30 | 2017-03-07 | Agrofresh Inc. | Volatile applications against pathogens |
JP2018511584A (en) * | 2015-03-10 | 2018-04-26 | コリア リサーチ インスティテュート オブ ケミカル テクノロジー | Method for producing tetracoordinate organoboron compound |
US10070649B2 (en) | 2013-01-30 | 2018-09-11 | Agrofresh Inc. | Volatile applications against pathogens |
US10966429B2 (en) | 2016-03-07 | 2021-04-06 | Agrofresh Inc. | Synergistic methods of using benzoxaborole compounds and preservative gases as an antimicrobial for crops |
US11039617B2 (en) | 2013-01-30 | 2021-06-22 | Agrofresh Inc. | Large scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness |
EP4122918A1 (en) * | 2021-07-19 | 2023-01-25 | Clariant International Ltd | Process for the preparation of n-hydroxypyridone compounds |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2071171A6 (en) * | 1969-12-19 | 1971-09-17 | Rhone Poulenc Sa | 1,1-diphenyl-azaborolidines - with insecticidal acaricidal - herbicidal and fungicidal activity |
US4983589A (en) * | 1989-12-14 | 1991-01-08 | Chevron Research And Technology Company | Fungicidal imidazole diphenylaliphaticboranes and derivatives thereof |
EP1980564A1 (en) * | 2002-12-18 | 2008-10-15 | Anacor Pharmaceuticals, Inc. | Antibiotics containing borinic acid complexes and methods of use |
-
2007
- 2007-11-21 EP EP07868837A patent/EP2069370A4/en not_active Withdrawn
- 2007-11-21 WO PCT/US2007/085448 patent/WO2008064345A2/en active Application Filing
Non-Patent Citations (1)
Title |
---|
See references of EP2069370A4 * |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012137164A1 (en) * | 2011-04-07 | 2012-10-11 | Biolinerx Ltd. | Antimicrobial compositions, antibiofilm compositions and uses thereof |
US10765117B2 (en) | 2013-01-30 | 2020-09-08 | Agrofresh Inc. | Volatile applications against pathogens |
US10070649B2 (en) | 2013-01-30 | 2018-09-11 | Agrofresh Inc. | Volatile applications against pathogens |
US11771089B2 (en) | 2013-01-30 | 2023-10-03 | Agrofresh Inc. | Large-scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness |
US9426996B2 (en) | 2013-01-30 | 2016-08-30 | Agrofresh Inc. | Use of benzoxaboroles as volatile antimicrobial agents on meats, plants, or plant parts |
US11202448B2 (en) | 2013-01-30 | 2021-12-21 | Agrofresh Inc. | Volatile applications against pathogens |
US11039617B2 (en) | 2013-01-30 | 2021-06-22 | Agrofresh Inc. | Large scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness |
US9138002B2 (en) | 2013-01-30 | 2015-09-22 | Agrofresh Inc. | Compounds and compositions |
US9585396B2 (en) | 2013-01-30 | 2017-03-07 | Agrofresh Inc. | Volatile applications against pathogens |
US11917997B2 (en) | 2013-01-30 | 2024-03-05 | Agrofresh Inc. | Volatile applications against pathogens |
US9452173B2 (en) | 2013-01-31 | 2016-09-27 | Merz Pharmaceuticals, Llc | Topical compositions and methods for making and using same |
US10695303B2 (en) | 2013-01-31 | 2020-06-30 | Sebela Ireland Limited | Topical compositions and methods for making and using same |
US9161914B2 (en) | 2013-01-31 | 2015-10-20 | Merz Pharmaceuticals, Llc | Topical compositions and methods for making and using same |
US10729667B2 (en) | 2013-01-31 | 2020-08-04 | Sebela Ireland Limited | Topical compositions and methods for making and using same |
US8778365B1 (en) | 2013-01-31 | 2014-07-15 | Merz Pharmaceuticals, Llc | Topical compositions and methods for making and using same |
US9446131B2 (en) | 2013-01-31 | 2016-09-20 | Merz Pharmaceuticals, Llc | Topical compositions and methods for making and using same |
US9433680B2 (en) | 2013-01-31 | 2016-09-06 | Merz Pharmaceuticals, Llc | Topical compositions and methods for making and using same |
US10166206B2 (en) | 2013-01-31 | 2019-01-01 | Sebela International Bermuda Limited | Topical compositions and methods for making and using same |
US10166205B2 (en) | 2013-01-31 | 2019-01-01 | Sebela International Bermuda Limited | Topical compositions and methods for making and using same |
JP2018511584A (en) * | 2015-03-10 | 2018-04-26 | コリア リサーチ インスティテュート オブ ケミカル テクノロジー | Method for producing tetracoordinate organoboron compound |
US10966429B2 (en) | 2016-03-07 | 2021-04-06 | Agrofresh Inc. | Synergistic methods of using benzoxaborole compounds and preservative gases as an antimicrobial for crops |
EP4122918A1 (en) * | 2021-07-19 | 2023-01-25 | Clariant International Ltd | Process for the preparation of n-hydroxypyridone compounds |
WO2023001781A1 (en) * | 2021-07-19 | 2023-01-26 | Clariant International Ltd | Process for the preparation of n-hydroxypyridone compounds |
Also Published As
Publication number | Publication date |
---|---|
EP2069370A4 (en) | 2011-05-04 |
WO2008064345A3 (en) | 2008-12-18 |
EP2069370A2 (en) | 2009-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008064345A2 (en) | Microorganism killing compounds | |
US20210070780A1 (en) | Boron-Containing Small Molecules | |
US8106031B2 (en) | Hydrolytically-resistant boron-containing therapeutics and methods of use | |
CA2692135C (en) | Boron-containing small molecules | |
MX2007009625A (en) | Boron-containing small molecules |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07868837 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007868837 Country of ref document: EP |
|
NENP | Non-entry into the national phase in: |
Ref country code: DE |